def14a
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
(Rule 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the Securities
Exchange Act of 1934
Filed by the Registrant þ
Filed by a Party other than the Registrant o
Check the appropriate box:
o Preliminary Proxy Statement
o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
þ Definitive Proxy Statement
o Definitive Additional Materials
o Soliciting Material Pursuant to §240.14a-12
NxSTAGE MEDICAL, INC.
(Name of Registrant as Specified in Its Charter)
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
Payment of Filing Fee (Check the appropriate box):
þ No fee required.
o Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
(1) |
|
Title of each class of securities to which transaction applies: |
|
|
(2) |
|
Aggregate number of securities to which transaction applies: |
|
|
(3) |
|
Per unit price or other underlying value of transaction computed pursuant to Exchange
Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it
was determined): |
|
|
(4) |
|
Proposed maximum aggregate value of transaction: |
|
|
(5) |
|
Total fee paid: |
o
Fee paid previously with preliminary materials:
o Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and
identify the filing for which the offsetting fee was paid previously. Identify the previous
filing by registration statement number, or the Form or Schedule and the date of its filing.
|
(1) |
|
Amount previously paid: |
|
|
(2) |
|
Form, Schedule or Registration Statement No.: |
|
|
(3) |
|
Filing Party: |
|
|
(4) |
|
Date Filed: |
NxSTAGE MEDICAL, INC.
439 South Union Street, 5th Floor
Lawrence, Massachusetts 01843
Dear NxStage Medical, Inc. stockholders:
I am pleased to report that the management and directors have
successfully negotiated a $43 million private placement
investment in our company, NxStage Medical, Inc. The attached
proxy statement and notice of special meeting of stockholders
describes in detail the proposal, which requires your support to
enable us to complete this important financing.
Proceeds from this private placement will be used for working
capital purposes.
THIS FINANCING WILL DILUTE YOUR
STOCKHOLDING. HOWEVER, IF STOCKHOLDERS DO NOT APPROVE
THE PROPOSAL, WE WILL NOT BE ABLE TO OBTAIN APPROXIMATELY $18
MILLION OF GROSS PROCEEDS NEEDED TO FUND OUR ONGOING
OPERATIONS, AS WE CONTINUE TO WORK TO DEVELOP AND EXPAND THE
MARKET FOR OUR PRODUCTS.
The proposal being considered requires that a majority of all
shares of our issued and outstanding common stock present in
person or represented by proxy and entitled to vote on the
proposal vote in favor of the proposal under the Delaware
General Corporation Law, except that in accordance with NASDAQ
Marketplace Rules, it is possible that votes cast in respect of
shares of common stock purchased in the private placement may
not be counted toward the applicable threshold needed for NASDAQ
purposes to approve the proposal. Each stockholder should take
the time to review the attached proxy statement and to complete
and return the enclosed proxy card.
YOUR VOTE IS IMPORTANT, NO MATTER HOW MANY OR HOW FEW SHARES
YOU OWN. As of June 24, 2008, or the Record Date,
investors in the private placement who may be deemed to be
affiliated with one of NxStages directors or who hold more
than 5% of NxStages outstanding shares of common stock
immediately prior to the entry into the share purchase
agreements in connection with the private placement (the
Affiliated Investors) hold in the aggregate
approximately 12 million shares of our common stock, or
approximately 29% of the outstanding shares of our common stock
as of the Record Date and approximately 33% of the outstanding
shares of our common stock that may be permitted to be counted
under the NASDAQ Marketplace Rules for this proposal. On
May 22, 2008, we entered into a voting agreement with each
of these Affiliated Investors, in their capacity as current
stockholders of NxStage, pursuant to which each of these
Affiliated Investors agreed to vote in favor of this proposal at
the special meeting and granted to us an irrevocable proxy to
vote all of the outstanding shares of NxStage beneficially owned
by it, him or her in favor of this proposal.
Thank you very much for your prompt attention to this important
matter.
PLEASE VOTE TODAY.
Jeffrey H. Burbank
President and Chief Executive Officer
The proxy statement is dated July 8, 2008, and is first
being mailed to stockholders of NxStage Medical, Inc. on or
about July 9, 2008.
NxSTAGE MEDICAL, INC.
439 South Union Street, 5th Floor
Lawrence, Massachusetts 01843
NOTICE OF SPECIAL MEETING OF
STOCKHOLDERS
To Be Held On July 31,
2008
To the stockholders of NxStage Medical, Inc.:
NOTICE IS HEREBY GIVEN THAT a special meeting of stockholders
(the Special Meeting) of NxStage Medical, Inc., a
Delaware corporation (NxStage), will be held
July 31, 2008 at 10:00 a.m., local time, at the offices of
WilmerHale, 60 State Street, Boston, Massachusetts 02109.
The purpose of the Special Meeting is to obtain approval for
(a) the issuance and sale of 4,000,000 shares of our
common stock, at $4.50 per share, and warrants exercisable for
800,000 shares of our common stock, at an initial exercise
price of $5.50 per share, to certain investors, including
investors who are affiliates, either directly or through
affiliates, of NxStage, among them a member of our board of
directors, in exchange for aggregate gross proceeds to NxStage
of $18 million at the second closing of our private
placement of securities, and (b) such other business as may
properly come before the meeting, including any adjournment or
postponement thereof.
Our board of directors (the Board of Directors or
Board) recommends that you vote in favor of the
foregoing proposal, which we describe more fully in the proxy
statement accompanying this notice (the Proxy
Statement).
Only stockholders of record at the close of business on June 24,
2008 are entitled to notice of and to vote at the meeting.
Your vote is very important. All stockholders are cordially
invited to attend the meeting in person. Whether or not you plan
to attend the special meeting, please take the time to vote by
completing and mailing the enclosed proxy card to us or, if the
option is available to you, by granting your proxy
electronically over the Internet or by telephone. If your shares
are held in street name, meaning they are held for
your account by a broker or other nominee, your shares will only
be voted at the Special Meeting if you direct your broker to
vote your shares by following the procedures established by your
broker.
By Order of the Board of Directors
Winifred L. Swan
Secretary
Lawrence, Massachusetts
July 8, 2008
TABLE OF
CONTENTS
|
|
|
|
|
|
|
|
ii
|
|
|
|
|
1
|
|
|
|
|
5
|
|
|
|
|
5
|
|
|
|
|
9
|
|
|
|
|
17
|
|
|
|
|
17
|
|
|
|
|
A-1
|
|
|
|
|
B-1
|
|
|
|
|
C-1
|
|
|
|
|
|
|
Questions
and Answers
Although we encourage you to read the enclosed Proxy Statement
in its entirety, we include this question and answer section to
provide some background information and brief answers to several
questions you might have about the enclosed proposal. In this
Proxy Statement, we refer to NxStage Medical, Inc. as
NxStage, the Company, we,
our, or us.
|
|
|
|
|
|
|
Q.
|
|
What proposal are stockholders being asked to consider at the
upcoming Special Meeting?
|
|
A.
|
|
We are seeking approval of our proposal for the issuance and
sale of 4,000,000 shares of our common stock, at $4.50 per
share, and warrants exercisable for 800,000 shares of our
common stock, at an initial exercise price of $5.50 per share,
to certain investors, including investors who are affiliates,
either directly or through affiliates, of NxStage, among them a
member of our Board of Directors, in exchange for aggregate
gross proceeds to NxStage of $18 million. We refer to this
proposal as the Proposal throughout this Proxy
Statement. This issuance and sale is part of our private
placement involving the issuance and sale by us to investors of
a total of 9,555,556 shares of our common stock and
warrants exercisable for 1,911,111 shares of our common
stock with aggregate proceeds before expenses to us of
approximately $43 million and net proceeds to us of
approximately $42.3 million. We describe the Proposal and
the private placement in greater detail below.
|
|
|
|
|
|
|
|
Q.
|
|
How is the private placement structured?
|
|
A.
|
|
On May 22, 2008, we entered into Securities Purchase
Agreements with certain investors, including investors who may
be deemed to be affiliated with one of the directors of NxStage
or hold more than 5% of our outstanding shares of common stock.
These Securities Purchase Agreements provide for the issuance
and sale by us to these investors of shares of our common stock
and warrants exercisable for shares of our common stock.
Pursuant to the Securities Purchase Agreements, we agreed to
sell to the investors, and they agreed to purchase from us, in
two closings, an aggregate of 9,555,556 shares of common
stock at $4.50 per share and warrants exercisable for
1,911,111 shares of common stock at an initial exercise
price of $5.50 per share (subject to potential adjustment either
to $3.00 per share or $6.50 per share, as described further
below), which are exercisable from the date of grant through the
earlier of (i) five years from the grant date or
(ii) the consummation of a change of control event, subject
to the fulfillment of certain terms and conditions:
|
|
|
|
|
|
|
In the first closing of the private placement, which
occurred on May 28, 2008, and which is referred to in this
Proxy Statement as the First Closing, an aggregate
of 5,555,556 shares of our common stock and warrants to
purchase 1,111,111 shares of our common stock were issued
and sold by us and purchased by investors not affiliated with
NxStage or with any of NxStages officers, directors or
stockholders or any party acting for or on behalf of the
foregoing. In this Proxy Statement, we refer to the investors in
the First Closing as First Closing Investors.
|
|
|
|
|
|
|
In the second closing of the private placement,
which is scheduled to take place on August 1, 2008, one
business day following the Special Meeting, and which is
referred to in this Proxy Statement as the Second
Closing, an aggregate of 4,000,000 shares of our
common stock and warrants to purchase 800,000 shares of our
common stock will be issued and sold by us and purchased by
(a) unaffiliated investors and (b) investors who are
affiliates of NxStage, including one investor who may be
affiliated with a member of the Board of Directors. In this
Proxy Statement, we refer to these affiliates as the
Second Closing Investors.
|
ii
|
|
|
|
|
|
|
|
|
|
|
|
|
Other than the different closing dates and the stockholder
approval requirement for the Second Closing, all other terms of
the private placement are identical in the two closings.
|
|
|
|
|
|
|
|
Q.
|
|
For which part of the private placement is NxStage seeking
stockholder approval?
|
|
A.
|
|
NxStage is seeking stockholder approval for the Proposal for the
issuance and sale, in the Second Closing, of shares of our
common stock and warrants exercisable for shares of our common
stock to the Second Closing Investors. NxStage is not required
to seek stockholder approval for the private placement in the
First Closing of shares and warrants to the First Closing
Investors.
|
|
|
|
|
|
|
|
Q.
|
|
Who are the Second Closing Investors?
|
|
A.
|
|
The Second Closing Investors include: Sprout Capital VII, L.P.,
Sprout Capital VIII, L.P., Sprout Capital IX, L.P., Sprout CEO
Fund, L.P., Sprout Entrepreneurs Fund, L.P., Sprout Venture
Capital, L.P., Sprout IX Plan Investors, L.P., Sprout Plan
Investors, L.P., DLJ ESC II, L.P., DLJ Capital Corporation
(collectively, the Sprout Group), MFS Variable
Insurance Trust, on behalf of one of its series, MFS Core Equity
Series (VVSK), MFS Variable Insurance Trust II, on behalf
of one of its series, MFS Core Equity Portfolio (RGS), MFS
Series Trust I, on behalf of one of its series, MFS
Core Equity Fund (RGI), Deerfield Special Situations
Fund International Limited, Deerfield Special Situations
Fund, L.P., Deerfield Private Design International, LP,
Deerfield Private Design Fund, LP, Cross Creek Capital
Employees Fund, L.P., Cross Creek Capital, L.P., Redmile
Capital Fund, LP, Redmile Capital Offshore Fund, Ltd., Redmile
Capital Offshore Fund II, Ltd., BVCF IV, L.P., Crosslink
Crossover Fund V, LP, Crosslink Emerging Growth Fund, LP,
Crosslink Crossover Fund IV, LP, Delta Growth, LP, HSMR
Capital Partners (QP) LP, and Broadfin Healthcare Master Fund,
Ltd. One Second Closing Investor, the Sprout Group, may be
deemed to be affiliated with the Chairman of our Board of
Directors, Dr. Philippe Chambon.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of June 24, 2008, or the Record Date, the Second Closing
Investors owned approximately 39% of the voting power of our
issued and outstanding common stock. On May 22, 2008, we
entered into Voting Agreements with those Second Closing
Investors who may be deemed to be affiliated with one of our
Board of Directors or who hold more than 5% of our outstanding
shares of common stock immediately prior the entry into the
share purchase agreements in connection with the private
placement (the Affiliated Investors), in their
capacities as current stockholders of NxStage, pursuant to which
each of the Affiliated Investors agreed to vote in favor of the
Proposal at the Special Meeting and granted to us an irrevocable
proxy to vote all of the outstanding shares of NxStage
beneficially owned by it or him in favor of this Proposal. As of
the Record Date, the Affiliated Investors collectively hold in
the aggregate approximately 29% of the Companys
outstanding common stock and approximately 33% of the
outstanding shares of our common stock that may be permitted to
be counted under the NASDAQ Marketplace Rules for this proposal.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
More details about our sale to the Affiliated Investors in the
Second Closing are described in the section under the heading
Proposal Interests of Certain Persons in the
Second Closing beginning on page 16 of this Proxy
Statement.
|
iii
|
|
|
|
|
|
|
Q.
|
|
Why is NxStage seeking stockholder approval for the Second
Closing?
|
|
A.
|
|
We are subject to NASDAQ Marketplace Rules because our common
stock is listed on the NASDAQ Global Market. Specifically,
NASDAQ Marketplace Rule 4350(i)(1)(D)
(Rule 4350(i)(1)(D)) requires us to obtain
stockholder approval for any issuance or sale of common stock,
or securities convertible into or exercisable for common stock,
that is (i) equal to 20% or more of our outstanding common
stock before such issuance or sale and (ii) at a price per
share below the greater of book or market value at the time of
such issuance or sale. Rule 4350(i)(1)(D) applies to the
Second Closing because:
|
|
|
|
|
|
|
the purchase price of the common stock we issued and
sold at the First Closing and intend to issue and sell at the
Second Closing will be at $4.50 per share, which is below $4.88
per share, the closing price of our common stock on NASDAQ on
May 21, 2008, the last day our common stock traded on
NASDAQ before the Securities Purchase Agreements were entered
into, and
|
|
|
|
|
|
|
the shares of common stock and warrants to purchase
shares of common stock that we intend to issue and sell at the
Second Closing, together with the shares and warrants issued and
sold in the First Closing, will comprise approximately 31% of
the shares of our common stock outstanding immediately prior to
the First Closing and approximately 25% of the outstanding
shares immediately after the Second Closing.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In addition, NASDAQ has taken the position pursuant to NASDAQ
Marketplace Rule 4350(i)(1)(A) that the issuance and sale
of securities to investors who may be deemed to be affiliated
with a director of the issuer at a discounted price to the
market value of the securities could constitute equity
compensation to such director if such director could be deemed
to directly or indirectly hold any of the securities issued in
the transaction, and in which case such issuance and sale would
require stockholder approval.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Certain investors in the Second Closing may be deemed to be
affiliated with one of our directors and therefore the sale and
issuance of shares of our common stock and warrants exercisable
for our common stock to such investors requires stockholder
approval. More details about our sale to the investors who may
be deemed to be affiliated with one of our directors in the
Second Closing are described in the section under the heading
Proposal Interests of Certain Persons in the
Second Closing beginning on page 16 of this Proxy
Statement.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the above reasons, we are required under NASDAQ Marketplace
Rules to obtain stockholder approval prior to issuing and
selling the shares and warrants at the Second Closing.
|
|
|
|
|
|
|
|
Q.
|
|
Why does NxStage need to do the private placement?
|
|
A.
|
|
NxStage has not yet achieved profitability, and requires
significant cash flow to support its ongoing operations.
Revenues from product sales are becoming an increasingly
important source of cash flow, but are not yet sufficient to
defray all operating expenses. As of March 31, 2008, we had
cash, cash equivalents and securities available-for-sale of
approximately $16.2 million. We anticipated that with our
existing financial resources and expected revenues from product
sales, our cash would be sufficient to meet our anticipated
operating and capital requirements through 2008, but would be
insufficient to satisfy our liquidity requirements beyond 2008.
|
iv
|
|
|
|
|
|
|
|
|
|
|
|
|
Additionally, beginning in 2009, we will need to begin paying
down the principal under our revolving credit facility that we
entered into in November 2007 with Merrill Lynch Capital, a
division of Merrill Lynch Business Services Inc., which was
acquired by General Electric Capital.
|
|
|
|
|
|
|
Consequently, our management and Board of Directors determined
in early 2008 that we will need to secure additional working
capital to fund our capital requirements. Accordingly, our
management and Board of Directors undertook extensive efforts to
identify and evaluate different strategic alternatives,
including various forms of private debt and equity financings.
Based on our stock price and the state of the medical device
capital market, our management and Board of Directors concluded
that it was unlikely that we would attract sufficient interest
among public investors and that a private placement of our
publicly-traded common stock (commonly referred to as a
PIPE financing), targeting private venture capital
investors and other institutional investors, had a higher
likelihood of success. In addition, in mid-May 2008, we engaged
an investment bank, Canaccord Adams Inc. (Canaccord)
to serve as the placement agent and advisor in the private
placement. The section under the heading
Proposal Background of the Private
Placement, beginning on page 9 of this Proxy
Statement, provides more details on our internal deliberation,
discussions with Canaccord and extensive meetings and
negotiations with prospective investors during May 2008. We
finally signed the Securities Purchase Agreements on
May 22, 2008, which provide for the First and Second
Closings of the private placement and set forth the terms and
conditions of the transaction, as described in more detail under
the heading Proposal Terms of the Private
Placement, beginning on page 12 of this Proxy
Statement. The First Closing took place on May 28, 2008,
and we currently plan to complete the Second Closing on
August 1, 2008, one business day after we receive
stockholder approval for the Proposal. Assuming the Second
Closing occurs, we will receive approximately $43 million
in total gross proceeds (before fees and expenses) from the
First Closing and Second Closing, and an additional
$10.5 million in aggregate gross proceeds if and when all
warrants are exercised in full and for cash (assuming an
exercise price of $5.50 per share and no net exercise).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from the Second Closing, together with the proceeds
from the First Closing, will enable us to advance further the
commercialization of our products and the development of new
products for our product pipeline. In particular, we anticipate
using the net proceeds for the expansion of sales and marketing
programs, the hiring of additional personnel and investment in
clinical research and product development activities. We also
intend to use the proceeds for general corporate purposes.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As described in more detail under the heading
Proposal Reasons for the Private Placement
Including the Second Closing, beginning on page 10 of
this Proxy Statement, if we do not receive the proceeds from the
Second Closing, meeting our capital needs on a timely basis and
on terms acceptable to us will be more difficult. We may be
required to delay, reduce the scope of, or eliminate one or more
aspects of our business, which would likely harm our business.
|
v
|
|
|
|
|
|
|
Q.
|
|
What if the Proposal is not approved?
|
|
A.
|
|
If the Proposal does not receive stockholder approval, the
issuance and sale to the First Closing Investors in the First
Closing will not be affected, but the issuance and sale to the
Second Closing Investors in the Second Closing, including the
Affiliated Investors, will be affected. Specifically, the Second
Closing Investors will not be obligated or permitted to purchase
the shares of our common stock and warrants, and we will not be
obligated or permitted to sell them the shares of our common
stock or warrants in the Second Closing. In that case, we could
request special relief from the NASDAQ Global Market to allow
the investors to proceed with the purchase of the securities as
contemplated by the Second Closing. The NASDAQ Global Market
grants special relief based on an issuers financial
circumstances only in limited instances. There is no guarantee,
however, that the NASDAQ Global Market would grant such
permission, or that the original Second Closing Investors would
purchase our securities even if the NASDAQ Global Market does
grant such permission.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
YOUR VOTE IS IMPORTANT, NO MATTER HOW MANY OR HOW FEW SHARES
YOU OWN. As described above, as of June 24, 2008, or
the Record Date, the Affiliated Investors beneficially owned,
either directly or through affiliates, approximately 29% of the
voting power of our issued and outstanding common stock, and
approximately 33% of the outstanding shares of our common stock
that may be permitted to be counted under the NASDAQ Marketplace
Rules for this proposal. On May 22, 2008, we entered into a
Voting Agreement with each of the Affiliated Investors, in his
or its capacity as current stockholders of NxStage, pursuant to
which each of the Affiliated Investors agreed to vote in favor
of the Proposal at the Special Meeting, and granted to us an
irrevocable proxy to vote all of the outstanding shares of
NxStage beneficially owned by it, him or her in favor of this
Proposal.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Our failure to raise additional capital could require us to
delay, reduce the scope of, or eliminate one or more aspects of
our business, which would likely harm our business and could
substantially diminish the value of our common stock and thus
your investment in our shares.
|
|
|
|
|
|
|
|
Q.
|
|
Will the Second Closing dilute our stockholders
ownership interest in NxStage?
|
|
A.
|
|
Our stockholders will incur dilution of their percentage of
stock ownership in NxStage if the Second Closing takes place.
Immediately prior to the Second Closing (assuming no issuance of
any shares after the First Closing), 42,350,131 shares of
our common stock would be outstanding after giving effect to the
issuance of 5,555,556 shares of common stock at the First
Closing. If the Second Closing occurs (assuming no issuance of
any shares after the First Closing), a total of
46,350,131 shares of common stock will be outstanding upon
the Second Closing. Stockholders immediately prior to the First
Closing will incur dilution, upon the consummation of the Second
Closing, of approximately 21% (24% if the total of
1,911,111 shares issuable upon exercise in full and for
cash of the warrants issued in the First and Second Closings are
included).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
However, as we explained above in the answer to the question
what if the Proposal is not approved, failure to
complete the Second Closing could significantly harm our
business and the value of our common stock, and the value of
your investment in our common stock could be substantially
diminished.
|
vi
|
|
|
|
|
|
|
Q.
|
|
Who will bear the costs of the proxy solicitation?
|
|
A:
|
|
We will bear the costs of soliciting proxies, including the
printing, mailing and filing of this Proxy Statement and any
additional information furnished to stockholders. We have
engaged Georgeson Shareholder Communications Inc., a proxy
solicitation firm, to solicit proxies from our stockholders. For
these services, we expect to pay a fee of approximately $7,500,
plus expenses. Our directors, officers and employees may also
solicit proxies by telephone, email, facsimile and in person,
without additional compensation. Upon request, we will reimburse
brokerage houses and other custodians, nominees and fiduciaries
for their reasonable out-of-pocket expenses for distributing
proxy materials.
|
|
|
|
|
|
|
|
Q.
|
|
Where can I find additional information? Who can help answer
my questions?
|
|
A:
|
|
You should carefully review the entire Proxy Statement, which
contains important information regarding the Proposal, before
voting on the Proposal. We filed a current report on
Form 8-K
with the Securities and Exchange Commission (the
SEC) on May 23, 2008, which contains a summary
of the private placement and attaches each of the relevant
agreements for the private placement as exhibits. These exhibits
are also attached for your convenience as Annexes to this Proxy
Statement. We strongly encourage you to carefully review the
Form 8-K
and the exhibits thereto describing the private placement. The
section under the heading Where You Can Find Additional
Information, beginning on page 17 of this Proxy
Statement, describes additional sources to obtain this Proxy
Statement, our public filings under the Securities Exchange Act
of 1934, as amended (including the
Form 8-K
described above), and other information about NxStage.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
If you would like copies of the current report on
Form 8-K
filed on May 23, 2008 (including the exhibits thereto) or
additional copies of this Proxy Statement, free of charge, or if
you have questions about the private placement or the procedures
for voting your shares, you should contact: NxStage Medical,
Inc., 439 South Union St.,
5th Floor,
Lawrence, Massachusetts 01843, Telephone: (978) 687-4700,
Attention: Investor Relations.
|
vii
NxSTAGE
MEDICAL, INC.
Proxy
Statement for the Special Meeting of Stockholders
To Be Held July 31, 2008
INFORMATION
CONCERNING SOLICITATION AND VOTING
General
This proxy is solicited on behalf of the Board of Directors of
NxStage Medical, Inc., a Delaware corporation, at a Special
Meeting of stockholders to be held July 31, 2008, at 10:00
a.m., local time, and at any adjournment, continuation or
postponement of the meeting, referred to throughout this Proxy
Statement as the Special Meeting, for the purposes set forth
herein and in the accompanying Notice of Special Meeting of
Stockholders. The Special Meeting will be held at the offices of
WilmerHale at 60 State Street, Boston, Massachusetts 02109.
These proxy solicitation materials were first mailed or given on
or about July 9, 2008 to all stockholders entitled to vote
at the meeting.
Purpose
of Special Meeting
As described above, the purpose of the Special Meeting is to
obtain approval for the Proposal and such other business as may
properly come before the meeting, including any adjournment or
postponement thereof.
Record
Date and Shares Outstanding
Only stockholders who owned shares of our common stock at the
close of business on June 24, 2008, referred to in this Proxy
Statement as the Record Date, are entitled to notice of, and to
vote at, the Special Meeting. Except as otherwise provided in
this Proxy Statement, the holders of common stock as of the
Record Date are entitled to one vote per share on matters
presented at the Special Meeting. As of the Record Date,
42,356,011 shares of NxStages common stock are issued
outstanding.
Vote
Required
The affirmative vote of the holders of a majority of all shares
of our common stock present in person or represented by proxy
and entitled to vote at the Special Meeting will be required to
approve the Proposal under the Delaware General Corporation Law,
except that in accordance with the NASDAQ Marketplace Rules, it
is possible that votes cast in respect of shares of common stock
purchased in the private placement may not be counted toward the
applicable threshold needed for NASDAQ purposes to approve the
Proposal. Accordingly, of the approximately
42,356,011 shares of the Companys common stock that
are issued and outstanding as of the Record Date, only
36,800,455 shares may be permitted to be counted under the
NASDAQ Marketplace Rules for this Proposal.
Revocability
of Proxies
You may revoke your proxy at any time before it is exercised.
Execution of the proxy will not in any way affect your right to
attend the Special Meeting in person. Revocation may be made
prior to the Special Meeting by written revocation or through a
duly executed proxy bearing a later date sent to NxStage,
Attention: Winifred L. Swan, Secretary, 439 South Union St.,
5th Floor,
Lawrence, Massachusetts 01843; or your proxy may be revoked
personally at the Special Meeting by written notice to the
Secretary at the Special Meeting prior to the voting of the
proxy. Any revocation sent to NxStage must include the
stockholders name and must be received the day prior to
the Special Meeting to be effective.
How Your
Proxy Will Be Voted
In the absence of specific instructions to the contrary, shares
represented by properly executed proxies received by NxStage,
including unmarked proxies, will be voted to approve the
Proposal. In addition, if any
other matters properly come before the Special Meeting, it is
the intention of the persons named in the enclosed proxy card to
vote the shares they represent as directed by the Board of
Directors. We have not received notice of any other matters that
may properly be presented at the Special Meeting.
Quorum
The presence, in person or by proxy, of the holders of a
majority of the outstanding shares of NxStages common
stock as of the Record Date eligible to vote is necessary to
constitute a quorum at the Special Meeting. As there were
42,356,011 shares eligible to vote on the Proposal as of
the Record Date, we will need at least 21,178,006 shares
present in person or by proxy at the Special Meeting for a
quorum to exist.
Voting
Tabulation
Shares of stockholders entitled to vote who are present at the
Special Meeting in person or by proxy, abstentions and broker
non-votes are counted as present or represented at the meeting
for purposes of determining whether a quorum exists. For the
Proposal, the affirmative vote of a majority of the shares of
common stock present in person or represented by proxy and
entitled to vote at the Special Meeting is necessary for
approval under the Delaware General Corporation Law, except that
in accordance with the NASDAQ Marketplace Rules, it is possible
that votes cast in respect of shares of common stock purchased
in the private placement may not be counted toward the
applicable threshold needed for NASDAQ purposes to approve the
Proposal. An automated system administered by the Companys
transfer agent tabulates the votes.
YOUR VOTE IS IMPORTANT, NO MATTER HOW MANY OR HOW FEW SHARES
YOU OWN. As of the Record Date, the Affiliated
Investors, beneficially owned, either directly or through
affiliates, approximately 29% of the voting power of our issued
and outstanding common stock, and approximately 33% of the
outstanding shares of our common stock that may be permitted to
be counted under the NASDAQ Marketplace Rules for this proposal.
On May 22, 2008, we entered into a Voting Agreement with
each of these Affiliated Investors, in their capacity as current
stockholders of NxStage, pursuant to which each of the these
Affiliated Investors agreed to vote in favor of this proposal at
the Special Meeting and granted to us an irrevocable proxy to
vote all of the outstanding shares of NxStage beneficially owned
by it, him or her in favor of this Proposal.
Voting
Instructions
The following section summarizes important information on how to
vote your shares of common stock.
Voting
by Proxy
If you are a record holder, meaning your shares are registered
in your name, you may vote over the Internet, by telephone, by
mail or in person at the Special Meeting pursuant to the
following instructions:
Over the Internet: Go to the website of our
tabulator, Computershare Investor Services
(Computershare), at www.investorvote.com/NXTM. Use
the vote control number printed on your enclosed proxy card to
access your account and vote your shares. You must specify how
you want your shares voted or your Internet vote cannot be
completed and you will receive an error message. Your shares
will be voted according to your instructions. You must submit
your Internet proxy before 11:59 p.m. Eastern Time on
July 30, 2008, the day before the Special Meeting, for your
proxy to be valid and your vote to count.
By Telephone: Call
1-800-652-VOTE
(8683) toll free from the United States, Canada and Puerto
Rico, and follow the instructions on your enclosed proxy card.
You must specify how you want your shares voted and confirm your
vote at the end of the call or your telephone vote cannot be
completed. Your shares will be voted according to your
instructions. You must submit your telephonic proxy before
11:59 p.m. Eastern Time on July 30, 2008, the day
before the Special Meeting, for your proxy to be valid and your
vote to count.
2
By Mail: Complete and sign your enclosed proxy
card and mail it in the enclosed postage prepaid envelope to
Computershare Investor Services. Your shares will be voted
according to your instructions. If you do not specify how you
want your shares voted, they will be voted as recommended by our
Board of Directors. Computershare must receive your proxy card
not later than July 30, 2008, the day before the Special
Meeting, for your proxy to be valid and your vote to count.
In Person at the Special Meeting: If you
attend the Special Meeting, you may deliver your completed proxy
card in person or you may vote by completing a ballot, which we
will provide to you at the Special Meeting.
Voting
of Shares Held in Street Name
If your shares are held in street name, meaning they
are held for your account by a broker or other nominee, you will
receive instructions from your broker or other nominee regarding
how to vote your shares over the Internet, by telephone or by
mail. You should follow those instructions. If you wish to vote
your shares in person at the Special Meeting, contact your
broker or other nominee who holds your shares to obtain a
brokers proxy card and bring it with you to the Special
Meeting. You will not be able to vote in person at the Special
Meeting unless you have a proxy from your broker issued in your
name giving you the right to vote your shares.
Voting
of Proxies at the Special Meeting
All properly executed proxies that we receive prior to the vote
at the Special Meeting, and that are not revoked, will be voted
in accordance with the instructions indicated on the proxies or,
if no direction is indicated, to approve the private placement.
Properly executed proxies, other than proxies voting against the
private placement, will also be voted for any adjournment or
postponement of the Special Meeting for the purpose of
soliciting additional votes to approve the Proposal, if
necessary. Our Board of Directors does not currently intend to
bring any other business before the Special Meeting and, so far
as our Board of Directors knows, no other matters are to be
brought before the Special Meeting. If other business properly
comes before the Special Meeting, the proxies will vote in
accordance with their own judgment.
Copies of solicitation materials will be furnished to banks,
brokerage houses, fiduciaries and custodians holding in their
names shares of our common stock beneficially owned by others to
forward to such beneficial owners. In addition to solicitation
by use of the mails, proxies may be solicited by directors,
officers, employees or agents of NxStage in person or by
telephone, telegram or other means of communication. No
additional compensation will be paid to directors, officers or
other regular employees of NxStage for such services.
Broker
Non-Votes; Abstentions
In the absence of controlling precedent to the contrary, we
intend to treat broker non-votes and abstentions in the
following manner.
A broker non-vote occurs when a nominee holding
shares for a beneficial owner does not vote on a particular
proposal because the nominee does not have the discretionary
voting power with respect to that item and has not received
instructions from the beneficial owner. Broker
non-votes and shares as to which proxy authority has
been withheld with respect to any matter are considered present
for purposes of calculating a quorum but are not deemed to be
entitled to vote for purposes of determining whether stockholder
approval of that matter has been obtained. As a result, broker
non-votes are not included in the tabulation of the
voting results on the election of directors or any other issues
requiring the approval of a majority of the shares of common
stock present and entitled to vote and, therefore, do not have
the effect of votes in opposition for such proposals. With
respect to the Proposal, which requires a majority vote, broker
non-votes have no effect.
3
Abstentions occur when a stockholder entitled to vote and
present in person or represented by proxy affirmatively votes to
abstain. Votes in abstention are considered present for purposes
of calculating a quorum but do not count as a vote FOR or
AGAINST any matter. While abstentions do not count as a vote FOR
or AGAINST, they have the same effect as a negative vote on the
Proposal because abstentions will be included in tabulations of
the shares of common stock entitled to vote for purposes of
determining whether a proposal has been approved.
Revocation
of Proxies
Stockholders may revoke their proxies at any time prior to use
by delivering to our corporate secretary a signed notice of
revocation or a later-dated signed proxy, or by attending the
Special Meeting in person and revoking the proxy by signing a
notice of revocation. If you vote your shares over the Internet
or by telephone, only your latest Internet or telephone vote
will be counted at the Special Meeting. Attendance at the
Special Meeting does not in itself constitute the revocation of
a proxy. Stockholders who have instructed their broker to vote
their shares of common stock must follow their brokers
directions in order to change those instructions. You may also
attend the Special Meeting in person instead of submitting a
proxy; however, please see the instructions above under
Voting of Shares Held in Street-Name if you wish to
vote such shares in person at the Special Meeting.
Solicitation
of Proxies
We will pay for all costs incurred in connection with the
solicitation of proxies from our stockholders on behalf of our
Board of Directors, including assembly, printing and mailing of
this document, its related attachments, and the proxy card. We
have engaged Georgeson Shareholder Communications, Inc., a proxy
solicitation firm, to solicit proxies from our stockholders. For
these services, we expect to pay a fee of approximately $7,500
plus expenses. Our directors, officers and employees may solicit
proxies by telephone, email, facsimile and in person, without
additional compensation. Upon request, we will reimburse
brokerage houses and other custodians, nominees and fiduciaries
for their reasonable out-of-pocket expenses for distributing
proxy materials.
Householding
of Proxy Materials
The Securities and Exchange Commission (the SEC) has
adopted rules that permit companies and intermediaries (e.g.,
brokers) to satisfy the delivery requirements for Proxy
Statements and annual reports with respect to two or more
stockholders sharing the same address by delivering a single
Proxy Statement addressed to those stockholders and enclosing
separate proxy cards for each stockholder. This process, which
is commonly referred to as householding, potentially
eliminates some duplicative mailings to stockholders and reduces
our mailing costs.
For this Special Meeting, a number of brokers with account
holders who are stockholders of NxStage will be
householding our proxy materials. A single Proxy
Statement will be delivered to multiple stockholders sharing an
address unless contrary instructions have been received from the
affected stockholders. Once you have received notice from your
broker that they will be householding communications
to your address, householding will continue until
you are notified otherwise or until you revoke your consent. If,
at any time, you no longer wish to participate in
householding and would prefer to receive a separate
Proxy Statement and annual report, please notify your broker, or
direct your written request to NxStage Medical, Inc., Attention:
Winifred L. Swan, Secretary, 439 South Union
St., 5th Floor, Lawrence, Massachusetts 01843. Stockholders
who currently receive multiple copies of the Proxy Statement at
their address and would like to request householding
of their communications should contact their broker.
Stockholder
Proposals for the 2009 Annual Meeting
Proposals of stockholders intended to be presented at the 2009
Annual Meeting of Stockholders must be received by us at our
principal office in Lawrence, Massachusetts not later than
January 2, 2009 for inclusion in the Proxy Statement for
that meeting.
4
In addition, our bylaws require that we be given advance notice
of stockholder nominations for election to our Board of
Directors and of other matters which stockholders wish to
present for action at an annual meeting of stockholders, other
than matters included in our Proxy Statement in accordance with
Rule 14a-8.
The required notice must be in writing and received by our
Secretary, Winifred L. Swan, at our principal offices not later
than 90 days nor more than 120 days prior to the first
anniversary of our 2008 Annual Meeting of Stockholders. However,
if the 2009 Annual Meeting of Stockholders is advanced by more
than 20 days, or delayed by more than 60 days, from
the first anniversary of the 2008 Annual Meeting of
Stockholders, notice must be received not earlier than the
120th day prior to such annual meeting and not later than
the close of business on the later of (1) the 90th day
prior to such annual meeting and (2) the 10th day
following the date on which notice of the date of such annual
meeting was mailed or public disclosure of the date of such
annual meeting was made, whichever occurs first. Our bylaws also
specify requirements relating to the content of the notice which
stockholders must provide, including a stockholder nomination
for election to the Board of Directors, to be properly presented
at the 2009 Annual Meeting of Stockholders.
Appraisal
Rights
Under the Delaware General Corporation Law, our stockholders are
not entitled to appraisal rights or other similar rights in
connection with the Second Closing or the other transactions
contemplated by the private placement.
INFORMATION
IN THIS PROXY STATEMENT
Unless otherwise specifically noted, all of the share numbers in
this Proxy Statement are based on 36,794,575 shares of
common stock outstanding as of May 27, 2008, the day prior
to the First Closing. When referencing the number of shares of
common stock that will be owned by the investors following the
Second Closing, unless otherwise stated or reasonably clear from
the context, we have taken into account the shares of common
stock we have issued or will issue to the investors in both
closings of the private placement, as well as the number of
shares of common stock underlying the warrants that we have
issued or will issue to the investors in both closings.
SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
As of June 24, 2008, or the Record Date, there were
42,356,011 shares of common stock outstanding. The
following table sets forth, as of the Record Date, or such
earlier date as indicated below, the shares of our common stock
beneficially owned by (1) each of our directors,
(2) our principal executive officer, our principal
financial officer and our three other most highly compensated
executive officers who were serving as executive officers on
December 31, 2007, whom we refer to collectively as our
named executive officers, (3) all of our
directors and executive officers as a group, and (4) all
persons known by us to beneficially own more than 5% of our
outstanding stock.
Beneficial ownership is determined in accordance with rules of
the SEC and includes shares over which the indicated beneficial
owner exercises voting
and/or
investment power. Shares of common stock subject to options or
warrants currently exercisable or exercisable within
60 days are deemed outstanding for computing the percentage
ownership of the person holding the options but are not deemed
outstanding for computing the percentage ownership of any other
person.
Except as otherwise indicated in the footnotes to this table and
subject to community property laws where applicable, we believe
that each stockholder identified in the table has sole voting
and investment power with respect to all shares listed opposite
their names.
5
Unless otherwise indicated below, the address for each person is
to the care of NxStage Medical, Inc., 439 South Union Street,
5th Floor, Lawrence, Massachusetts 01843.
|
|
|
|
|
|
|
|
|
|
|
Amount and Nature
|
|
|
Percent
|
|
|
|
of Beneficial
|
|
|
of Common
|
|
Name and Address of Beneficial Owner
|
|
Ownership
|
|
|
Stock Outstanding
|
|
|
5% Stockholders
|
|
|
|
|
|
|
|
|
David S. Utterberg
|
|
|
8,538,463
|
(1)(7)(8)
|
|
|
20.1
|
%
|
c/o Medisystems
Corporation
701 Pike Street,
16th Floor
Seattle, Washington 98101
|
|
|
|
|
|
|
|
|
Credit Suisse (Sprout Entities)
|
|
|
6,185,874
|
(2)
|
|
|
14.6
|
%
|
Eleven Madison Avenue
New York, New York 10010
|
|
|
|
|
|
|
|
|
OrbiMed Advisors LLC
|
|
|
6,666,667
|
(3)
|
|
|
15.7
|
%
|
767 Third Avenue
New York, NY 10017
|
|
|
|
|
|
|
|
|
Massachusetts Financial Services Company
|
|
|
3,424,930
|
(4)
|
|
|
8.1
|
%
|
500 Boylston Street
Boston, MA 02116
|
|
|
|
|
|
|
|
|
Deerfield Management Co.
|
|
|
2,583,028
|
(5)
|
|
|
6.1
|
%
|
780 Third Avenue, 37th Floor
New York, NY 10017
|
|
|
|
|
|
|
|
|
Atlas Venture entities
|
|
|
1,905,608
|
(6)
|
|
|
4.5
|
%
|
890 Winter Street, Suite 320
Waltham, Massachusetts 02451
|
|
|
|
|
|
|
|
|
Directors(7)
|
|
|
|
|
|
|
|
|
Jeffrey H. Burbank
|
|
|
874,738
|
(8)
|
|
|
2.0
|
%
|
Philippe O. Chambon
|
|
|
5,979,027
|
(8)(9)
|
|
|
14.1
|
%
|
Daniel A. Giannini
|
|
|
62,235
|
(8)
|
|
|
|
*
|
Reid S. Perper
|
|
|
1,340,817
|
(8)(10)
|
|
|
3.2
|
%
|
Peter P. Phildius
|
|
|
113,555
|
(8)
|
|
|
*
|
|
Craig W. Moore
|
|
|
85,418
|
(8)
|
|
|
*
|
|
Other Named Executive Officers
|
|
|
|
|
|
|
|
|
Robert S. Brown
|
|
|
95,333
|
(8)
|
|
|
*
|
|
Winifred L. Swan
|
|
|
139,096
|
(8)
|
|
|
*
|
|
Joseph E. Turk, Jr.
|
|
|
218,593
|
(8)
|
|
|
*
|
|
Michael J. Webb
|
|
|
120,267
|
(8)
|
|
|
*
|
|
Augustin Azel
|
|
|
47,950
|
|
|
|
*
|
|
All directors and executive officers as a group (12 persons)
|
|
|
17,615,492
|
(11)
|
|
|
40.3
|
%
|
|
|
|
* |
|
Represents holdings of less than one percent. |
|
(1) |
|
David Utterberg holds (a) 8,482,966 shares of our
common stock and (b) 55,497 shares of common stock
which Mr. Utterberg has the right to acquire upon exercise
of outstanding stock options (See Note 8 below). |
|
(2) |
|
This information is provided by Credit Suisse jointly with its
affiliates, the Sprout Entities, and is as of May 27, 2008.
As of May 27, 2008, the Sprout Entities may be deemed to
beneficially own an aggregate of 6,185,874 shares of common
stock, consisting of (i) 2,359,547 shares of common
stock held directly by Sprout Capital IX, L.P.,
(ii) 2,108,034 shares of common stock held directly by
Sprout Capital VIII, L.P., (iii) 830,437 shares of
common stock held directly by Sprout Capital VII, L.P.,
(iv) 9,666 shares of |
6
|
|
|
|
|
common stock held directly by Sprout CEO Fund, L.P.,
(v) 9,402 shares of common stock held directly by
Sprout Entrepreneurs Fund, L.P., (vi) 112,061 shares
of common stock held directly by Sprout IX Plan Investors, L.P.,
(vii) 47,203 shares of common stock held directly by
Sprout Plan Investors, L.P., (viii) 126,517 shares of
common stock held directly by Sprout Venture Capital, L.P.,
(ix) 135,480 shares of common stock held directly by
DLJ ESC II, L.P., (x) 174,845 shares of common stock
held directly by DLJ Capital Corporation, or DLJCC,
(xi) 272,582 shares of common stock held directly by
CSFB
Fund Co-Investment
Program, L.P., and (xii) 100 shares held directly by
CS SEC USA LLC. |
|
(3) |
|
This information is taken from the Schedule 13D/A filed on
June 3, 2008 by OrbiMed Advisors LLC jointly with its
affiliated entities and is as of June 3, 2008. OrbiMed
Associates III, LP, or Associates, is the record holder of
62,893 shares of common stock, including 10,482 shares
of common stock issuable upon exercise of outstanding warrants.
Caduceus Private Investments III, LP, or Caduceus, is the record
holder of 6,603,774 shares of common stock, including
1,100,629 shares of common stock issuable upon exercise of
outstanding warrants. OrbiMed Advisors LLC acts as the
investment manager of Associates and may be deemed to
beneficially own 62,893 shares of common stock. OrbiMed
Capital GP III LLC is the general partner of Caduceus and may be
deemed to beneficially own 6,603,774 shares of common
stock. In addition, Mr. Samuel D. Isaly is the owner of a
controlling interest in both OrbiMed Advisors LLC and
OrbiMed Capital GP III LLC. Thus, OrbiMed Advisors LLC, OrbiMed
Capital GP III LLC and Mr. Isaly may be deemed directly or
indirectly, including by reason of their mutual affiliation, to
be the beneficial owners of 6,666,667 shares of common
stock, including shares issuable upon exercise of warrants. |
|
(4) |
|
This information is as of June 12, 2008 and consists of
shares of common stock held by mutual funds and other client
accounts for which Massachusetts Financial Services Company,
d/b/a MFS Investment Management, or a subsidiary of
Massachusetts Financial Services Company (collectively,
MFS) act as investment adviser. As investment
adviser, MFS has sole voting and investment power over all of
the shares beneficially held by these funds and accounts. |
|
(5) |
|
This information is taken from a Schedule 13G filed on
June 12, 2008 by Deerfield Management Co. and its
affiliated entities (Deerfield) and is as of
June 5, 2008. As of June 5, 2008, the Deerfield
entities beneficially owned, either directly or indirectly an
aggregate of 1,947,436 shares of common stock, consisting
of (i) 923,651 shares beneficially owned by Deerfield
Capital, L.P., (ii) 437,709 shares beneficially owned
by Deerfield Partners, L.P., (iii) 485,942 shares
beneficially owned by Deerfield Special Situations Fund, L.P.,
(iv) 1,659,377 shares beneficially owned by Deerfield
Management Company, L.P., (v) 764,787 shares
beneficially owned by Deerfield International Limited,
(vi) 894,590 shares beneficially owned by Deerfield
Special Situations International Limited. In addition,
Mr. James E. Flynn holds controlling interests in all
Deerfield entities and may be deemed to beneficially own
2,583,028 shares of common stock. |
|
(6) |
|
This information is taken from a Schedule 13G/A filed on
February 1, 2008 by Atlas Venture jointly with its
affiliates and is as of December 31, 2007. Atlas Venture
Fund III, L.P., or Atlas III, is the record holder of
497,232 shares of Common Stock as of December 31,
2007, referred to as the Atlas III Shares. Atlas Venture
Entrepreneurs Fund III, L.P., or AVE III, is the
record holder of 10,807 shares of Common Stock as of
December 31, 2007, referred to as the AVE III Shares. Atlas
Venture Fund V, L.P., or Atlas V, is the record holder
of 1,379,180 shares of Common Stock as of December 31,
2007, referred to as the Atlas V Shares. Atlas Venture
Entrepreneurs Fund V, L.P., or AVE V, is the
record holder of 18,389 shares of Common Stock as of
December 31, 2007, referred to as the AVE V Shares. By
virtue of their relationship as affiliated limited partnerships,
each Fund may be deemed to share the power to direct the
disposition of and vote the Atlas III Shares, the AVE III
Shares, the Atlas V Shares and the AVE V Shares, for an
aggregate of 1,905,608 shares of Common Stock, or the
Record Shares. As general partner of the Funds, and by virtue of
the Funds relationship as affiliated limited partnerships, each
of Atlas Venture Associates III, L.P., or AVA III, and Atlas
Venture Associates V, L.P., or AVA V, may also be
deemed to beneficially own the Record Shares. As the general
partner of AVA III and AVA V, respectively, Atlas Venture
Associates III, Inc., or AVA III Inc., and Atlas Venture
Associates V, Inc., or AVA V Inc., may also be deemed to
beneficially own the Record Shares. In their capacities as
directors of AVA III Inc. and AVA V Inc., each of
Messrs. Axel Bichara, Jean-Francois Formela and Christopher
Spray may be deemed to beneficially own the Record Shares. |
7
|
|
|
(7) |
|
David Utterberg, a 5% stockholder, is also a member of our Board
of Directors. |
|
(8) |
|
The number of shares of our common stock that each person is
deemed to beneficially own includes the number of shares of our
common stock which such person has the right to acquire upon
exercise of outstanding stock options as set forth opposite his
or her name: |
|
|
|
|
|
Name
|
|
Shares
|
|
|
Jeffrey H. Burbank
|
|
|
437,182
|
|
Philippe O. Chambon
|
|
|
54,000
|
|
Daniel A. Giannini
|
|
|
57,000
|
|
Reid S. Perper
|
|
|
54,000
|
|
Peter P. Phildius
|
|
|
109,913
|
|
David S. Utterberg
|
|
|
55,497
|
|
Craig W. Moore
|
|
|
72,791
|
|
Robert S. Brown
|
|
|
95,333
|
|
Winifred L. Swan
|
|
|
116,666
|
|
Joseph E. Turk, Jr.
|
|
|
117,298
|
|
Michael J. Webb
|
|
|
120,267
|
|
Augustin Azel
|
|
|
24,959
|
|
|
|
|
(9) |
|
Includes 5,913,192 shares held by various Sprout Entities.
Dr. Chambon is a managing director of New Leaf Venture
Partners, L.L.C, or NLVP, and is a limited partner of DLJ
Associates IX, L.P., which is a general partner of Sprout
Capital IX, L.P. NLVP has entered into a sub-management
agreement with DLJ Capital Corporation, or DLJCC, whereby NLVP
and its principals, including Dr. Chambon, provide DLJCC
with investment management services on the investments held by
various of the Sprout venture capital funds, including
(i) 2,359,547 shares of common stock held directly by
Sprout Capital IX, L.P., (ii) 2,108,034 shares of
common stock held directly by Sprout Capital VIII, L.P.,
(iii) 830,437 shares of common stock held directly by
Sprout Capital VII, L.P., (iv) 9,666 shares of common
stock held directly by Sprout CEO Fund, L.P.,
(v) 9,402 shares of common stock directly by Sprout
Entrepreneurs Fund, L.P., (vi) 112,061 shares of
common stock held directly by Sprout IX Plan Investors, L.P.,
(vii) 47,203 shares of common stock held directly by
Sprout Plan Investors, L.P., (viii) 126,517 shares of
common stock held directly by Sprout Venture Capital, L.P.,
(ix) 135,480 shares of common stock held directly by
DLJ ESC II, L.P., and (x) 174,845 shares of common
stock held directly by DLJCC. Dr. Chambon expressly
disclaims beneficial ownership of these shares except to the
extent of his pecuniary interest therein. |
|
(10) |
|
Includes 1,276,112 shares held by Healthcare Investment
Partners Holdings LLC, of which Mr. Perper is a Managing
Director. Mr. Perper disclaims beneficial ownership of
these shares except to the extent of his proportionate pecuniary
interest in such shares. |
|
(11) |
|
Includes an aggregate of 1,314,906 shares of our common
stock which all executive officers and directors have the right
to acquire upon exercise of outstanding stock options. |
8
PROPOSAL:
APPROVAL
OF TERMS OF SECOND CLOSING OF PRIVATE PLACEMENT
Background
of the Private Placement
In early 2008, our management and Board of Directors determined
that we needed to secure additional working capital to fund our
capital requirements. A finance committee of the Board of
Directors was formed in March 2008 to help evaluate financing
alternatives. Dr. Philippe O. Chambon and
Messrs. Jeffrey H. Burbank, Reid S. Perper and
Daniel A. Giannini served on the committee. The finance
committee, working together with our management and our full
Board of Directors, undertook extensive efforts to identify and
evaluate different strategic alternatives, including various
forms of private debt and equity financings. Based on our stock
price and the state of the medical device capital market, our
management and Board of Directors concluded that it was unlikely
that we would attract sufficient interest among public investors
and that a private placement of our publicly-traded common stock
(commonly referred to as a PIPE financing),
targeting private venture capital investors and other
institutional investors, had a higher likelihood of success.
During the week of May 12, 2008, our senior management had
discussions with potential unaffiliated investors, including the
First Closing Investors, regarding the possibility of a private
placement. On May 16, 2008, our finance committee and the
full Board each held telephonic meetings to discuss the proposed
private placement. At the Board meeting, the full Board
expressly authorized our senior management to negotiate with the
First Closing Investors. During this meeting, the Board and
senior management discussed the possibility that the Affiliated
Investors would participate in the private placement, on terms
identical to those negotiated with the unaffiliated investors.
The Audit Committee of the Board (comprised of Messrs. Daniel A.
Giannini, Craig W. Moore and Reid S. Perper, none of
whom intended to or did invest in the private placement) met on
May 19, 2008 to review and discuss the participation of the
Affiliated Investors in the private placement. The Audit
Committee followed the terms of the Companys Related
Person Transaction Policy in reviewing and evaluating the
proposed transaction. The full Board also met on May 19,
2008 and reviewed the terms of the transaction. On May 19,
2008, we reached tentative agreement with the First Closing
Investors to pursue a private placement.
Also on May 19, 2008, we engaged an investment bank,
Canaccord Adams Inc. (Canaccord) to serve as the
placement agent and advisor in the private placement. Canaccord
contacted 18 potential investors, including the Affiliated
Investors, on behalf of NxStage. During this period, we
continued to negotiate the terms of the private placement with
the First Closing Investors.
On May 21, 2008, our Audit Committee held a telephonic
meeting to consider the private placement and the participation
of the Affiliated Investors in the private placement. After
extensive discussion of the terms and conditions among Audit
Committee members and with our senior management and advisors,
the Audit Committee approved the private placement and
recommended to the Board that it also approve the private
placement. On May 21, 2008, the Audit Committee of the
Board and the Board each held an additional telephonic meeting
to discuss and finalize changes in the terms of the private
placement, including the final size of the private placement and
certain warrant terms. The Audit Committee of the Board and the
Board, with all of the members in attendance and voting,
unanimously approved the terms and conditions of the transaction.
On May 22, 2008, we entered into Securities Purchase
Agreements with all of the investors, pursuant to which we
agreed to sell to those investors an aggregate of
9,555,556 shares of our common stock at $4.50 per share and
warrants exercisable for 1,911,111 shares of our common
stock at an initial exercise price of $5.50 per share (subject
to potential adjustment to $3.00 or $6.50 per share, as
described below). To ensure that stockholder approval would not
be required at the First Closing, we did not allow any
Affiliated Investors to participate in the First Closing and
required that the aggregate number of shares of common stock and
warrants to purchase our common stock that were purchased in the
First Closing did not exceed 20% of our issued and outstanding
shares immediately prior to the First Closing.
9
A form of the Securities Purchase Agreement and a form of
Warrant are provided for your reference as Annexes A
and B, respectively, to this Proxy Statement and were
also included as exhibits to our
Form 8-K
filed on May 23, 2008.
On May 22, 2008, we also entered into Voting Agreements
with the Affiliated Investors, in their capacities as current
stockholders of NxStage, pursuant to which each of the
Affiliated Investors agreed to vote in favor of the Proposal at
the Special Meeting and granted to us an irrevocable proxy to
vote all of the outstanding shares of NxStage stock owned
beneficially by it, him or her in favor of the Proposal. A form
of the Voting Agreement is provided for your reference as
Annex C to this Proxy Statement and was also
included as an exhibit to our
Form 8-K
filed on May 23, 2008. As discussed above, we entered into
a Voting Agreement with each of the Affiliated Investors, who as
of June 24, 2008 beneficially owned approximately
12 million shares of our common stock, or approximately 29%
of our outstanding shares of our common stock and approximately
33% of the outstanding shares of our common stock that may be
permitted to be counted under the NASDAQ Marketplace Rules for
the Proposal.
The First Closing took place on May 28, 2008, and we
currently plan to complete the Second Closing on August 1,
2008, one business day after we receive stockholder approval of
the Proposal. Assuming the Second Closing occurs, NxStage will
receive approximately $43 million in total proceeds, net of
fees and our expenses, from the First and Second Closings of the
private placement, and an additional $10.5 million in
aggregate proceeds if and when all warrants issued to the
investors in the two closings are exercised in full and for cash
(assuming an exercise price of $5.50 and no net exercise of
warrants, as described below under the heading Terms of
the Private Placement).
The following table sets forth, for the periods indicated, the
high and low sales prices per share of our common stock as
reported on the NASDAQ Global Market.
|
|
|
|
|
|
|
|
|
|
|
High
|
|
|
Low
|
|
|
2008
|
|
|
|
|
|
|
|
|
First Quarter
|
|
$
|
15.23
|
|
|
$
|
3.61
|
|
Second Quarter (through June 23, 2008)
|
|
$
|
6.83
|
|
|
$
|
4.38
|
|
2007
|
|
|
|
|
|
|
|
|
First Quarter
|
|
$
|
14.16
|
|
|
$
|
8.04
|
|
Second Quarter
|
|
$
|
14.28
|
|
|
$
|
11.53
|
|
Third Quarter
|
|
$
|
14.92
|
|
|
$
|
12.00
|
|
Fourth Quarter
|
|
$
|
15.35
|
|
|
$
|
11.89
|
|
2006
|
|
|
|
|
|
|
|
|
First Quarter
|
|
$
|
15.17
|
|
|
$
|
11.50
|
|
Second Quarter
|
|
$
|
13.33
|
|
|
$
|
8.33
|
|
Third Quarter
|
|
$
|
10.18
|
|
|
$
|
6.86
|
|
Fourth Quarter
|
|
$
|
9.80
|
|
|
$
|
7.29
|
|
Under the heading Terms of the Private Placement
below, we discuss the terms of the private placement, including
the Second Closing. We also discuss the material factors
considered by our Board of Directors in determining to proceed
with the two closings of the private placement and recommend the
approval of the Second Closing by our stockholders under the
heading Reasons for the Private Placement Including the
Second Closing below.
Reasons
for the Private Placement Including the Second
Closing
In reaching their unanimous decision to approve the private
placement, including the Second Closing, and in determining that
the private placement is fair to, and in the best interests of,
NxStage and its stockholders, the Audit Committee and our Board
of Directors carefully considered a number of factors and
consulted with NxStages senior management as well as
outside advisors. In view of the complexity and wide variety of
information and factors considered in connection with its
evaluation of the private placement, including the
10
necessity of the Second Closing, the Audit Committee and the
Board of Directors did not find it practicable to and did not
quantify or otherwise assign relative or specific weights to the
factors it considered in reaching its determination. Instead,
the material factors and the advantages and disadvantages of the
private placement, including the Second Closing, considered by
the Audit Committee and the Board are set forth below:
|
|
|
|
|
NxStage believes that the home hemodialysis market is our
largest market opportunity. In this market, a significant
percentage of our home customers rent rather than purchase our
System One equipment. As a result, we generate, and expect to
continue generating in the future, a significant percentage of
our revenues and cash flow from the use of System One equipment
over time rather than upfront from the sale of System One
equipment. This sales model requires significant amounts of
working capital to manufacture System One equipment for rental
to dialysis clinics. We have also not yet achieved
profitability, which imposes additional requirements for cash.
|
|
|
|
Our ability to raise funds depends on many factors, including,
among others, the growth of our product sales, improvements in
our product gross margins, leverage in our operating expenses,
and cost and availability of third-party financing. Many of
these factors are subject to significant uncertainty.
|
|
|
|
In order to secure additional working capital for NxStage to
improve our financial condition and our ability to fund ongoing
operations, our management and Board of Directors have
undertaken extensive efforts to identify and evaluate different
strategic alternatives, including various forms of private debt
and equity financings. Based on our stock price and the state of
the medical device capital market, our management and Board of
Directors agreed, after extensive discussions, that it was
unlikely that we would attract sufficient interest among public
investors in a public offering and that a private placement,
structured as a PIPE transaction, targeting private venture
capital investors and other institutional investors, had a
higher likelihood of success.
|
|
|
|
In determining the size of the private placement and the
necessity of the Second Closing, the Board also considered the
possibility of raising a lower amount of interim financing so as
to reduce the dilution on our current stockholders, but given
the volatility of the market price of our common stock and the
uncertain economic climate, it was determined to be a less
attractive alternative as there could be no assurance that we
would be able to obtain sufficient additional financing on
attractive terms in a timely fashion.
|
|
|
|
Furthermore, in determining the size of the private placement
for both closings, the Board weighted the fact that this private
placement would result in additional dilution to our
stockholders versus the fact that the $43 million would
allow us to fund our capital needs more fully. The section under
the heading Proposal Dilutive Effect
below provides more detailed analysis of the dilution to our
stockholders from the private placement, including the Second
Closing.
|
The Board also evaluated certain additional obligations that
NxStage will agree to in order to complete the private placement
and subsequent consequences, including:
|
|
|
|
|
The obligation to file and maintain a registration statement for
resale by the investors of the shares issued and sold to the
investors in the private placement (including the shares
issuable upon exercise of the warrants), which obligation exists
even if we consummate only the First Closing, and (2) the
potential liquidated damages NxStage would be subjected to if
such registration obligation is not met on a timely basis (see
the section under the heading Terms of the Private
Placement Terms of the Security Purchase Agreement
Applicable to the Second Closing - Registration Obligations and
Liquidated Damages below);
|
|
|
|
Once the shares covered by the registration statements become
freely tradeable without restriction, their transferability
could potentially reduce the market price of our common stock
significantly; and
|
|
|
|
Upon the announcement of NxStages earnings for the fourth
quarter and year ended December 31, 2008, the exercise
price of the warrants shall be adjusted automatically to either
$3.00 per share or $6.50 per share, depending upon whether
NxStage achieves certain targets relating to the number of
end-stage renal disease, or ESRD, patients prescribed to receive
therapy with the NxStage System One
|
11
|
|
|
|
|
as of December 31, 2008 (see the section under the heading
Terms of the Private Placement Terms of the
Warrants Exercise Price, Adjustment to Exercise
Price and Number of Shares below).
|
After a thorough analysis of the advantages and disadvantages of
the private placement and an extensive discussion of the terms
and conditions, including the necessity of the Second Closing,
the Board of Directors determined that the importance of the
timely and sufficient amount of capital provided by the two
closings outweighed the actual or potential adverse impact on
our Company or our common stock, and therefore the terms and
conditions of the private placement are favorable to our Company
given market conditions and the condition of our business.
Terms of
the Private Placement
On May 28, 2008, we held the First Closing, consisting of
the issuance and sale of 5,555,556 shares of common stock
at $4.50 per share for an aggregate purchase price of
approximately $25 million and warrants exercisable for
1,111,111 shares of common stock at an initial exercise
price of $5.50 per share (subject to potential adjustments to
$3.00 or $6.50 per share based upon performance targets) for an
aggregate exercise price of approximately $6.1 million if
exercised in full and for cash (assuming an exercise price of
$5.50 and no net exercise, as described below). We are
requesting in the Proposal that the stockholders approve the
sale and issuance by NxStage, in the Second Closing, of
4,000,000 shares of common stock at $4.50 per share for an
aggregate purchase price of approximately $18 million and
warrants exercisable for 800,000 shares of common stock at
an initial exercise price of $5.50 per share (subject to
potential adjustments to $3.00 or $6.50 per share based upon
performance targets) for an aggregate exercise price of
approximately $4.4 million if exercised in full and for
cash (assuming an exercise price of $5.50 and no net exercise,
as described below). The sale of common stock and warrants in
the private placement is intended to be exempt from the
registration requirements of the Securities Act of 1933, as
amended (the Securities Act), and we expect to rely
upon Section 4(2) of the Securities Act or the
Regulation D safe harbor provisions. This
Second Closing is subject to the fulfillment of conditions that
we describe below. We have set forth below the major terms of
the private placement.
THIS SUMMARY OF THE TERMS OF THE PRIVATE PLACEMENT IS
INTENDED TO PROVIDE YOU WITH BASIC INFORMATION CONCERNING THE
TRANSACTION; HOWEVER, IT IS NOT A SUBSTITUTE FOR REVIEWING THE
FORM OF SECURITIES PURCHASE AGREEMENT, THE FORM OF THE
WARRANT AND THE FORM OF THE VOTING AGREEMENT IN THEIR
ENTIRETY, WHICH WE HAVE INCLUDED AS ANNEXES A,
B, AND C, RESPECTIVELY, TO THIS PROXY STATEMENT.
YOU SHOULD READ THIS SUMMARY IN CONJUNCTION WITH THE
AGREEMENT.
Terms
of the Securities Purchase Agreements Applicable to the Second
Closing
Securities to be Issued to Investors upon Second
Closing. At the Second Closing, we will issue and
sell 4,000,000 shares of common stock at $4.50 per share
for an aggregate purchase price of approximately
$18 million along with five-year warrants exercisable for
800,000 shares of common stock at $5.50 per share (subject
to customary anti-dilution and other adjustments described
below) for an aggregate exercise price of approximately
$4.4 million (assuming no net exercise, as described
below). The warrants may be exercised at any time from grant
date through the earlier of (i) five years from the grant
date or (ii) the consummation of a change of control event.
We currently expect the Second Closing to take place on
August 1, 2008, one business day following the Special
Meeting.
Registration Obligations and Liquidated
Damages. No later than the earlier (the
Filing Date) of 30 days after the Second
Closing and 120 days after the First Closing, we are
required, at our expense, to file with the SEC a registration
statement with respect to the resale of the shares of common
stock (A) issued at both the First Closing and the Second
Closing of the private placement, and (B) issuable upon
exercise of the warrants issued at both the First Closing and
the Second Closing. We are required to use reasonable commercial
efforts to have such registration statement declared effective
by the SEC prior to the date which is 120 days after the
Second Closing, or if the Second Closing does not occur within
120 days after the First
12
Closing, the later (the Required Effective Date) of
(i) 180 days after the First Closing and
(ii) 90 days after the receipt of all necessary
information from the investors in the First Closing, and subject
to our right to suspend the resale of stock under the
registration statement in certain circumstances, we are required
to maintain the effectiveness of this registration statement
until the earlier of (a) the date on which the investors
may sell all shares (including shares issuable upon exercise of
the warrants) then held by the investors without restriction by
the volume limitations of Rule 144 of the Securities Act or
(b) such time as all of those shares (including shares
issued upon exercise of those warrants) have been sold. If the
registration statement (a) is not filed by the Required
Effective Date, or (b) once effective, ceases to be
effective and available to investors in the private placement
for any continuous period that exceeds 30 days in any
365 day period, NxStage is required to pay the investors in
the private placement a cash payment as liquidated damages and
not as a penalty. This cash payment is calculated as 1% of the
aggregate purchase price paid by the investors in the private
placement then held by the investors that have not been sold
under a registration statement or pursuant to Rule 144 for
each 30 day period. The liquidated damages apply on a pro
rata basis for any portion of such a
30-day
period.
Board Representation. NxStage has agreed that,
upon the earlier of the Second Closing or 60 days after the
First Closing, the Company shall appoint one individual
nominated by the First Closing Investors to the vacant seat on
the Companys Board.
Indemnification. NxStage has granted the
investors in the private placement customary indemnification
rights in connection with the registration statement. The
investors have also granted NxStage customary indemnification
rights in connection with the registration statement.
Terms
of the Warrants
Exercise Period. The warrants are exercisable
from the grant date through the earlier of (i) five years
from the grant date or (ii) the consummation of a change of
control event.
Methods of Exercise. The warrants may be
exercised in cash at all times during the exercise period,
whereby the holders of the warrants deliver the certificates
representing the warrants to NxStage and the then-applicable
exercise price for the warrants in exchange for the shares
issuable thereunder. In addition, the warrants may be net
exercised at any time through the exercise period of the
warrants. The net exercise provision allows the holder to
receive shares of common stock equal to the value of the warrant
without paying the exercise price in cash, but rather with the
shares underlying the warrant.
Exercise Price, Adjustment to Exercise Price and Number of
Shares. The exercise price of the warrants is
initially $5.50 per share. Upon the announcement of
NxStages earnings for the fourth quarter and year ended
December 31, 2008, the exercise price shall be adjusted
automatically to either $3.00 per share or $6.50 per share,
depending upon whether NxStage achieves certain targets relating
to the number of ESRD patients prescribed to receive therapy
with the NxStage System One as of December 31, 2008. In
addition, the exercise price and the number of shares issuable
under the warrants are subject to customary adjustment in
certain events, including reclassification of NxStages
securities, certain mergers, consolidations, sales of
substantially all of the assets of NxStage, subdivision or
combination of shares of NxStage, stock dividends and other
distributions of NxStage. In addition, upon a change of control
event, NxStage shall pay to the holders of the warrants amounts
calculated in accordance with the Black-Scholes Option Pricing
formula defined in the warrants.
Registration Rights. The warrants and the
shares of NxStages common stock issuable upon exercise of
the warrants are not registered under the Securities Act or any
state securities laws. NxStage has granted registration rights,
described above, to the investors for the shares of common stock
issuable upon the exercise of the warrants.
Terms
of the Voting Agreements
Each Affiliated Investor has entered into a Voting Agreement
with NxStage, pursuant to which such Affiliated Investor has
agreed, solely in its capacity as a stockholder, to vote all of
its issued and outstanding
13
shares of NxStages common stock in favor of any matter
that could reasonably be expected to facilitate the private
placement investments and has granted to NxStage an irrevocable
proxy to vote all of its issued and outstanding shares of
NxStages common stock in favor of the Second Closing. As
of the Record Date, the Affiliated Investors collectively hold
in the aggregate approximately 12 million shares of our
common stock, or approximately 29% of our outstanding shares of
our common stock and approximately 33% of the outstanding shares
of our common stock that may be permitted to be counted under
the NASDAQ Marketplace Rules for the Proposal.
Restrictions on Transfer of Shares. Pursuant
to the Voting Agreements, each Affiliated Investor has agreed
not to, (a) sell, assign, transfer (including by merger or
otherwise) its shares of NxStages common stock,
(b) deposit any of such shares into a voting trust or enter
into a voting trust or arrangement with respect to such shares
or grant any proxy or power of attorney with respect to such
shares which is inconsistent with the Voting Agreements, or
(c) enter into any contract or other arrangement regarding
the sale assignment or transfer of such shares unless, in each
case, the transferee agrees to be bound by the terms of such
Voting Agreement.
Termination of Voting Agreements. Each Voting
Agreement will terminate upon the earlier to occur of
(a) the Second Closing of the private placement,
(b) the one year anniversary of the date of the Voting
Agreement, or (c) the date that the Securities Purchase
Agreement between NxStage and the First Closing Investors
terminates under its own terms.
Conditions
to Consummating the Second Closing of the Private
Placement
Under the terms of the Securities Purchase Agreements that
govern the private placement, the investors obligation to
consummate the Second Closing of the private placement is
subject to meeting the conditions enumerated in the Securities
Purchase Agreements, including the following major conditions:
|
|
|
|
|
Our stockholders have approved the Proposal in this Proxy
Statement.
|
|
|
|
Each Affiliated Investor has executed and delivered to NxStage a
copy of the Voting Agreement, in the form set forth in the
attachment to the Securities Purchase Agreement, with respect to
the voting of all of such investors shares.
|
|
|
|
Our representations and warranties set forth in the Securities
Purchase Agreements were true and correct in all material
respects as of the date of the Second Closing (or such other
specific date indicated in the Securities Purchase Agreement).
|
|
|
|
No provision of any applicable law or regulation and no
judgment, injunction, order or decree shall prohibit the Second
Closing or shall prohibit or restrict the investor or its
affiliates from owning, voting, or exercising, any of the Shares
or Warrants in accordance with the terms thereof and no lawsuit
shall have been commenced by any court, administrative agency or
commission or other governmental authority or instrumentality,
whether federal, state, local or foreign, or any applicable
industry self-regulatory organization seeking to effect any of
the foregoing.
|
Stockholder
Approval and NASDAQ Marketplace Rules
We are subject to the rules of NASDAQ Marketplace Rules because
our common stock is listed on the NASDAQ Global Market.
Specifically, Rule 4350(i)(1)(D) requires us to obtain
stockholder approval for any issuance or sale of common stock,
or securities convertible into or exercisable for common stock,
that is (i) equal to 20% or more of our outstanding common
stock before such issuance or sale, and (ii) is at a price
per share below the greater of book or market value at the time
of such issuance or sale. Rule 4350(i)(1)(D) apply to the
Second Closing because:
|
|
|
|
|
the purchase price of the common stock we issued and sold at the
First Closing and intend to issue and sell at the Second Closing
will be at $4.50 per share, which is below $4.88 per share, the
closing price of our common stock on NASDAQ on May 21,
2008, the last day our common stock traded on NASDAQ before we
entered into the Securities Purchase Agreements, and
|
14
|
|
|
|
|
the shares of common stock and warrants exercisable for our
common stock that we intend to issue and sell at the Second
Closing, together with the shares issued and sold in the First
Closing, will comprise approximately 31% of the shares of our
common stock outstanding immediately prior to the First Closing
and approximately 25% of the outstanding shares immediately
after the Second Closing.
|
In addition, NASDAQ has taken the position pursuant to
Rule 4350(i)(1)(A) that the issuance and sale of securities
to investors who may be deemed to be affiliated with a director
of the issuer at a discounted price to the market value of the
securities could constitute equity compensation to such director
if such director could be deemed to directly or indirectly hold
any of the securities issued in the transaction, and in which
case such issuance and sale would require stockholder approval.
Certain investors in the Second Closing may be deemed to be
affiliated with one of our directors and therefore the sale and
issuance of shares of our common stock and warrants exercisable
for our common stock to such investors requires stockholder
approval.
Use of
Proceeds
We will receive approximately $43 million in gross proceeds
from the private placement if we successfully complete the
Second Closing. After paying approximately $0.7 million in
fees and expenses of private placement, we intend to use the net
proceeds of approximately $42.3 million to advance further
the commercialization of our products and the development of new
products for our product pipeline. In particular, we anticipate
using the net proceeds for the expansion of sales and marketing
programs, the hiring of additional personnel and investment in
clinical research and product development activities. We also
intend to use the proceeds for general corporate purposes.
Our ability to raise funds in the future will depend on many
factors, as described in more detail under the heading
Proposal Reasons for the Private Placement
Including the Second Closing. If we do not receive the
proceeds from the Second Closing, meeting our capital needs on a
timely basis and on terms acceptable to us will be more
difficult. We may be required to delay, reduce the scope of, or
eliminate one or more aspects of our business, which would
likely harm our business. While we expect the private placement
to provide us with sufficient capital to fund our operations in
the foreseeable future, we may, from time to time, consider
opportunities for additional capital.
Dilutive
Effect
The Second Closing will have a dilutive effect on current
stockholders in that the percentage ownership of current
stockholders will decline as a result of the Second Closing of
the private placement. The number of shares issued pursuant to
the Second Closing will increase the number of shares of common
stock currently outstanding or potentially outstanding upon the
exercise of warrants. This means that our current stockholders
will own a smaller percentage interest in NxStage as a result of
the Second Closing. Immediately prior the First Closing of the
private placement, 36,794,575 shares of our common stock
were outstanding. If the Second Closing occurs, and after giving
effect to the issuances at the First Closing, a total of
9,555,556 shares of common stock will have been issued in
both closings and warrants to purchase a total of
1,911,111 share of common stock will have been issued.
Based on the shares of common stock outstanding immediately
prior to the First Closing, if the Second Closing is completed,
stockholders immediately prior to the First Closing will incur
dilution of 21% (24% if the warrants issued in both closings
were exercised in full and for cash).
For purposes of example only, a stockholder who owned 1% of our
outstanding stock immediately prior to the First Closing would
own approximately 0.79% of the shares outstanding immediately
after the Second Closing (or 0.76% had all the warrants issued
in the First and Second Closings been immediately exercisable,
and were exercised in full and for cash, after the respective
closings).
15
Interests
of Certain Persons in the Second Closing
Some of the investors in the Second Closing are Affiliated
Investors, which means they may be deemed to be affiliated with
one of our directors or they hold more than 5% of NxStages
outstanding shares of common stock immediately prior to the
entry into the share purchase agreements in connection with the
private placement. The following table sets forth the beneficial
ownership of each Affiliated Investor in our common stock
immediately prior to the Second Closing, the number of shares
and warrants that such Affiliated Investor has agreed to
purchase in the Second Closing, and the beneficial ownership of
such Affiliated Investor immediately following the Second
Closing:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Beneficial Ownership(1)
|
|
|
|
|
|
|
|
|
|
Warrant
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares
|
|
|
|
|
|
Percentage
|
|
|
|
|
|
|
|
|
|
to be
|
|
|
|
|
|
of Shares
|
|
|
|
|
|
|
Shares to be
|
|
|
Issued in
|
|
|
Shares
|
|
|
Outstanding
|
|
|
|
Prior to
|
|
|
Issued in
|
|
|
Second
|
|
|
after
|
|
|
after
|
|
Affiliated Investors in the
|
|
Second
|
|
|
Second
|
|
|
Closing
|
|
|
Second
|
|
|
Second
|
|
Second Closing(1)
|
|
Closing
|
|
|
Closing
|
|
|
(2)
|
|
|
Closing
|
|
|
Closing(3)
|
|
|
Credit Suisse (Sprout Entities)(4)
|
|
|
6,185,874
|
(5)
|
|
|
1,022,221
|
(6)
|
|
|
204,445
|
|
|
|
7,208,095
|
|
|
|
15.6
|
%
|
Eleven Madison Avenue
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7,412,540
|
)
|
|
|
(16.0
|
)%
|
New York, New York 10010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Massachusetts Financial Services Company
|
|
|
3,424,930
|
(7)
|
|
|
444,444
|
(8)
|
|
|
88,889
|
|
|
|
3,869,374
|
|
|
|
8.3
|
%
|
500 Boylston Street
Boston, MA 02116
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3,958,263
|
)
|
|
|
(8.5
|
)%
|
Deerfield Management Co.
|
|
|
2,583,028
|
(9)
|
|
|
1,255,556
|
(10)
|
|
|
251,111
|
|
|
|
3,838,584
|
|
|
|
8.3
|
%
|
780 Third Avenue, 37th Floor
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(4,089,695
|
)
|
|
|
(8.8
|
)%
|
New York, NY 10017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Beneficial ownership is computed on the same basis as that in
the table beginning on page 5, except as noted in footnote
(2) below. Ownership in parenthetical under Shares
After Second Closing assumes the full exercise of
warrants, which is shown here solely for purpose of illustration
and does not indicate beneficial ownership of all such shares
under the SEC rules for calculating beneficial ownerships, which
are referred to on page 5 under the heading Security
Ownership of Certain Beneficial Owners and Management. |
|
(2) |
|
Refers to shares issuable upon exercise of warrants in the
Second Closing, which equal 20% of the shares to be acquired by
the investor in the Second Closing and are exercisable from
grant date through the earlier of (i) five years from the
grant date or (ii) the consummation of a change of control
event. |
|
(3) |
|
Based on 46,350,131 shares outstanding immediately after
the Second Closing, including all of the 5,555,556 shares
issue in the First Closing and 4,000,000 shares expected to
be issued in the Second Closing. |
|
(4) |
|
See details in footnote (2) to the table beginning on
page 6. |
|
(5) |
|
See details in footnote (9) to the table beginning on
page 6 for the relationship between the Sprout Entities and
Dr. Philippe O. Chambon, Chairman of NxStages Board
of Directors. |
|
(6) |
|
Includes 143,868 shares to be purchased by Sprout Capital
VII, L.P., 365,202 shares to be directly purchased by
Sprout Capital VIII, L.P., 408,776 shares to be directly
purchased by Sprout Capital IX, L.P., 1,674 shares to be
directly purchased by Sprout CEO Fund, L.P., 1,628 shares
to be directly purchased by Sprout Entrepreneurs Fund, L.P.,
21,918 shares to be directly purchased by Sprout Venture
Capital, L.P., 19,413 shares to be directly purchased by
Sprout IX Plan Investors, L.P., 8,177 shares to be directly
purchased by Sprout Plan Investors, L.P., 23,470 shares to
be directly purchased by DLJ ESC II, L.P. and 28,096 shares
to be directly purchased by DLJ Capital Corporation. |
|
(7) |
|
See details in footnote (4) to the table beginning on
page 6. |
|
(8) |
|
Includes 33,830 shares to be directly purchased by MFS
Variable Insurance Trust, on behalf of one of its series, MFS
Core Equity Series (VVSK), 68,214 shares to be directly
purchased by MFS Variable |
16
|
|
|
|
|
Insurance Trust II, on behalf of one of its series, MFS
Core Equity Portfolio (RGS), and 342,400 shares to be
directly purchased by MFS Series Trust I, on behalf of
one of its series, MFS Core Equity Fund (RGI). |
|
(9) |
|
See details in footnote (5) to the table beginning on
page 6. |
|
(10) |
|
Includes 525,577 shares to be directly purchased by
Deerfield Special Situations Fund International Limited,
285,513 shares to be directly purchased by Deerfield
Special Situations Fund, L.P., 274,213 shares to be
directly purchased by Deerfield Private Design International,
LP, and 170,253 shares to be directly purchased by
Deerfield Private Design Fund, LP. |
Pursuant to the terms of the Securities Purchase Agreements and
in connection with our issuance of shares of our common stock
and warrants to the OrbiMed Advisors LLC in the First Closing,
we have agreed to appoint a nominee of OrbiMed Advisors to the
vacant seat on our Board upon the earlier of the Second Closing
or 60 days after the First Closing. The person we have
agreed to appoint to our Board will have an interest in the
outcome of the vote on the Proposal.
Recommendation
of the Board of Directors
The Board of Directors unanimously recommends that the
stockholders vote FOR the approval of the issuance and sale of
4,000,000 shares of our common stock, at $4.50 per share,
and warrants exercisable for 800,000 shares of our common
stock, at an initial exercise price of $5.50 per share, to
certain investors, including investors who are affiliates,
either directly or through affiliates, of NxStage, among them a
member of our Board of Directors, in exchange for aggregate
gross proceeds NxStage of $18 million at the Second Closing
of our private placement of securities.
OTHER
MATTERS
NxStage knows of no other matters that will be presented for
consideration at the Special Meeting. Our Board of Directors
does not currently intend to bring any other business before the
Special Meeting and, so far as our Board of Directors knows, no
other matters are to be brought before the Special Meeting. If
other business properly comes before the Special Meeting, the
proxies will vote in accordance with their own judgment.
WHERE YOU
CAN FIND ADDITIONAL INFORMATION
The SEC allows us to incorporate by reference
information into this Proxy Statement, which means that we can
disclose important information to you by referring you to
another document that we filed separately with the SEC. The
information incorporated by reference is considered a part of
this Proxy Statement, and all information appearing in this
Proxy Statement is qualified in its entirety by the information
incorporated herein by reference. Information in this Proxy
Statement updates and, in some cases, supersedes information
incorporated by reference from documents that NxStage has filed
with the SEC prior to the date of this Proxy Statement, while
information that we file later with the SEC will automatically
supplement, update and, in some cases, supersede the information
in this Proxy Statement.
The following documents and information we previously filed with
the SEC are incorporated by reference into this Proxy Statement:
|
|
|
|
|
our Annual Report filed on
Form 10-K
for the fiscal year ended December 31, 2007 filed with the
SEC on March 7, 2008;
|
|
|
|
our Quarterly Report filed on
Form 10-Q
for the quarterly period ended March 31, 2008 filed with
the SEC on May 12, 2008; and
|
|
|
|
our Current Reports on
Form 8-K
filed with the SEC on April 2, 2008, May 8, 2008 and
May 23, 2008.
|
17
In addition, all documents we file under Section 13(a),
13(c), 14 or 15(d) of the Exchange Act after the date of this
Proxy Statement and before the date of the Special Meeting are
incorporated by reference into and deemed a part of this Proxy
Statement from the date of filing of those documents.
Documents incorporated by reference are available from us
without charge, excluding all exhibits unless we have
specifically incorporated by reference an exhibit in this Proxy
Statement. You may obtain documents that we have filed with the
SEC and incorporated by reference in this document, without
charge, by making an oral or written request to NxStage Medical,
Inc., 439 South Union Street, 5th Floor,
Lawrence, Massachusetts 01843, Telephone:
(978) 687-4700,
Attention: Investor Relations.
In addition, you may read and copy any reports, statements or
other information that NxStage files with the SEC at the
SECs public reference Room, 450 Fifth Street, N.W.,
Room 1024, Washington, D.C. 20549. Please call the SEC
at
1-800-SEC-0330
for further information on the public reference room. These SEC
filings are also available to the public from commercial
document retrieval services and at the website maintained by the
SEC at
http://www.sec.gov.
You should rely only on the information contained (or
incorporated by reference) in this Proxy Statement. We have not
authorized anyone to provide you with information that is
different from what is contained in this Proxy Statement. This
Proxy Statement is dated July 8, 2008. You should not
assume that the information contained in this Proxy Statement is
accurate as of any date other than that date (or as of an
earlier date if so indicated in this Proxy Statement).
THE BOARD OF DIRECTORS
Lawrence, Massachusetts
July 8, 2008
18
Annex A
FORM OF
SHARE PURCHASE AGREEMENT
NXSTAGE
MEDICAL, INC.
SECURITIES
PURCHASE AGREEMENT
THIS SECURITIES PURCHASE AGREEMENT (this
Agreement) is made as of the 22nd day of
May, 2008, by and between NxStage Medical, Inc., a corporation
organized under the laws of the State of Delaware (the
Company), with its principal offices at
439 S. Union Street, 5th Floor, Lawrence, MA, and
each of the Investors whose name and address is set forth on the
signature page hereof (each, an Investor).
RECITALS
A. The Company has authorized the sale and issuance of up
to 9,555,556 shares (the Shares) of the
Companys common stock, par value $0.001 per share (the
Common Stock) and warrants (the
Warrants) to purchase 1,911,111 shares
of the Companys Common Stock (the Warrant
Shares) to certain investors in a private placement
(the Offering).
B. The Company and the Investors agree that the Investors
whose names appear on the signature pages hereto will purchase
from the Company and the Company will issue and sell to the
Investors in
aggregate Shares
and a Warrant to
purchase Warrant
Shares, for a purchase price of $4.50 per share, or an
aggregate purchase price of $ , in
the amounts set forth opposite their respective names on the
signature pages hereto and upon the terms and conditions set
forth in this Agreement. In addition, the Other Investors (as
defined below) may purchase up to 4,000,000 additional Shares
and Warrants to purchase up to 800,000 additional Warrant
Shares, for a purchase price of $4.50 per share, or an aggregate
purchase price of up to $18,000,000. Unless otherwise requested
by an Investor, the Warrants and certificates representing such
Shares purchased by any Investor will be registered in the
Investors name and address as set forth below. The
Warrants shall have the rights, preferences, privileges and
restrictions as set forth in the form of Warrant attached as
Exhibit A.
C. The Company and each of the Investors are executing and
delivering this Agreement in reliance upon the exemption from
securities regulation afforded by Section 4(2) of the
Securities Act (as defined in Section 3), and Rule 506
under Regulation D.
IN CONSIDERATION of the premises and mutual covenants contained
in this Agreement and other good and valuable consideration the
receipt and sufficiency of which are hereby acknowledged, the
Company and the Investor agree as follows:
Section 1. Authorization
and Sale of the Shares and Warrants. Subject
to the terms and conditions of this Agreement, the Company has
authorized the sale of up to 9,555,556 Shares and Warrants
to purchase up to 1,911,111 Warrant Shares.
Section 2. Agreement
to Sell and Purchase the Shares and Warrants; Subscription
Date.
2.1 At the Closing (as defined in Section 3), the
Company will sell to the Investors and each Investor will buy
from the Company, upon the terms and conditions hereinafter set
forth, the number of Shares and Warrants to purchase the number
of Warrant Shares set forth opposite such Investors name
on the signature pages hereto.
2.2 With respect to all other sales of Shares and Warrants
in the Offering, the Company will enter into the same form of
Securities Purchase Agreement, on substantially the same terms
as this Agreement (and in any event on terms no more favorable
to such other purchasers), with the purchasers of such other
Shares and Warrants (the Other Investors).
The initial Investors party hereto and the Other Investors are
hereinafter sometimes collectively referred to as the
Investors or individually as the
Investor, and this Agreement and the
agreements executed by the Other Investors are hereinafter
sometimes collectively referred to as the
A-1
Agreements. The Company may accept executed
Agreements from Other Investors for the purchase of Shares and
Warrants commencing upon the date on which the Company provides
the Investors with the proposed purchase price per Share and
concluding upon the date (the Subscription
Date) on which the Company has executed Agreements
with Investors for the purchase of up to 9,555,556 Shares
and Warrants to purchase up to 1,911,111 Warrant Shares. The
Company may not enter into any Agreements after the Subscription
Date.
2.3 Notwithstanding any contrary provisions of the
Agreements, the obligations of each Investor under any Agreement
are several and not joint with the obligations of any other
Investor, and no Investor shall be responsible in any way for
the representations and warranties and the performance of the
obligations of any other Investor. Nothing contained herein, and
no action taken by any Investor, shall be deemed to constitute
the Investors as a partnership, an association, a joint venture
or any other kind of entity, or create a presumption that the
Investors are in any way acting in concert or as a group with
respect to such obligations or the transactions contemplated by
the Agreements. Each Investor shall be entitled to protect and
enforce its rights independently, including without limitation
the rights arising out of its Agreement and it shall not be
necessary for any other Investor to be joined as an additional
party in any proceeding for such purpose.
Section 3. Delivery
of the Shares and Warrants at the Closings.
3.1 The completion of the purchase and sale of the Shares
and Warrants by the Investors (the First
Closing) shall occur on May 28, 2008 at the
offices of OMelveny & Myers LLP, 2765 Sand Hill
Road, Menlo Park, California 94025; provided, however, that the
closing (the Second Closing) for the purposes
of (i) any sale of Shares and Warrants to Investors who are
officers or directors of the Company, or their affiliates, or to
Investors who are currently holders of more than 5% of the
Companys outstanding stock (collectively, the
Affiliate Investors) and (ii) any sale
of Shares and Warrants to non-Affiliate Investors other than
OrbiMed shall be subject to such stockholder approval and shall
be the date which is one business day following such stockholder
approval; provided, further, that no Other Investor shall be
included in the First Closing without the consent of OrbiMed
(which consent shall not be unreasonably withheld). The
Investors participating in the Second Closing shall place the
full purchase price for the Shares and Warrants being purchased
by them hereunder in escrow (the Escrow)
pursuant to the terms of the Escrow Agreement (defined below) at
the First Closing. Each of the First Closing and the Second
Closing shall be referred to as a Closing.
The date of the Second Closing shall be referred to as the
Closing Date. Promptly following the
applicable Closing, the Company shall deliver to the Investor
one or more stock certificates representing the number of Shares
and Warrants to purchase the number of Warrant Shares, each as
set forth pursuant to Section B of the Recitals of the
Agreement, each such certificate to be registered in the name of
the Investor or, if so indicated on the signature page of the
Agreement, in the name of a nominee designated by the Investor.
For the avoidance of doubt, for the purpose of the First
Closing, the only Investors are those represented by OrbiMed.
3.2 The Companys obligation to issue and deliver the
Shares and Warrants to the Investors shall be subject to the
following conditions, any one or more of which may be waived by
the Company: (a) receipt by U.S. Bank National
Association (the Escrow Agent) under the
Escrow Agreement to be entered into by and between the Company
and the Escrow Agent (the Escrow Agreement)
of a certified or official bank check or wire transfer of funds
in the full amount of the purchase price for the Shares and
Warrants being purchased hereunder as set forth in
Section B of the Recitals herein; and (b) the accuracy
of the representations and warranties made by the Investors and
the fulfillment of those undertakings of the Investors to be
fulfilled prior to the Closing.
3.3 The Investors obligation to purchase the Shares
and Warrants shall be subject to the following conditions, any
one or more of which may be waived by the Investor in its sole
discretion: (a) each of the Affiliate Investors shall have
executed and delivered to the Company voting agreements
substantially in the form attached as Exhibit C with
respect to the voting of the shares of Common Stock;
(b) the representations and warranties of the Company set
forth herein shall be true and correct in all material respects
(and shall be true and correct in all respects in the case of
any representations and warranties qualified by materiality or
Material Adverse Effect) as of the Closing Date (except for
representations and warranties that speak as of a
A-2
specific date, which representations and warranties shall be
true and correct as of such date); (c) no provision of any
applicable law or regulation and no judgment, injunction, order
or decree shall prohibit the Closing or shall prohibit or
restrict the Investor or its Affiliates from owning, voting, or
exercising, any of the Shares or Warrants in accordance with the
terms thereof and no lawsuit shall have been commenced by any
court, administrative agency or commission or other governmental
authority or instrumentality, whether federal, state, local or
foreign, or any applicable industry self-regulatory organization
(each, a Governmental Entity) seeking to effect any
of the foregoing; and (d) the Investor shall have received
such documents as such Investor shall reasonably have requested,
including, a certificate signed on behalf of the Company by a
senior executive officer certifying to the effect that the
conditions set forth herein have been satisfied and a standard
opinion of the Companys counsel as to the matters set
forth in Section 4.2 and as to exemption from the
registration requirements of the Securities Act of 1933, as
amended (the Securities Act), of the sale of
the Shares and Warrants.
3.4 Form D. No later
than fifteen (15) days after the Closing, the Company shall
file a Form D with respect to the Shares as required under
Regulation D and shall provide a copy thereof to the
Investor promptly after filing.
3.5 Legal Opinion. Prior to
the Closing, OMelveny & Myers LLP, counsel to
the Company, will deliver its legal opinion to the Investors
substantially in the form attached as Exhibit D to
this Agreement. Such opinion shall also state that each of the
Investors may rely thereon as though it were addressed directly
to such Investor.
3.6 Certificate. At the
Closing, the Company will deliver to the Investor a certificate
executed by the chief executive officer, or the chief financial
or accounting officer of the Company, dated the Closing Date, in
form and substance reasonably satisfactory to the Investor, to
the effect that the representations and warranties of the
Company set forth in Section 4 are true and correct in all
material respects (and in all respects with respect to
representations and warranties qualified by materiality or
Material Adverse Effect) as of the Closing Date (except for
representations and warranties made as of a certain date, which
were true and correct in all material respects as of such date),
and the Company has complied in all material respects with all
the agreements and satisfied all the conditions herein on its
part to be performed or satisfied on or prior to such Closing
Date.
3.7 Special Meeting. The
Company shall call a special meeting of its stockholders, as
promptly as practicable following the First Closing, to vote on
proposals and to approve the issuance of shares contemplated by
the Second Closing (the Stockholder
Proposal). The Board of Directors shall unanimously
recommend to the Companys stockholders that such
stockholders vote in favor of the Stockholder Proposal.
Section 4. Representations,
Warranties and Covenants of the
Company. Except as described in or
specifically contemplated by the Companys Exchange Act
Documents, the Company hereby represents and warrants to, and,
as applicable, covenants with, the Investor as follows:
4.1 Organization and
Qualification. The Company is a corporation
duly incorporated, validly existing and in good standing under
the laws of the State of Delaware and the Company is qualified
to do business as a foreign corporation in each jurisdiction in
which qualification is required, except where failure to so
qualify would not reasonably be expected to have a Material
Adverse Effect (as defined in Section 4.18).
4.2 Authorized Capital
Stock. As of March 31, 2008,
(i) the authorized capital stock of the Company consisted
of 100,000,000 shares of Common Stock and
5,000,000 shares of preferred Stock, par value $0.001 per
share, of which 36,794,096 shares of Common Stock and no
shares of Preferred Stock were issued and outstanding;
(ii) outstanding non-qualified options granted by the
Company to purchase 40,622 shares of Common Stock;
(iii) outstanding options and restricted stock granted
pursuant to the Companys 1999 Stock Option and Grant Plan
and 2005 Stock Incentive Plan to purchase a total of
5,276,313 shares of Common Stock; (iv) there were
available for future grant under the Companys stock option
and employee stock purchase plans a total of
1,923,354 shares of Common Stock; and (v) there were
no outstanding warrants to purchase shares of Common Stock. The
issued and outstanding shares of
A-3
the Companys Common Stock have been duly authorized and
validly issued, are fully paid and nonassessable, have been
issued in compliance with all federal and state securities laws
and were not issued in violation of or subject to any preemptive
rights or other rights to subscribe for or purchase securities.
Except for stock options and other awards granted under the
option, award and purchase plans of the Company as described in
or specifically contemplated by the Companys Exchange Act
Documents, the Company does not have outstanding any options to
purchase, or any preemptive rights or other rights to subscribe
for or to purchase, any securities or obligations convertible
into, or any contracts or commitments to issue or sell, shares
of its capital stock or any such options, rights, convertible
securities or obligations.
4.3 Due Authorization, Due Execution, and Valid
Issuance. The Company has all requisite power
and authority to execute, deliver and perform its obligations
under the Agreements and the Warrants, and the Agreements and
the Warrants have been duly authorized and validly executed and
delivered by the Company. The Shares and the Warrants being
purchased by the Investor hereunder and the Warrant Shares
issuable pursuant to the Warrants will, upon issuance and
payment therefor pursuant to the terms hereof and thereof, be
duly authorized, validly issued, fully-paid, nonassessable and
free and clear of all liens. The Company has reserved from its
duly authorized capital stock, the maximum number of shares of
Common Stock and Warrant Shares issuable pursuant to this
Agreement and the Warrants.
4.4 Delivery and Performance of this
Agreement. The execution, delivery and
performance of this Agreement by the Company and the
consummation of the transactions herein contemplated will not
violate any provision of the certificate of incorporation or
bylaws of the Company and will not result in the creation of any
lien, charge, security interest or encumbrance upon any assets
of the Company pursuant to the terms or provisions of, nor will
it conflict with, result in the breach or violation of, or
constitute, either by itself or upon notice or the passage of
time or both, a default under or resulting in the termination
of, or result in the loss of any benefit or creation of any
right on the part of any third party under, or accelerate the
performance required by, or result in a right of termination or
acceleration of, any agreement, mortgage, deed of trust, lease,
license, credit facility, indenture, permit or other instrument
to which the Company is a party or by which the Company or any
of its respective properties may be bound or affected or any
statute or any authorization, judgment, decree, order, rule or
regulation of any court or any regulatory body, administrative
agency or other governmental body applicable to the Company or
any of its respective properties, except in such case where such
conflict, breach, violation or default would not reasonably be
expected to result in a Material Adverse Effect. No consent,
approval, authorization, waiver or other order of, or filing,
registration with, or notice to, any court, regulatory body,
administrative agency or other governmental body is required for
the execution and delivery of this Agreement or the consummation
of the transactions contemplated by this Agreement, except for
compliance with the Blue Sky laws and federal securities laws
applicable to the offering of the Shares. The Company has
validly executed and delivered this Agreement, and assuming the
valid execution hereof by the Investor, this Agreement will
constitute a valid and binding obligation of the Company,
enforceable in accordance with its terms, except as
enforceability may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium or similar laws affecting
creditors and contracting parties rights generally
and except as enforceability may be subject to general
principles of equity (regardless of whether such enforceability
is considered in a proceeding in equity or at law).
4.5 Accountants. The firm of
Ernst & Young, LLP, which has expressed its
opinion with respect to the consolidated financial statements
included in the Companys Annual Report on
Form 10-K
for the fiscal year ended December 31, 2007, has
represented that it is an independent accountant as required by
the Securities Act and the rules and regulations promulgated
thereunder (the Rules and Regulations).
4.6 Contracts. Except as
described in or contemplated by the Companys Exchange Act
Documents, the contracts that are material to the Company are in
full force and effect on the date hereof; neither the Company
nor, to the Companys knowledge, any other party thereto,
is in breach of or default under any of such contracts; to the
Companys knowledge no event has occurred that with the
giving of notice or the passage of time or both would give rise
to such breach or default in each case, except where such breach
or default would not reasonably be expected to have a Material
Adverse Effect;
A-4
4.7 No Actions. Except as
described in or contemplated by the Companys Exchange Act
Documents, (i) there are no legal or governmental actions,
suits, proceedings, investigations pending and (ii) to the
Companys knowledge, there are no legal or governmental
actions, suits, proceedings or investigations threatened, to
which the Company is or may be a party or subject or of which
property of the Company is or may be the subject, or related to
applicable environmental or discrimination matters, or
instituted by the Securities and Exchange Commission (the
SEC), the Financial Industry Regulatory
Authority, any state securities commission or other governmental
or regulatory entity, except for such actions, suits,
proceedings or investigations which, individually or in the
aggregate, would not prevent or reasonably be expected to
prevent or materially and adversely affect the transactions
contemplated by this Agreement or result in a Material Adverse
Effect; and, to the Companys knowledge, no labor
disturbance by the employees of the Company exists, or is
imminent which is reasonably expected to have a Material Adverse
Effect. The Company is not party to or subject to the provisions
of any material injunction, judgment, decree or order of any
court, regulatory body administrative agency or other
governmental body.
4.8 Properties. The Company
has good and marketable title to all the tangible properties and
assets reflected as owned by it in the consolidated financial
statements incorporated by reference in the Companys
Exchange Act Documents, subject to no lien, mortgage, pledge,
charge or encumbrance of any kind except (i) those, if any,
reflected in such consolidated financial statements, or
disclosed in or contemplated by the Companys Exchange Act
Documents, or (ii) those which are not material in amount
and do not materially adversely affect the use made of such
property by the Company. Except as described in or contemplated
by the Companys Exchange Act Documents, the Company holds
its leased properties under valid and binding leases, subject to
such exceptions as are not materially significant in relation to
its business.
4.9 Patents and
Trademarks. To the knowledge of the Company,
the Company has, or has rights to use, all patents, patent
applications, trademarks, trademark applications, service marks,
trade names, copyrights, licenses and other similar rights that
are necessary or material for use in connection with its
businesses as described in the Companys Exchange Act
Documents and which the failure to so have could have or
reasonably be expected to result in a Material Adverse Effect
(collectively, the Intellectual Property
Rights). The Company has not received a written notice
that the Intellectual Property Rights used by the Company
violates or infringes upon the rights of any person. To the
knowledge of the Company, all such Intellectual Property Rights
are valid and enforceable.
4.10 Insurance. The Company
is insured by insurers of recognized financial responsibility
against such losses and risks and in such amounts as are, to the
best knowledge of the Company, prudent and customary in the
businesses in which the Company is engaged. The Company does not
have any reason to believe that it will not be able to renew its
existing insurance coverage as and when such coverage expires or
to obtain similar coverage from similar insurers as may be
necessary to continue its business without a significant
increase in cost.
4.11 No Material
Change. Since December 31, 2007 and
except as described in or contemplated by the Exchange Act
Documents, (i) the Company has conducted its business in
all material respects in the ordinary course, consistent with
past practice, (ii) the Company has not incurred any
material liabilities or obligations, indirect, or contingent, or
entered into any material agreement or other transaction and no
event or events have occurred, in each case which individually
or in the aggregate has had or could reasonably be expected to
have a Material Adverse Effect; (iii) the Company has not
sustained any material loss or damage to its physical properties
or assets from fire, flood, windstorm, accident or other
calamity not covered by insurance; (iv) the Company has not
paid or declared any dividends or other distributions with
respect to its capital stock, and the Company has not defaulted
in the payment of principal or interest on any outstanding debt
obligations; and (v) there has not been any change in the
capital stock of the Company other than the sale of the Shares
hereunder and shares or options issued pursuant to employee
equity incentive or stock purchase plans, or any increase in
indebtedness material to the Company.
A-5
4.12 Taxes. Except as
described in or contemplated by the Companys Exchange Act
Documents, the Company has filed all necessary federal, state
and foreign income and franchise tax returns and has paid or
accrued all taxes shown as due thereon, and the Company has no
knowledge of a material tax deficiency which has been or might
be asserted or threatened against it nor to the Companys
knowledge is there any basis for any such claims to be asserted
or threatened which could reasonably be expected to have a
Material Adverse Effect.
4.13 Investment Company. The
Company is not an investment company or an
affiliated person of, or promoter or
principal underwriter for an investment company,
within the meaning of the Investment Company Act of 1940, as
amended.
4.14 Securities Act. Neither
the Company nor any person acting on its behalf has in the past
or will hereafter take any action to sell, offer for sale or
solicit offers to buy any securities of the Company (including
any offering of any securities of the Company under
circumstances which would require the integration of such
offering with the offering of any securities to be issued
pursuant to this Agreement) which would subject the offer,
issuance or sale of the Shares contemplated by this Agreement to
the registration requirements of Section 5 of the
Securities Act.
4.15 Additional Information.
(a) The information contained in the following documents,
did not, as of the date of the applicable document, include any
untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary to make
the statements therein, in the light of the circumstances in
which they were made, not misleading, as of their respective
filing dates or, if amended, as so amended (the following
documents, collectively, the Exchange Act
Documents):
1. The Companys Annual Report on
Form 10-K
for the year ended December 31, 2007 filed with the SEC on
March 7, 2008;
2. The Companys Quarterly Reports on
Form 10-Q
for the quarters ended March 31, 2008 filed with the SEC on
May 12, 2008;
3. The Companys Current Reports on
Form 8-K,
filed with the SEC on April 2, 2008, May 8, 2008,
May 12, 2008;
4. The Companys Proxy Statement on Schedule 14A
for the 2008 Annual Meeting of Stockholders filed with the SEC
on April 29, 2008; and
5. Any future filings the Company makes with the SEC under
Sections 13(a), 13(c), 14, or 15(d) of the Securities Exchange
Act of 1934, as amended (the Exchange Act),
until the Closing, the existence of which filings the Company
will promptly make known to the Investors prior to the Closing.
(b) In furtherance and not in limitation of the provisions
of Section 4.15(a), the financial statements of the Company
and the related notes contained in or incorporated by reference
into any Company Report filed with the SEC prior to the date of
this Agreement (the Company Financial
Statements) (i) have been prepared from and in
accordance with the books and records of the Company,
(ii) complied as to form, as of their respective dates of
filing with the SEC, in all material respects, with the
applicable accounting requirements and with the published
regulations of the SEC with respect thereto and
(iii) present fairly in all respects, in accordance with
generally accepted accounting principles, the financial position
of the Company as of the dates indicated, and the results of its
operations, cash flows, and the changes in stockholders
equity for the periods therein specified, except to the extent
any inaccuracies or omissions therein do not represent events or
conditions that would reasonably be expected to have a Material
Adverse Effect and subject, in the case of unaudited financial
statements for interim periods, to normal year-end audit
adjustments and the absence of full footnote disclosure as
required by generally accepted accounting principles. Such
consolidated financial statements (including the related notes)
have been prepared in all material respects in accordance with
generally accepted accounting principles applied on a consistent
basis throughout the periods therein specified, subject, in the
case of
A-6
unaudited financial statements for interim periods, to normal
year-end adjustments, and except as otherwise described therein
and except that unaudited financial statements may not contain
all footnotes required by generally accepted accounting
principles.
4.16 Reporting Company;
Form S-3.
(a) The Company is subject to the reporting requirements of
the Exchange Act and since April 30, 2007 has filed all
reports registrations, documents, filings, statements and
submissions, together with any amendments thereto, that it was
required to file with any Governmental Entity (collectively, the
Company Reports) and has paid all material
fees and assessments due and payable in connection therewith. As
of their respective dates of filing, the Company Reports
complied in all material respects with all statutes and
applicable rules and regulations of the applicable Governmental
Entities. To the knowledge of the Company, as of the date of
this Agreement, there are no outstanding comments from the SEC
or any other Governmental Entity with respect to any Company
Report. In the case of each such Company Report filed with or
furnished to the SEC, such Company Report did not, as of its
date or if amended prior to the date of this Agreement, as of
the date of such amendment, contain an untrue statement of a
material fact or omit to state a material fact required to be
stated therein or necessary in order to make the statements made
in it, in light of the circumstances under which they were made,
not misleading and complied as to form in all material respects
with the applicable requirements of the Securities Act and the
Exchange Act. With respect to all other Company Reports, the
Company Reports were complete and accurate in all material
respects as of their respective dates. No executive officer of
the Company has failed in any respect to make the certifications
required of him or her under Section 302 or 906 of the
Sarbanes-Oxley Act of 2002.
(b) The Company satisfies the registrant requirements for
the use of a registration statement on
Form S-3
to register the Shares and the Warrant Shares for resale by the
Investor under the Securities Act. To the Companys
knowledge, there exist no facts or circumstances (including
without limitation any required approvals or waivers or any
circumstances that may delay or prevent the obtaining of
accountants consents) that reasonably could be expected to
prohibit or delay the preparation and filing of the registration
statement on
Form S-3
for the resale of the Shares and Warrant Shares by the Investor
contemplated by Section 7 of this Agreement.
4.17 Quotation on
Nasdaq. The Company has not, in the twelve
(12) months preceding the date hereof, received notice
(written or oral) from the Nasdaq Global Market System
(Nasdaq), any stock exchange, market or
trading facility on which the Common Stock is or has been listed
(or on which it has been quoted) to the effect that the Company
is not in compliance with the listing or maintenance
requirements of such exchange, market or trading facility. The
Company is in material compliance with all such listing and
maintenance requirements. The Company shall use its commercially
reasonable efforts to maintain the designation and quotation, or
listing, of the Common Stock on the Nasdaq or on another
national securities exchange for a minimum of two (2) years
following the Closing Date.
4.18 Material Adverse
Effect. As used in this Section 4, the
term Material Adverse Effect means any circumstance
or event which, individually or in the aggregate with any other
circumstances or event, has a material adverse effect on the,
business as it is currently conducted, assets, liabilities,
financial condition or operations of the Company.
(a) No Defaults; Compliance With
Law. The Company is not in violation or
default of any provision of its certificate of incorporation or
bylaws, or in breach of or default with respect to any provision
of any agreement, judgment, decree, order, mortgage, deed of
trust, lease, franchise, license, indenture, credit facility,
permit or other instrument to which it is a party or by which it
or any of its properties are bound except where such violation,
breach or default would not reasonably be expected to result in
a Material Adverse Effect. Except as described in or
contemplated by the Companys Exchange Act Documents, the
Company has all material permits, licenses, franchises,
authorizations, orders and approvals of, and have made all
filings, applications and registrations with, Governmental
Entities that are required in order to permit it to own or lease
its properties and assets and to carry on its business as
presently conducted and that are material to the business of the
Company. Except as described in or
A-7
contemplated by the Companys Exchange Act Documents, the
Company has complied in all material respects and is not in
default or violation in any respect of, and none of them is, to
the knowledge of the Company, under investigation with respect
to or, to the knowledge of the Company, has been threatened to
be charged with or given notice of any material violation of,
any applicable material domestic (federal, state or local) or
foreign law, statute, ordinance, license, rule, regulation,
policy or guideline, order, demand, writ, injunction, decree or
judgment of any Governmental Entity, other than such
noncompliance, defaults or violations that would not reasonably
be expected to have a Material Adverse Effect. Except for
statutory or regulatory restrictions of general application, to
the knowledge of the Company, no Governmental Entity has placed
any material restriction on the business or properties of the
Company.
4.19 Transfer Taxes. On the
Closing Date, all stock transfer or other taxes (other than
income or similar taxes) which are required to be paid in
connection with the sale and transfer of the Shares to be sold
to the Investor hereunder will be, or will have been, fully paid
or provided for by the Company, and all laws imposing such taxes
will be or will have been complied with.
4.20 Use of Proceeds. The
Company will use the proceeds from the sale of the Shares for
continued research and development, manufacturing and marketing,
working capital and general corporate purposes.
4.21 Price of Common
Stock. The Company has not taken any action
intended to stabilize or manipulate the price of the
Companys shares of the Common Stock to facilitate the sale
or resale of the Shares.
4.22 Transactions With Affiliates and
Employees. Except as described in or
contemplated by the Companys Exchange Act Documents, none
of the officers or directors of the Company and, to the
knowledge of the Company, none of the employees of the Company
is presently a party to any transaction with the Company (other
than for services as employees, officers and directors),
including any contract, agreement or other arrangement providing
for the furnishing of services to or by, providing for rental of
real or personal property to or from, or otherwise requiring
payments to or from any officer, director or such employee or,
to the knowledge of the Company, any entity in which any
officer, director, or any such employee has a substantial
interest or is an officer, director, trustee or partner, in each
case in excess of $60,000 other than (a) for payment of
salary or consulting fees for services rendered,
(b) reimbursement for expenses incurred on behalf of the
Company and (c) for other employee benefits, including
stock option agreements under any stock option plan of the
Company.
4.23 Internal Accounting
Controls. Except to the extent that the
failure to do so would not be expected to result in a Material
Adverse Effect, the Company maintains a system of internal
accounting controls sufficient to provide reasonable assurance
that (i) transactions are executed in accordance with
managements general or specific authorizations,
(ii) transactions are recorded as necessary to permit
preparation of financial statements in conformity with GAAP and
to maintain asset accountability, (iii) access to assets is
permitted only in accordance with managements general or
specific authorization, and (iv) the recorded
accountability for assets is compared with the existing assets
at reasonable intervals and appropriate action is taken with
respect to any differences. Except to the extent that the
failure to do so would not be expected to result in a Material
Adverse Effect, the Company has established disclosure controls
and procedures (as defined in Exchange Act
Rules 13a-14
and 15d-14)
for the Company and designed such disclosures controls and
procedures to ensure that material information relating to the
Company is made known to the certifying officers by others
within those entities, particularly during the period in which
the Companys
Form 10-K
or 10-Q, as
the case may be, is being prepared.
Section 5. Representations,
Warranties and Covenants of the Investor.
5.1 The Investor represents and warrants to, and covenants
with, the Company that: (i) (A) the Investor is an
accredited investor as defined in Regulation D
under the Securities Act and the Investor is also knowledgeable,
sophisticated and experienced in making, and is qualified to
make decisions with respect to investments in shares presenting
an investment decision like that involved in the purchase of the
Shares and the Warrants, including investments in securities
issued by the Company and investments in comparable
A-8
companies, and subject to the accuracy of the Companys
representations and warranties, has requested, received,
reviewed and considered all information it deemed relevant in
making an informed decision to purchase the Shares and the
Warrants and (B) the Company has made available to the
Investor, prior to the date hereof, the opportunity to ask
questions of and receive complete and correct answers from
representatives of the Company concerning the terms and
conditions of the Shares and the Warrants and to obtain any
additional information relating to the financial condition and
business of the Company and the Investor has such knowledge and
experience in financial and business matters that the Investor
is capable of evaluating the merits and risks of the investment
in the Shares and the Warrants; (ii) the Investor is
acquiring the number of Shares and the Warrants to purchase the
number of Warrant Shares, each as set forth in Section 3 of
the Agreement in the ordinary course of its business and for its
own account and with no present intention of distributing any of
such Shares, Warrants or Warrant Shares or any arrangement or
understanding with any other persons regarding the distribution
of such Shares, Warrants or Warrant Shares (other than pursuant
to the Registration Statement or in compliance with applicable
laws); (iii) the Investor will not, directly or indirectly,
offer, sell, pledge, transfer or otherwise dispose of (or
solicit any offers to buy, purchase or otherwise acquire or take
a pledge of) any of the Shares and the Warrants except in
compliance with the Securities Act, applicable state securities
laws and the respective rules and regulations promulgated
thereunder; (iv) the Investor has answered all questions on
the Investor Questionnaire, a form of which is attached hereto
as Exhibit B (the Investor
Questionnaire) and the answers thereto are true,
correct and complete as of the date hereof and will be true,
correct and complete as of the Closing Date and the Filing Date;
(v) upon request of the Company, the Investor will notify
the Company of any change in any of the information provided to
the Company pursuant to Section 7.1(a) until such time as
the Investor has sold all of its Shares and Warrant Shares or
until the Company is no longer required to keep the Registration
Statement effective; and (vi) the Investor has, in
connection with its decision to purchase the number of Shares
and the Warrants to purchase the number of Warrant Shares, each
as set forth in Section 3 of the Agreement, relied only
upon the Exchange Act Documents and the representations and
warranties of the Company contained herein. The Investor
understands that its acquisition of the Shares and the Warrants
has not been registered under the Securities Act or registered
or qualified under any state securities law in reliance on
specific exemptions therefrom, which exemptions may depend upon,
among other things, the bona fide nature of the Investors
investment intent as expressed herein.
5.2 The Investor acknowledges, represents and agrees that
no action has been or will be taken in any jurisdiction outside
the United States by the Company that would permit an offering
of the Shares, Warrants or Warrant Shares, or possession or
distribution of offering materials in connection with the issue
of the Shares, Warrants or Warrant Shares, in any jurisdiction
outside the United States where legal action by the Company for
that purpose is required. Each Investor outside the United
States will comply with all applicable laws and regulations in
each foreign jurisdiction in which it purchases, offers, sells
or delivers the Shares, Warrants or Warrant Shares or has in its
possession or distributes any offering material, in all cases at
its own expense.
5.3 The Investor hereby covenants with the Company not to
make any sale of the Shares, Warrants or Warrant Shares without
complying with the provisions of this Agreement and without
causing the prospectus delivery requirement under the Securities
Act to be satisfied (whether by delivery of the Prospectus or
pursuant to and in compliance with an exemption from such
requirement), and the Investor acknowledges that, subject to
removal in accordance with the terms hereof, the Warrants and
certificates evidencing the Shares will be imprinted with a
legend that prohibits their transfer except in accordance
therewith.
5.4 The Investor further represents and warrants to, and
covenants with, the Company that (i) the Investor has full
right, power, authority and capacity to enter into this
Agreement and to consummate the transactions contemplated hereby
and has taken all necessary action to authorize the execution,
delivery and performance of this Agreement, and
(ii) assuming the valid execution hereof by the Company,
this Agreement constitutes a valid and binding obligation of the
Investor enforceable against the Investor in accordance with its
terms, except as enforceability may be limited by applicable
bankruptcy, insolvency, reorganization, moratorium or similar
laws affecting creditors and contracting parties
rights generally and except as enforceability may be subject to
general principles of equity (regardless of whether such
enforceability is considered in a proceeding in equity or at
law).
A-9
5.5 Neither the Investor nor any person acting on its
behalf or at its direction has engaged in any sale of Common
Stock (including without limitation any short sale, pledge,
transfer or establishment of an open put equivalent
position within the meaning of
Rule 16a-1(h)
under the Exchange Act) during the 90 days immediately
preceding the date of this Agreement (other than program
trades). Investor will not use any of the restricted
Shares acquired pursuant to this Agreement, or the Warrant
Shares acquired pursuant to the Warrants, to cover any short
position in the Common Stock of the Company if doing so would be
in violation of applicable securities laws and otherwise will
comply with federal securities laws in the holding and sale of
the Shares, Warrants and Warrant Shares.
5.6 The Investor understands that nothing in the Exchange
Act Documents, this Agreement, the Warrant or any other
materials presented to the Investor in connection with the
purchase and sale of the Shares and the Warrants constitutes
legal, tax or investment advice. The Investor has consulted such
legal, tax and investment advisors as it, in its sole
discretion, has deemed necessary or appropriate in connection
with its purchase of Shares and the Warrants.
5.7 The Company acknowledges and agrees that Investor does
not make or has not made any representations or warranties with
respect to the transactions contemplated hereby other than those
specifically set forth in this Agreement.
5.8 The Investor acknowledges the following disclosure,
which is set forth herein as required pursuant to
Section 25102(a) of the California Corporate Securities Law
of 1968 (provided that, subject to the accuracy of the
Investors representations and warranties to the Company,
the Company represents that the sale of the Shares is so exempt):
THE SALE OF THE SECURITIES THAT ARE THE SUBJECT OF THIS
AGREEMENT HAS NOT BEEN QUALIFIED WITH THE COMMISSIONER OF
CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF THE
SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE
CONSIDERATION THEREFOR PRIOR TO THE QUALIFICATION IS UNLAWFUL,
UNLESS THE SALE OF SECURITIES IS EXEMPT FROM THE QUALIFICATION
BY SECTION 25100, 25102, OR 25105 OF THE CALIFORNIA
CORPORATIONS CODE. THE RIGHTS OF ALL PARTIES TO THIS AGREEMENT
ARE EXPRESSLY CONDITIONED UPON THE QUALIFICATION BEING OBTAINED,
UNLESS THE SALE IS SO EXEMPT.
5.9 The Investor covenants that the Investor shall deliver
to the Company the completed Investor Questionnaire prior to the
Second Closing.
Section 6. Other
Agreements.
6.1 Survival of Representations and
Warranties. Notwithstanding any investigation
made by any party to this Agreement, all covenants, agreements,
representations and warranties made by the Company and the
Investor herein shall survive the execution of this Agreement,
the delivery to the Investor of the Shares and the Warrants
being purchased and the payment therefor until the expiration
date of the Companys obligation to keep the Registration
Statement effective pursuant to Section 7.1(c).
6.2 Legends. Certificates
evidencing the Shares and Warrant Shares (other than those
evidencing the Shares and Warrant Shares held by the Investor or
any Affiliate Investors, which shall bear the least restrictive
legend the Company requires for certificates
evidencing shares
of the Companys Common Stock held by affiliates of the
Company) shall not contain any legend (including the legend set
forth in Section 7(a) of the Warrants), (i) while a
registration statement (including the Registration Statement (as
defined herein)) covering the resale of such security is
effective under the Securities Act and such security has been
sold pursuant to such registration statement, or
(ii) following any sale of such Shares or Warrant Shares
pursuant to Rule 144, or (iii) if such Shares or
Warrant Shares are eligible for sale under Rule 144(d)(1),
or (iv) if such legend is not required under applicable
requirements of the Securities Act (including judicial
interpretations and pronouncements issued by the Staff of the
Commission). The Company shall cause its counsel to issue a
legal opinion to the Companys transfer agent promptly
after the Required Effective Date (as defined herein) if
required by the Companys transfer agent to effect the
removal of the legend hereunder. The Company agrees
A-10
that following the Required Effective Date or at such time as
such legend is no longer required under this Section 6.2,
it will, no later than ten (10) business days following the
delivery by the Investor to the Company or the Companys
transfer agent of: (i) a certificate representing Shares or
Warrant Shares, as the case may be, issued with a restrictive
legend; and (ii) any other documentation reasonably
requested by the Company, its counsel or its transfer agent,
deliver or cause to be delivered to the Investor a certificate
representing such Securities that is free from all restrictive
and other legends. The Company may not make any notation on its
records or give instructions to any transfer agent of the
Company that enlarge the restrictions on transfer set forth in
this Section 6.2.
Section 7. Registration
of the Shares and Warrant Shares; Compliance with the Securities
Act.
7.1 Registration Procedures and Other
Matters. The Company shall:
(a) Subject to receipt by the Company of a completed
Investor Questionnaire from the Investor as of the Closing Date,
as soon as reasonably practicable, but in no event later than
the earlier (the Filing Date) of
(i) thirty (30) calendar days following the Closing
Date and (ii) one hundred and twenty (120) calendar
days following the First Closing, prepare and file with the SEC
a Registration Statement on
Form S-3
relating to the sale of the Shares, the Warrant Shares and any
other shares of capital stock or other equity interests issued
or issuable with respect to the foregoing by way of stock
dividends, stock split or distribution or in connection with any
combination of shares, merger, recapitalization, reorganization
or similar event (collectively, Registrable
Securities) by the Investor and the Other Investors
from time to time on the Nasdaq or the facilities of any
national securities exchange on which the Common Stock is then
traded or in privately negotiated transactions (the
Registration Statement). If
Form S-3
is not available at that time, the Company will file a
registration statement or such form as is then available to
effect a registration of the Registrable Securities, subject to
the consent of the holders of a majority of the Registrable
Securities, which consent shall not be unreasonably withheld;
(b) use its commercially reasonable efforts, subject to
receipt of necessary information from the Investors, to cause
the SEC to declare the Registration Statement effective within
one hundred and twenty (120) calendar days after the
Closing Date, or if no Second Closing has occurred within one
hundred and twenty (120) days of the date hereof, the later
(the Required Effective Date) of (i) one
hundred and eighty (180) days after the First Closing or
(ii) ninety (90) days after the Company has received
completed Investor Questionnaires from any Investor
participating in the First Closing. The Companys
reasonable commercial efforts will include, but not be limited
to, promptly responding to all comments received from the staff
of the SEC. If the Company receives notification from the SEC
that the Registration Statement will receive no action or review
from the SEC, then the Company will, subject to its rights under
this Agreement, use its commercially reasonable efforts to cause
the Registration Statement to become effective within five
(5) business days after such SEC notification;
(c) use its reasonable best efforts to promptly prepare and
file with the SEC such amendments and supplements to the
Registration Statement and the prospectus used in connection
therewith as may be necessary to keep the Registration Statement
effective until the earliest of (i) the date on which the
Investors and any other holder of Registrable Securities to whom
the registration rights conferred by this Agreement have been
transferred in compliance with Section 7.2 (each, a
Holder), may sell all Registrable Securities
held thereby without registration, pursuant to Rule 144 of
the Securities Act and can be sold in one transaction without
limitation in accordance with the volume limitations contained
in Rule 144(e)(1)(i) under the Securities Act, if
applicable, or (ii) such time as all Shares and Warrant
Shares purchased by all Investors in the Offering have been sold
pursuant to a Registration Statement. Thereafter, the Company
shall be entitled to withdraw the Registration Statement and the
Holders shall have no further right to offer or sell any of the
Shares and Warrant Shares pursuant to the Registration Statement;
(d) furnish to each Holder and the underwriters, such
number of copies of the Registration Statement and each
amendment and supplement thereto (including in each case all
exhibits) and of prospectuses or preliminary prospectuses, in
conformity with the Securities Act, and such other documents as
the Holder or underwriter may reasonably request, in order to
facilitate the public sale or other disposition or
A-11
distribution of all or any of the Registrable Securities by the
Holders; provided, however, that the obligation of the Company
to deliver copies of prospectuses or preliminary prospectuses to
the Holders shall be subject to the receipt by the Company of
reasonable assurances from the Holder that the Holder will
comply with the applicable provisions of the Securities Act and
of such other securities or blue sky laws as may be applicable
in connection with any use of such prospectuses or preliminary
prospectuses;
(e) use its reasonable best efforts to register and qualify
the securities covered by such registration statement under such
other securities or Blue Sky laws of such jurisdictions as shall
be reasonably requested by the Holders or any managing
underwriter(s), to keep such registration or qualification in
effect for so long as such registration statement remains in
effect, and to take any other action which may be reasonably
necessary to enable such seller to consummate the disposition in
such jurisdictions of the securities owned by such Holder;
provided, however, that the Company shall not be required
to (i) qualify to do business in any jurisdiction where it
would not otherwise be required to qualify but for this
Section 7.1; (ii) file a general consent to service of
process in any such jurisdiction; (iii) subject itself to
taxation in any such jurisdiction; (iv) provide any
undertakings that cause material expense or burden to the
Company; or (v) make any change to its organizational
documents, which in each case the Board of Directors of the
Company determines to be contrary to the best interests of the
Company and its stockholders;
(f) notify each Holder of Registrable Securities at any
time when a prospectus relating thereto is required to be
delivered under the Securities Act of the happening of any event
as a result of which the applicable prospectus, as then in
effect, includes an untrue statement of a material fact or omits
to state a material fact required to be stated therein or
necessary to make the statements therein not misleading in light
of the circumstances then existing;
(g) bear all expenses in connection with the procedures in
this Section 7.1 and the registration of the Registrable
Securities pursuant to the Registration Statement, including
reasonable fees and expenses, if any, of one counsel
representing the Investors, if any;
(h) give prompt written notice to each Holder:
(i) when the Registration Statement is filed or any
amendment thereto has been filed with the SEC and upon the
effectiveness of the Registration Statement, and any
post-effective amendments thereto;
(ii) of any request by the SEC for amendments or
supplements to the Registration Statement or the prospectus
included therein or for additional information;
(iii) of the receipt by the Company of any stop orders of
the SEC with respect to the Registration Statement or the
initiation of any proceedings for that purpose, and of the
lifting of any such order;
(iv) of the receipt by the Company or its legal counsel of
any notification with respect to the suspension of the
qualification of the Common Stock for sale in any jurisdiction
or the initiation or threatening of any proceeding for such
purpose;
(v) of the happening of any event that requires the Company
to make changes in any effective registration statement or the
prospectus related to the Registration Statement in order to
make the statements therein not misleading (which notice shall
be accompanied by an instruction to suspend the use of the
prospectus until the requisite changes have been made); and
(vi) if at any time the representations and warranties of
the Company contained in any underwriting agreement contemplated
by Section 7.1(l) cease to be true and correct.
(i) use its reasonable best efforts to prevent the issuance
or obtain the withdrawal of any order suspending the
effectiveness of any registration statement referred to in
Section 7.1(h)(iii) at the earliest practicable time;
A-12
(j) upon the occurrence of any event contemplated by
Section 7.1(f) or 7.1(h)(vi), promptly prepare a
post-effective amendment to such registration statement or a
supplement to the related prospectus or file any other required
document so that, as thereafter delivered to the Holders and any
underwriters, the prospectus will not contain an untrue
statement of a material fact or omit to state any material fact
necessary to make the statements therein, in light of the
circumstances under which they were made, not misleading. If the
Company notifies the Holders in accordance with
Section 7.1(h)(v) to suspend the use of the prospectus
until the requisite changes to the prospectus have been made,
then the Holders and any underwriters shall suspend use of such
prospectus and use their reasonable best efforts to return to
the Company all copies of such prospectus (at the Companys
expense) other than permanent file copies then in such
Holders or underwriters possession. The total number
of days that any such suspension (each, a
Suspension) may be in effect in any
365 day period shall not exceed 30 days. The Company
acknowledges and agrees that nothing contained in this Agreement
(including any Suspension of the prospectus as contemplated
herein) shall limit in any way the Investors trading
activity with respect to securities of the Company other than
Shares and Warrant Shares;
(k) use reasonable best efforts to procure the cooperation
of the Companys transfer agent in settling any offering or
sale of Registrable Securities, including with respect to the
transfer of physical stock certificates into book entry form in
accordance with any procedures reasonably requested by Holder or
any managing underwriter(s);
(l) if selling Registrable Securities in a public offering
for which the reasonably anticipated aggregate price to the
public, net of expenses, would exceed U.S. $20,000,000,
enter into an underwriting agreement in customary form, scope
and substance and take all such other actions reasonably
requested by the Holders of a majority of the Registrable
Securities being sold in connection therewith or by the managing
underwriter(s), if any, to expedite or facilitate the
underwritten disposition of such Registrable Securities, and in
connection therewith in any underwritten offering (including
making members of management and executives of the Company
available to participate in road shows, similar
sales events and other marketing activities), (i) make such
representations and warranties to the Holders that are selling
stockholders and the managing underwriter(s), if any, with
respect to the business of the Company, and the Registration
Statement, Prospectus and documents, if any, incorporated or
deemed to be incorporated by reference therein, in each case, in
customary form, substance and scope, and, if true, confirm the
same if and when requested, (ii) use its reasonable best
efforts to furnish underwriters opinions of counsel to the
Company, addressed to the managing underwriter(s), if any,
covering the matters customarily covered in such opinions
requested in underwritten offerings, (iii) use its
reasonable best efforts to obtain cold comfort
letters from the independent certified public accountants of the
Company (and, if necessary, any other independent certified
public accountants of any business acquired by the Company for
which financial statements and financial data are included in
the Registration Statement) who have certified the financial
statements included in such Registration Statement, addressed to
each of the managing underwriter(s), if any, such letters to be
in customary form and covering matters of the type customarily
covered in cold comfort letters, (iv) if an
underwriting agreement is entered into, the same shall contain
indemnification provisions and procedures customary in
underwritten offerings, and (v) deliver such documents and
certificates as may be reasonably requested by the Holders of a
majority of the Registrable Securities being sold in connection
therewith, their counsel and the managing underwriter(s), if
any, to evidence the continued validity of the representations
and warranties made pursuant to clause (i) above and to
evidence compliance with any customary conditions contained in
the underwriting agreement or other agreement entered into by
the Company. Notwithstanding anything contained herein to the
contrary, the Company shall not be required to (i) enter
into any underwriting agreement or permit any underwritten
offering absent an agreement by the applicable underwriter(s) to
indemnify the Company in form, scope and substance as is
customary in underwritten offerings by the Company in which an
affiliate of the Company acts as an underwriter; (ii) enter
more than one underwriting agreement or permit more than one
underwritten offering pursuant to this Agreement; or
(iii) extend any underwritten offering beyond the period
recommended by the underwriters;
A-13
Notwithstanding the foregoing, it shall be a condition precedent
to the obligations of the Company to take any action pursuant to
paragraphs (a) through (f) of this Section 7.1,
that the Investor shall furnish to the Company a completed
Investor Questionnaire, a form of which is attached hereto as
Exhibit B, providing such information regarding
itself, the Registrable Securities to be sold by the Investor,
and the intended method of disposition of such Registrable
Securities as shall be required to effect the registration of
such Registrable Securities, all of which information shall be
furnished to the Company in writing specifically for use in the
Registration Statement.
The Company understands that the Investor disclaims being an
underwriter, but the Investor being deemed an underwriter shall
not relieve the Company of any obligations it has hereunder,
provided, however, that if the Company receives
notification from the SEC that the Investor is deemed an
underwriter, then the period in which the Company is obligated
to submit an acceleration request to the SEC shall be extended
to the earlier of (i) one hundred twenty (120) days
after such SEC notification, or (ii) one hundred fifty
(150) days after the initial filing of the Registration
Statement with the SEC. Notwithstanding the foregoing, the
parties understand and agree that the Company shall not be
obligated to retain an underwriter with respect to the offer and
sale of Shares pursuant to the Registration Statement except as
set forth in Section 7.7 herein.
7.2 Transfer of Shares and Warrant Shares After
Registration; Assignment of Rights.
(a) While the Registration Statement is effective and
available for resale, the Investor agrees that it will not
effect any disposition of the Shares or Warrant Shares or its
right to purchase the Shares or Warrant Shares that would
constitute a sale within the meaning of the Securities Act,
except as contemplated in the Registration Statement referred to
in Section 7.1 hereof or pursuant to an applicable
exemption from registration, the availability of which is
confirmed in writing by counsel to the Investor (the form,
substance and scope of which opinion shall be reasonably
acceptable to the Company) and delivered to the Company, and
that it will promptly notify the Company of any changes in the
information set forth in the Registration Statement regarding
the Investor or its plan of distribution.
(b) The rights of the Investor to registration of
Registrable Securities pursuant to Section 7.1 may be
assigned by Investor to (i) an Affiliate or other
investment vehicle managed or advised by OrbiMed or one or more
of its affiliates, to which Registrable Securities are
transferred, or (ii) to any transferee or assignee of
Registrable Securities to which there is transferred to such
transferee no less than $10,000,000 in Registrable Securities;
provided, however, the transferor shall, within ten days after
such transfer, furnish to the Company written notice of the name
and address of such transferee or assignee and the number and
type of Registrable Securities that are being assigned.
7.3 Indemnification; Liquidated Damages.
(i) For Purpose of this Agreement, the term
Holder/Affiliate shall mean any affiliate of
the Holder (as defined in Rule 405 under the Securities
Act) and any person who controls the Holder or any affiliate of
the Holder within the meaning of Section 15 of the
Securities Act or Section 20 of the Exchange Act and their
respective directors, officers, employees agents and
Affiliates; and
(ii) For purpose of this Section 7.3, the term
Registration Statement shall include any
final prospectus, exhibit, supplement or amendment included in
or relating to, and any document incorporated by reference in,
the Registration Statement referred to in Section 7.1
hereof.
(a) The Company agrees to indemnify and hold harmless the
Holder and each Holder/Affiliate against any and all losses,
claims, damages, liabilities or expenses, joint or several, to
which the Holder or Holder/Affiliate may become subject, under
the Securities Act, the Exchange Act, or any other federal or
state statutory law or regulation, or at common law or otherwise
(including in settlement of any litigation, if such settlement
is effected with the written consent of the Company), insofar as
such losses, claims, damages, liabilities or expenses (or
actions in respect thereof as contemplated below) arise out of
or are based upon any untrue statement or alleged untrue
statement of any material fact contained in the Registration
Statement, including the prospectus, financial statements and
schedules, and all other documents filed as a part thereof, as
amended at the time of effectiveness of the Registration
Statement, including any information deemed to be a part thereof
as of the time of effectiveness
A-14
pursuant to paragraph (b) of Rule 430A, or pursuant to
Rule 434, of the Rules and Regulations, or the prospectus,
in the form first filed with the SEC pursuant to
Rule 424(b) of the Rules and Regulations, or filed as part
of the Registration Statement at the time of effectiveness if no
Rule 424(b) filing is required (the
Prospectus), or any amendment or supplement
thereto, or arise out of or are based upon the omission or
alleged omission to state in any of them a material fact
required to be stated therein or necessary to make the
statements in the Registration Statement or any amendment or
supplement thereto not misleading or in the Prospectus or any
amendment or supplement thereto not misleading in the light of
the circumstances under which they were made, or arise out of or
are based in whole or in part on any material breach of the
representations and warranties of the Company contained in this
Agreement, or any material breach by the Company of its
obligations hereunder, and will reimburse the Holder or
Holder/Affiliate for any legal and other expenses as such
expenses are reasonably incurred by the Holder or
Holder/Affiliate in connection with investigating, defending,
settling, compromising or paying any such loss, claim, damage,
liability, expense or action; provided, however,
that the Company will not be liable in any such case to the
extent, but only to the extent, that any such loss, claim,
damage, liability or expense arises out of or is based upon
(i) an untrue statement or alleged untrue statement or
omission or alleged omission made in the Registration Statement,
the Prospectus or any amendment or supplement thereto in
reliance upon and in conformity with written information
furnished to the Company by or on behalf of the Holder expressly
for use therein, or (ii) the failure of the Holder to
comply with the covenants and agreements contained in
Section 5.3 or Section 7.2 hereof respecting the sale
of the Shares and Warrant Shares, or (iii) the inaccuracy
of any representations made by the Investor herein or
(iv) any statement or omission in any Prospectus that is
corrected in any subsequent Prospectus that was delivered to the
Investor prior to the pertinent sale or sales by the Investor.
(b) The Investor will severally, but not jointly, indemnify
and hold harmless the Company, each of its directors, each of
its officers who signed the Registration Statement and each
person, if any, who controls the Company within the meaning of
Section 15 of the Securities Act or Section 20 of the
Exchange Act, against any losses, claims, damages, liabilities
or expenses to which the Company, each of its directors, each of
its officers who signed the Registration Statement or
controlling person may become subject, under the Securities Act,
the Exchange Act, or any other federal or state statutory law or
regulation, or at common law or otherwise (including in
settlement of any litigation, if such settlement is effected
with the written consent of the Investor) insofar as such
losses, claims, damages, liabilities or expenses (or actions in
respect thereof as contemplated below) arise out of or are based
upon (i) any failure to comply with the covenants and
agreements contained in Section 5.3 or Section 7.2
hereof respecting the sale of the Shares and Warrant Shares, or
(ii) any untrue or alleged untrue statement of any material
fact contained in the Registration Statement, the Prospectus, or
any amendment or supplement thereto, or omission or alleged
omission to state therein a material fact required to be stated
therein or necessary to make the statements in the Registration
Statement or any amendment or supplement thereto not misleading
or in the Prospectus or any amendment or supplement thereto not
misleading in the light of the circumstances under which they
were made, in each case to the extent, but only to the extent,
that such untrue statement or alleged untrue statement or
omission or alleged omission was made in the Registration
Statement, the Prospectus, or any amendment or supplement
thereto, in reliance upon and in conformity with written
information furnished to the Company by the Investor expressly
for use therein; provided, however, that the obligations of the
Investor under this Section 7.3 shall not exceed the net
proceeds to such Investor from the sale of Shares and Warrant
Shares pursuant to such Registration Statement.
(c) Promptly after receipt by an indemnified party under
this Section 7.3 of notice of the threat or commencement of
any action, such indemnified party will, if a claim in respect
thereof is to be made against an indemnifying party under this
Section 7.3, promptly notify the indemnifying party in
writing thereof, provided, that the failure of an indemnified
party to give such notice shall not relieve the indemnifying
party of its obligations or liabilities pursuant to this
Agreement, except (and only) to the extent that it shall be
finally determined by a court of competent jurisdiction that
such failure shall have prejudiced the indemnifying party.
Subject to provisions hereinafter stated, in case any such
action is brought against any indemnified party and such
indemnified party seeks or intends to seek indemnity from an
indemnifying party, the indemnifying party will be entitled to
participate in, and, to the extent that it may wish, jointly
with all other indemnifying parties similarly notified, to
assume the defense thereof with counsel reasonably satisfactory
to such indemnified party; provided, however, if the
defendants in any such action include both the indemnified party
and the indemnifying party, and the indemnifying party and the
indemnified party, based upon the advice of such indemnified
partys
A-15
counsel, shall have reasonably concluded that there is an actual
conflict of interest between the positions of the indemnifying
party and the indemnified party in conducting the defense of any
such action or that there may be legal defenses available to it
and/or other
indemnified parties which are different from or additional to
those available to the indemnifying party, the indemnified party
or parties shall have the right to select separate counsel to
assume such legal defenses and to otherwise participate in the
defense of such action on behalf of such indemnified party or
parties. Upon receipt of notice from the indemnifying party to
such indemnified party of its election so to assume the defense
of such action and approval by the indemnified party of counsel,
the indemnifying party will not be liable to such indemnified
party under this Section 7.3 for any legal or other
expenses subsequently incurred by such indemnified party in
connection with the defense thereof unless the indemnified party
shall have employed such counsel in connection with the
assumption of legal defenses in accordance with the proviso to
the preceding sentence (it being understood, however, that the
indemnifying party shall not be liable for the expenses of more
than one separate counsel, approved by such indemnifying party
in the case of paragraph (a), representing the indemnified
parties who are parties to such action (including indemnified
parties under Agreements with Other Investors, plus local
counsel, if appropriate). In no event shall any indemnifying
person be liable in respect of any amounts paid in settlement of
any action unless the indemnifying person shall have approved
the terms of such settlement; provided that such consent
shall not be unreasonably withheld. No indemnifying person
shall, without the prior written consent of the indemnified
person, effect any settlement of any pending or threatened
proceeding in respect of which any indemnified person is or
could have been a party and indemnification could have been
sought hereunder by such indemnified person, unless such
settlement includes an unconditional release of such indemnified
person from all liability on claims that are the subject matter
of such proceeding.
(d) The Investor hereby acknowledges that it is a
sophisticated business person who was represented by counsel
during the negotiations regarding the provisions hereof
including, without limitation, the provisions of this
Section 7.3, and is fully informed regarding said
provisions. Each of the Company and the Investor is advised that
federal or state public policy as interpreted by the courts in
certain jurisdictions may be contrary to certain of the
provisions of this Section 7.3, and each of the Company and
the Investor hereby expressly waives and relinquishes any right
or ability to assert such public policy as a defense to a claim
under this Section 7.3 and further agrees not to attempt to
assert any such defense.
(e) Contribution. If a claim for
indemnification under Section 7.3(a) or 7.3(b) is
unavailable to an indemnified party, in lieu of indemnifying
such indemnified party, shall contribute to the amount paid or
payable by such indemnified party as a result of such losses,
claims, damages, liabilities or expenses, in such proportion as
is appropriate to reflect the relative fault of the indemnifying
party and indemnified party in connection with the actions,
statements or omissions that resulted in such losses, claims,
damages, liabilities or expenses as well as any other relevant
equitable considerations. The relative fault of such
indemnifying party and indemnified party shall be determined by
reference to, among other things, whether any action in
question, including any untrue or alleged untrue statement of a
material fact or omission or alleged omission of a material
fact, has been taken or made by, or relates to information
supplied by, such indemnifying party or indemnified party, and
the parties relative intent, knowledge, access to
information and opportunity to correct or prevent such action,
statement or omission. The amount paid or payable by a party as
a result of any losses, claims, damages, liabilities or expenses
shall be deemed to include any reasonable attorneys or
other reasonable fees or expenses incurred by such party in
connection with any proceeding to the extent such party would
have been indemnified for such fees or expenses if the
indemnification provided for in this Section 7.3 was
available to such party in accordance with its terms. The
parties hereto agree that it would not be just and equitable if
contribution pursuant to this Section 7.3(e) were
determined by pro rata allocation or by any other method of
allocation that does not take into account the equitable
considerations referred to in the immediately preceding
paragraph. Notwithstanding the provisions of this
Section 7.3(e), the Investor shall not be required to
contribute, in the aggregate, any amount in excess of the amount
by which the proceeds actually received by such Investor from
the sale of the Registrable Securities subject to the proceeding
exceeds the amount of any damages that the Investor has
otherwise been required to pay by reason of such untrue or
alleged untrue statement or omission or alleged omission, except
in the case of fraud or intentional misrepresentation by the
Investor.
A-16
(f) The Company and the Investor agree that the Investor
and each other Holder will suffer damages if the Registration
Statement is not declared effective by the SEC on or prior to
the Required Effective Date. The Company and the Investor
further agree that it would not be feasible to ascertain the
extent of such damages with precision. Accordingly, if the
Registration Statement is not declared effective by the SEC on
or prior to the Required Effective Date, the Company shall pay
as liquidated damages for such failure and not as a penalty (the
Liquidated Damages) to each Holder an amount
equal to one percent (1%) of the total purchase price paid by
the applicable Investor pursuant to this Agreement for the
Registrable Securities then held by such Holder that have not
been sold under a registration statement or pursuant to
Rule 144 for each 30 day period after or the Required
Effective Date, pro rated for any period less than 30 days,
following or the Required Effective Date, until the Registration
Statement has been declared effective by the SEC. Payments to be
made pursuant to this Section 7.3(f) shall be due and
payable in cash to a Holder immediately upon demand of such
Holder. Furthermore, after the effectiveness of the Registration
Statement, if the Holder shall be unable or prohibited from
selling Shares and Warrant Shares under the Registration
Statement other than as a result of a Suspension of not more
than thirty (30) days in any 365 day period and if the
Holder is unable during this period to sell Shares and Warrant
Shares under Rule 144 or an exemption from registration,
then the Company shall pay as Liquidated Damages to the Holder
an amount equal to one percent (1%) of the total purchase price
paid by the applicable Investor pursuant to this Agreement for
the Registrable Securities then held by such Holder that have
not been sold under a registration statement or pursuant to
Rule 144 for each 30 day period in which such
inability to sell is in effect or a Suspension is in effect that
exceeds the maximum allowed period for a Suspension or
Suspensions, but not including any day on which a Suspension is
lifted, pro rated in each case for any period less than
30 days. For purposes of this Section 7.3, a
Suspension shall be deemed lifted on the date that notice that
the Suspension has been lifted is delivered to the Holder
pursuant to Section 9 of this Agreement. Notwithstanding
the foregoing provisions, in no event shall the Company be
obligated to pay any Liquidated Damages to more than one Holder
in respect of the same Shares or Warrant Shares for the same
period of time. The parties agree that the Liquidated Damages
represent a reasonable estimate on the part of the parties, as
of the date of this Agreement, of the amount of damages that may
be incurred by the Holder if the Registration Statement has not
been declared effective by the SEC on or prior to the Required
Effective Date, or if a Suspension exceeds the maximum allowed
period.
7.4 Termination of Conditions and
Obligations. The conditions precedent imposed
by Section 5 or this Section 7 upon the
transferability of the Shares and Warrant Shares shall cease and
terminate as to any particular number of the Shares upon the
earliest to occur of (i) the sale of the Shares and Warrant
Shares pursuant to the Registration Statement or (ii) the
sale of the Shares and Warrant Shares pursuant to Rule 144
under the Securities Act and in one transaction in accordance
with the volume limitations contained in Rule 144(e)(1)(i)
under the Securities Act, if applicable, or at such time as an
opinion of counsel satisfactory in form and substance to the
Company shall have been rendered to the effect that such
conditions are not necessary in order to comply with the
Securities Act.
7.5 Information
Available. As long as any Investor owns the
Shares or Warrant Shares and the Company is subject to the
filing requirements of the Exchange Act, the Company covenants
to timely file (or obtain extensions in respect thereof and file
within the applicable grace period) all reports required to be
filed by the Company after the date hereof pursuant to the
Exchange Act. So long as the Registration Statement is effective
covering the resale of Shares owned by the Investor, the Company
will furnish to the Investor upon such Investors request
and at no cost to the Investor:
(a) as soon as practicable after available (but in the case
of the Companys Annual Report to Stockholders,
concurrently with delivery to its shareholders generally) one
copy of (i) its Annual Report to Stockholders (which Annual
Report shall contain financial statements audited in accordance
with U.S. generally accepted accounting principles by a
national firm of certified public accountants), (ii) if not
included in substance in the Annual Report to Stockholders, upon
the request of the Investor, its Annual Report on
Form 10-K,
(iii) upon the request of the Investor, its Quarterly
Reports on
Form 10-Q,
(iv) upon the request of the Investor, its Current Reports
on
Form 8-K,
and (v) a full copy of the particular Registration
Statement covering the Shares and Warrant Shares (the foregoing,
in each case, excluding exhibits);
A-17
(b) all exhibits excluded by the parenthetical to
subparagraph (a)(v) of this Section 7.5; and
(c) upon the reasonable request of the Investor, a
reasonable number of copies of the prospectuses and supplements
thereto to supply to any other party requiring such prospectuses
and supplements; and the Company, upon the reasonable request of
the Investor, will meet with the Investor or a representative
thereof at the Companys headquarters to discuss
information relevant for disclosure in the Registration
Statement covering the Shares and Warrant Shares;
provided, that the Company shall disclose any
confidential information to the Investor only if the Investor
has requested such information in writing and shall have entered
into a confidentiality agreement with the Company in form and
substance reasonably satisfactory to the Company with respect
thereto.
7.6 Company Registration.
(a) Whenever the Company proposes to register any of its
securities in an underwritten public offering, other than a
registration pursuant to Section 7.1, and the registration
form to be filed may be used for the registration or
qualification for distribution of Registrable Securities, the
Company will give prompt written notice to the Investor and all
other Holders of its intention to effect such a registration
(but in no event less than ten days prior to the anticipated
filing date) and will include in such registration all
Registrable Securities with respect to which the Company has
received written requests for inclusion therein within ten
business days after the date of the Companys notice (a
Piggyback Registration). Any such person that
has made such a written request may withdraw its Registrable
Securities from such Piggyback Registration by giving written
notice to the Company and the managing underwriter, if any, on
or before the fifth business day prior to the planned effective
date of such Piggyback Registration. The Company may terminate
or withdraw any registration under this Section 7.6 prior
to the effectiveness of such registration, whether or not such
Investor or any other Holders have elected to include
Registrable Securities in such registration.
(b) The right of such Investor and all other Investors to
registration pursuant to Section 7.6(a) will be conditioned
upon such persons participation in such underwriting and
the inclusion of such persons Registrable Securities in
the underwriting, and each such person will (together with the
Company and the other persons distributing their securities
through such underwriting) enter into an underwriting agreement
in customary form with the underwriter or underwriters selected
for such underwriting by the Company. If any participating
person disapproves of the terms of the underwriting, such person
may elect to withdraw therefrom by written notice to the
Company, the managing underwriter and such Investor.
(c) If a Piggyback Registration relates to an underwritten
primary offering on behalf of the Company, and the managing
underwriters advise the Company that in their reasonable opinion
the number of securities requested to be included in such
registration exceeds the number which can be sold without
adversely affecting the marketability of such offering
(including an adverse effect on the per share offering price),
the Company will include in such registration or prospectus only
such number of securities that in the reasonable opinion of such
underwriters can be sold without adversely affecting the
marketability of the offering (including an adverse effect on
the per share offering price), which securities will be so
included in the following order of priority: (i) first, the
securities the Company proposes to sell, (ii) second,
Registrable Securities of each Holder and registrable securities
of other investors in the Company to the extent such shares are
subject to piggyback registration rights pursuant to the
Companys Investor Rights Agreement dated as of
June 30, 1999, as amended (the Investor Rights
Agreement) on a pro-rata basis, subject to the terms
of this Agreement and the Investor Rights Agreement, and
(iii) third, any other securities of the Company that have
been requested to be sold.
7.7 Form S-3
Registration. The Investor may request the
Company in writing to file a registration statement on
Form S-3
(or any successor form to
Form S-3,
or any comparable form for registration) for a public offering
of Registrable Securities for which the reasonably anticipated
aggregate price to the public, net of expenses, would exceed
U.S. $20,000,000. Upon receipt of such a request, the
Company shall use commercially reasonable efforts to engage
underwriters to sell the Registrable Securities on a best
efforts basis and shall pay out-of-pocket-expenses (including
registration fees and fees of counsel and auditors, but
excluding underwriters commission which shall be paid from
the proceeds of such underwritten offering) related to such
registration and offering.
A-18
Section 8. Appointment
of Director. The Company hereby covenants to
OrbiMed that upon the earlier of the Second Closing and sixty
(60) days after the First Closing, the Company shall
appoint one (1) individual nominated by OrbiMed and
approved by the Company (such approval not to be unreasonably
withheld) to the vacant seat on the Companys Board of
Directors. The Investor hereby acknowledges and consents that
(a) a designee of OrbiMed will be appointed to the
Companys Board of Directors and (b) certain other
Investors are affiliated with members of the Companys
Board of Directors.
Section 9. Brokers
Fee. Each of the Investor and the Company
agrees to indemnify the other party against any claim for fees
by any broker or finder employed by the indemnifying party in
connection with the sale of the Shares and Warrant Shares to the
Investor. Each of the parties hereto hereby represents that, on
the basis of any actions and agreements by it, there are no
brokers or finders entitled to compensation in connection with
the sale of the Shares and Warrant Shares to the Investor.
Section 10. Expenses. Each
of the parties hereto shall be responsible for the costs, fees
and expenses incurred by it in connection with the negotiation
of this Agreement and the transactions contemplated thereby;
provided that the Company agrees to reimburse OrbiMed for
its reasonable costs, fees and expenses (including, but not
limited to, reasonable legal fees and expenses) up to a maximum
of $50,000. The Company shall be responsible for any
registration fees payable to the SEC in connection with the
issuance of the Warrants or otherwise in connection with the
transactions contemplated by this Agreement.
Section 11. Notices. All
notices, requests, consents and other communications hereunder
shall be in writing, shall be mailed (A) if within the
United States by first-class registered or certified airmail, or
nationally recognized overnight express courier, postage
prepaid, or by facsimile or electronic mail, or (B) if
delivered from outside the United States, by International
Federal Express (or other recognized international express
courier) or facsimile, and shall be deemed given (i) if
delivered by first-class registered or certified mail, three
business days after so mailed, (ii) if delivered by
nationally recognized overnight carrier, one business day after
so mailed, (iii) if delivered by International Federal
Express (or other recognized international express courier), two
business days after so mailed, or (iv) if delivered by
facsimile or electronic mail, upon electronic confirmation of
receipt and shall be delivered as addressed as follows:
if to the Company, to:
NxStage Medical, Inc.
439 S. Union St., 5th Floor
Lawrence, MA 01843
Phone:
(978) 687-4700
Fax:
(978) 687-4825
Attn: Winifred Swan
Email: wswan@nxstage.com
With a copy to:
OMelveny & Myers LLP
2765 Sand Hill Road
Menlo Park, CA 94025
Fax:
(650) 473-2601
Attn: Sam Zucker
if to the Investor, to:
Fax:
Attn:
A-19
With a copy to:
Fax:
Attn:
Section 12. Changes. No
provision of this Agreement may be waived, modified or amended
except pursuant to an instrument in writing signed by the
Company and the Investor.
Section 13. Headings. The
headings of the various sections of this Agreement have been
inserted for convenience of reference only and shall not be
deemed to be part of this Agreement.
Section 14. Severability. In
case any provision contained in this Agreement should be
invalid, illegal or unenforceable in any respect, the validity,
legality and enforceability of the remaining provisions
contained herein shall not in any way be affected or impaired
thereby.
Section 15. Governing
Law; Jurisdiction. This Agreement shall be
governed by and construed in accordance with the laws of the
State of New York without giving effect to the principles of
conflicts of law. Any legal suit, action or proceeding arising
out of or based upon this Agreement or the transactions
contemplated hereby (Related Proceedings) may
be instituted in the federal courts of the United States of
America located in New York, New York (collectively, the
Specified Courts), and each party irrevocably
submits to the non-exclusive jurisdiction of such Specified
Courts of such courts in any such suit, action or proceeding.
Service of any process, summons, notice or document by mail to
such partys address set forth above shall be effective
service of process for any suit, action or other proceeding
brought in any such court. The parties irrevocably and
unconditionally waive any objection to the laying of venue of
any suit, action or other proceeding in the Specified Courts and
irrevocably and unconditionally waive and agree not to plead or
claim in any such court that any such suit, action or other
proceeding brought in any such court has been brought in an
inconvenient forum. With respect to any Related Proceeding, each
party irrevocably waives, to the fullest extent permitted by
applicable law, all immunity (whether on the basis of
sovereignty or otherwise) from jurisdiction, service of process,
attachment (both before and after judgment) and execution to
which it might otherwise be entitled in the Specified Courts or
any other court of competent jurisdiction.
Section 16. Counterparts. This
Agreement may be executed in two (2) or more counterparts,
each of which shall constitute an original, but all of which,
when taken together, shall constitute but one instrument, and
shall become effective when one or more counterparts have been
signed by each party hereto and delivered to the other parties.
Facsimile signatures shall be deemed original signatures.
Section 17. Entire
Agreement. This Agreement and the instruments
referenced herein contain the entire understanding of the
parties with respect to the matters covered herein and therein
and, except as specifically set forth herein or therein, neither
the Company nor the Investor makes any representation, warranty,
covenant or undertaking with respect to such matters. This
Agreement supersedes all prior agreements and understandings
among the parties hereto with respect to the subject matter
hereof. As it relates to OrbiMed only, the parties agree that
the obligations of OrbiMed under paragraph 9 of the letter
agreement between the Company and the Investor dated
April 17, 2008 shall be terminated upon the First Closing;
provided that, as of the date of the First Closing, OrbiMed
shall be subject to the Companys existing Insider Trading
Policy as if OrbiMed were controlled by a director of the
Company.
Section 18. Specific
Performance. The Company acknowledges and
agrees that the Investor would suffer irreparable damage if any
of the provisions of this Agreement were not performed in
accordance with their specific terms and that any breach of this
Agreement by the Company could not be adequately compensated in
all cases by monetary damages alone. Accordingly, in addition to
any other right or remedy to which the Investor may be entitled,
at law or in equity, it shall be entitled to enforce any
provision of this
A-20
Agreement by a decree of specific performance and to temporary,
preliminary and permanent injunctive relief to prevent breaches
or threatened breaches of any of the provisions of this
Agreement, without posting any bond or other undertaking.
Section 19. Third
Party Beneficiaries. This Agreement is
intended for the benefit of the parties hereto and their
respective permitted successors and assigns, and is not for the
benefit of, nor may any provision hereof be enforced by, any
other person.
Section 20. Successors
and Assigns. This Agreement is binding upon
and inures to the benefit of the parties and their successors
and assigns. The Company may assign, after the Closing, this
Agreement or any rights or obligations hereunder in connection
with a merger, consolidation, sale of all or substantially all
of the Companys assets or sale of 50% or more of the
outstanding equity securities of the Company without the prior
written consent of the Investor, and the Investor may not assign
this Agreement or any rights or obligations hereunder except as
provided in Section 7.2 hereof.
Section 21. Further
Assurances. Each party will do and perform,
or cause to be done and performed, all such further acts and
things, and will execute and deliver all other agreements,
certificates, instruments and documents, as another party may
reasonably request in order to carry out the intent and
accomplish the purposes of this Agreement and the consummation
of the transactions contemplated hereby.
Section 22. No
Strict Construction. The language used in
this Agreement is deemed to be the language chosen by the
parties to express their mutual intent, and no rules of strict
construction will be applied against any party.
Section 23. Publicity. Each
party hereto shall have the right to approve before issuance any
press release or any other public statements with respect to the
transactions contemplated by this Agreement.
A-21
[Remainder of page intentionally blank]
A-22
IN WITNESS WHEREOF, the parties hereto have caused this
Agreement to be executed by their duly authorized
representatives as of the day and year first above written.
NXSTAGE MEDICAL, INC.
Name:
Number of Shares to be purchased by Investor:
Number of Shares underlying the Warrant to be purchased by
Investor:
Price Per Share:
$
Aggregate Purchase price for Shares and the Warrant to be
purchased by Investor:
$
Print or Type:
Name of Investor:
Name of Individual representing Investor:
Title of Individual representing Investor:
Signature by:
Signature of Individual representing
Investor (if an Institution):
Address:
Telephone:
Facsimile:
A-23
Annex B
FORM OF
WARRANT
THIS WARRANT AND THE SHARES OF COMMON STOCK TO BE ISSUED UPON
EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. NO SALE
OR DISPOSITION MAY BE EFFECTED WITHOUT (I) AN EFFECTIVE
REGISTRATION STATEMENT RELATED THERETO, (II) AN OPINION OF
COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE
COMPANY, THAT SUCH REGISTRATION IS NOT REQUIRED,
(III) RECEIPT OF NO-ACTION LETTERS FROM THE APPROPRIATE
GOVERNMENTAL AUTHORITIES OR (IV) OTHERWISE COMPLYING WITH
THE PROVISIONS OF SECTION 7 OF THIS WARRANT.
NXSTAGE
MEDICAL, INC.
WARRANT
TO
PURCHASE
SHARES
OF COMMON
STOCK
Warrant
No. W-[ ]
THIS CERTIFIES THAT, for value
received,
and its assigns are entitled to subscribe for and
purchase shares
(as adjusted pursuant to Section 4 hereof, the
Shares) of the fully paid and nonassessable
common stock, par value $0.001 per share (Common
Stock), of NxStage Medical, Inc., a Delaware
corporation (the Company), at the price of
$5.50 per share (such price and such other price as shall
result, from time to time, from the adjustments specified in
Section 4 hereof is herein referred to as the
Warrant Price), subject to the provisions and
upon the terms and conditions set forth herein and in the
Securities Purchase Agreement, dated as of even date herewith,
by and between the Company and the initial holder of this
Warrant. As used herein, the term Date of
Grant
means ,
2008. As used herein, the term Warrant shall be
deemed to include any warrants issued in exchange or upon
transfer or partial exercise of this Warrant unless the context
clearly requires otherwise.
1. Term. (a) The
purchase right represented by this Warrant is exercisable, in
whole or in part, at any time and from time to time from the
Date of Grant through the earlier of
(i) ,
2013 or (ii) the consummation of any of the following
transactions: (A) the sale, lease, exchange, conveyance or
other disposition of all or substantially all of the
Companys property or business or (B) its merger into
or consolidation with any other corporation (other than a
wholly-owned subsidiary of the Company) or (C) any
transaction (including a merger or other reorganization) or
series of related transactions, in which more than 50% of the
voting power of the Company is disposed of (each event described
in the foregoing clauses (A) to (C) being a
Change of Control Event), provided that the
Company shall give the holder reasonably prior written notice of
the proposed consummation of such Change of Control Event to
permit the holder to exercise the rights under this Warrant.
(b) If a Change of Control Event occurs, the Company shall
promptly pay to the holder of this Warrant an amount calculated
in accordance with the Black-Scholes Option Pricing formula set
forth in Appendix A hereto. Such payment shall be made
(i) in cash from the Company to the holder of the Warrant
upon the occurrence of a Change of Control Event and upon the
shareholders of the Company receiving cash from the third party
acquirer of the Company at the closing of the transaction,
(ii) in shares of Common Stock of the Company (with the
value of each share of Common Stock of the Company being
determined according to SCorp in Appendix A hereto) in the
event that the Change of Control Event results in the
shareholders of the Company receiving shares in the third party
acquirer or another entity at the closing of the transaction, or
(iii) in the event that the shareholders of the Company
receive both cash and shares upon the occurrence of a Change of
Control Event at the closing of the transaction, shall be also
be made in both cash and shares in the same proportion as the
consideration received by the shareholders of the Company.
B-1
2. Method of Exercise; Payment; Issuance of New
Warrant.
(a) Subject to Section 1 hereof, the purchase right
represented by this Warrant may be exercised by the holder
hereof, in whole or in part and from time to time, at the
election of the holder hereof, by the surrender of this Warrant
(with the notice of exercise substantially in the form attached
hereto as Exhibit A duly completed and executed) at
the principal office of the Company and by the payment to the
Company, by certified or bank check, or by wire transfer to an
account designated by the Company (a Wire
Transfer) of an amount equal to the then applicable
Warrant Price multiplied by the number of Shares then being
purchased. The person or persons in whose name(s) any
certificate(s) representing the Shares shall be issuable upon
exercise of this Warrant shall be deemed to have become the
holder(s) of record of, and shall be treated for all purposes as
the record holder(s) of, the Shares represented thereby (and
such Shares shall be deemed to have been issued) immediately
prior to the close of business on the date or dates upon which
this Warrant is exercised. As soon as practicable after the
exercise of this Warrant and in any event within three trading
days thereafter, upon the terms and subject to the conditions of
this Warrant, the Company at its expense will cause to be issued
in the name of and delivered to the holder, or as the holder may
direct to a broker or other persons, a certificate or
certificates for the number of Shares to which the holder shall
be entitled on such exercise, in such denominations as may be
requested by the holder. In lieu of delivering physical
certificates for the Shares issuable upon any exercise of this
Warrant, provided the Companys transfer agent is
participating in the Depository Trust Company
(DTC) Fast Automated Securities Transfer
(FAST) program, and that any legend upon the
certificates for the Shares shall have been removed pursuant to
Section 7 below, upon request of the holder, the Company
shall use commercially reasonable efforts to cause its transfer
agent electronically to transmit such Shares by crediting the
account of the holders broker with DTC through its Deposit
Withdrawal Agent Commission system (provided that the same time
limitations herein as for stock certificates shall apply).
(b) [On and after the Required Effective Date of the
Registration Statement (as defined in the Securities Purchase
Agreement) through the Term of this Warrant], in lieu of
exercising this Warrant for cash, the holder may elect to
receive shares equal to the value of this Warrant (or the
portion thereof being exercised) by surrender of this Warrant at
the principal office of the Company together with notice of such
election substantially in the form attached hereto as
Exhibit A duly completed and executed (Net
Exercise). The Company shall issue to a holder who Net
Exercises a number of Shares computed using the following
formula:
|
|
|
Where
|
|
|
|
X =
|
|
The number of Shares to be issued to the holder.
|
Y =
|
|
The number of Shares purchasable under this Warrant or, if only
a portion of the Warrant is being exercised, the portion of the
Warrant being cancelled (at the date of such calculation).
|
A =
|
|
The fair market value of one (1) Share (at the date of such
calculation).
|
B =
|
|
The Warrant Price (as adjusted to the date of such calculation
(the Determination Date)).
|
For purposes of this Section 2, the fair market value of a
Warrant Share shall mean: the Volume Weighted Average Price
(VWAP) of the Companys common stock for the 10 consecutive
Trading Days ending on the date immediately preceding the date
of the Exercise Notice, or if the VWAP cannot be calculated for
a security on a particular date, the fair market value shall be
mutually determined by the Company and the holder of this
Warrant. All such determinations to be appropriately adjusted
for any stock dividend, stock split, stock combination or other
similar transaction during the applicable calculation period.
VWAP means, for any security as of any date,
an average price calculated by adding up the dollars traded for
every transaction (price multiplied by number of shares traded)
and then dividing by the total shares traded for the day for
such security on the NASDAQ Global Market, as reported by
Bloomberg, or, if the NASDAQ Global Market begins to operate on
an extended hours basis and does not designate the closing bid
B-2
price or the closing trade price, as the case may be, then the
last bid price or the last trade price, respectively, of such
security prior to 4:00:00 p.m., New York time, as reported
by Bloomberg, or, if the NASDAQ Global Market is not the
principal securities exchange or trading market for such
security, the VWAP of such security on the principal securities
exchange or trading market where such security is listed or
traded as reported by Bloomberg, or if the foregoing do not
apply, the VWAP, of such security in the over-the-counter market
on the electronic bulletin board for such security as reported
by Bloomberg, or, if no price is reported for such security by
Bloomberg, the average of the bid prices, or the ask prices,
respectively, of any market makers for such security as reported
in the pink sheets by Pink Sheets LLC (formerly the
National Quotation Bureau, Inc.).
Trading Day means any day on which the Common
Stock are traded on the Principal Market, or, if the Principal
Market is not the principal trading market for the Common Stock,
then on the principal securities exchange or securities market
on which the Common Stock are then traded; provided that
Trading Day shall not include any day on which the
Common Stock are scheduled to trade on such exchange or market
for less than 4.5 hours or any day that the Common Stock
are suspended from trading during the final hour of trading on
such exchange or market (or if such exchange or market does not
designate in advance the closing time of trading on such
exchange or market, then during the hour ending at
4:00:00 p.m., New York time).
If there is no public market for the Common Stock, the fair
market value shall be the price per Share that the Company could
obtain from a willing buyer for Shares sold by the Company from
authorized but unissued Shares, as such prices shall be
determined in good faith by the Companys Board of
Directors.
(c) In the event that this Warrant is exercised pursuant to
this Section 2 in connection with the consummation of the
Companys sale of its Common Stock or other securities
pursuant to a registration statement under the Securities Act of
1933, as amended (other than a registration statement relating
either to sale of securities to employees of the Company
pursuant to its stock option, stock purchase or similar plan or
a Rule 145 transaction) (Public
Offering), the fair market value per Share shall be
the per share offering price to the public of the Public
Offering.
3. Stock Fully Paid; Reservation of
Shares. All Shares that may be issued upon
the exercise of the rights represented by this Warrant will,
upon issuance pursuant to the terms and conditions herein, be
fully paid and nonassessable, and free from all taxes, liens and
charges with respect to the issue thereof. During the period
within which the rights represented by this Warrant may be
exercised, the Company will at all times have authorized, and
reserved for the purpose of the issue upon exercise of the
purchase rights evidenced by this Warrant, a sufficient number
of shares of its Common Stock to provide for the exercise of the
rights represented by this Warrant.
4. Adjustment of Warrant Price and Number of
Shares. The number and kind of securities
purchasable upon the exercise of this Warrant and the Warrant
Price shall be subject to adjustment from time to time upon the
occurrence of certain events, as follows:
(a) Reclassification or Merger. In
case of any reclassification or change of securities of the
class issuable upon exercise of this Warrant (other than a
change in par value, or from par value to no par value, or from
no par value to par value, or as a result of a subdivision or
combination), or in case of any merger of the Company with or
into another corporation (other than a merger with another
corporation in which the Company is the acquiring and the
surviving corporation and which does not result in any
reclassification or change of outstanding securities issuable
upon exercise of this Warrant), or in case of any sale of all or
substantially all of the assets of the Company, then any such
transaction shall not be consummated unless the Company, or such
successor or purchasing corporation, as the case may be, shall
have or shall have agreed to in writing to duly execute and
deliver to the holder of this Warrant a new Warrant (in form and
substance satisfactory to the holder of this Warrant), or the
Company shall make appropriate provision without the issuance of
a new Warrant, so that the holder of this Warrant shall have the
right to receive upon exercise of this Warrant, at a total
purchase price not to exceed that payable upon the exercise of
the unexercised portion of this Warrant, and in lieu of the
shares of Common Stock theretofore issuable upon exercise of
this Warrant, the kind and amount of shares of stock, other
B-3
securities, money and property receivable upon such
reclassification, change or merger by a holder of the number of
shares of Common Stock then purchasable under this Warrant. Such
new Warrant shall provide for adjustments that shall be as
nearly equivalent as may be practicable to the adjustments
provided for in this Section 4. The provisions of this
subparagraph (a) shall similarly apply to successive
reclassifications, changes, mergers and transfers.
(b) Subdivision or Combination of
Shares. If the Company at any time while this
Warrant remains outstanding and unexpired shall subdivide or
combine its outstanding shares of Common Stock, the Warrant
Price shall be proportionately decreased and the number of
Shares issuable hereunder shall be proportionately increased in
the case of a subdivision or the Warrant Price shall be
proportionately increased and the number of Shares issuable
hereunder shall be proportionately decreased in the case of a
combination.
(c) Stock Dividends and Other
Distributions. If the Company at any time
while this Warrant is outstanding and unexpired shall pay a
dividend or make a distribution to all of its stockholders with
respect to its Common Stock payable in Common Stock, then the
Warrant Price shall be adjusted, from and after the date of
determination of stockholders entitled to receive such dividend
or distribution, to that price determined by multiplying the
Warrant Price in effect immediately prior to such date of
determination by a fraction (A) the numerator of which
shall be the total number of shares of Common Stock outstanding
immediately prior to such dividend or distribution, and
(B) the denominator of which shall be the total number of
shares of Common Stock outstanding immediately after such
dividend or distribution.
(d) Milestone Adjustment. Upon the
announcement of the Companys earnings for the fourth
quarter and year ended December 31, 2008, the Warrant Price
shall be adjusted automatically to either (i) $3.00 per
share, if the number of ESRD patients prescribed to receive
therapy using the NxStage System One is less than 3,100 as
reported in the Company Reports on December 31, 2008, or
(ii) $6.50 per share, if the number of ESRD
patients prescribed to receive therapy using the NxStage System
is more than 3,500 as reported in the Company Reports on
December 31, 2008. Any adjustment to the Warrant Price
required by the preceding sentence shall be subject to any
additional adjustment to such Warrant Price required due to the
prior occurrence of any of the events set forth in
clauses (a) to (c) and (e) of this Section 4.
(e) Adjustment of Number of
Shares. Upon each adjustment in the Warrant
Price, the number of Shares purchasable hereunder shall be
adjusted, to the nearest whole share, to the product obtained by
multiplying the number of Shares purchasable immediately prior
to such adjustment in the Warrant Price by a fraction, the
numerator of which shall be the Warrant Price immediately prior
to such adjustment and the denominator of which shall be the
Warrant Price immediately thereafter.
5. Notice of
Adjustments. Whenever the Warrant Price or
the number of Shares purchasable hereunder shall be adjusted
pursuant to Section 4 hereof, the Company shall make a
certificate signed by its chief executive officer, chief
financial officer or any vice president setting forth, in
reasonable detail, the event requiring the adjustment, the
amount of the adjustment, the method by which such adjustment
was calculated, and the Warrant Price and the number of Shares
purchasable hereunder after giving effect to such adjustment,
and shall cause copies of such certificate to be mailed (without
regard to Section 13 hereof, by first class mail, postage
prepaid) to the holder of this Warrant at such holders
last known address.
6. Fractional Shares. No
fractional shares of Common Stock will be issued in connection
with any exercise hereunder, but in lieu of such fractional
shares the Company shall make a cash payment therefor based on
the fair market value of the Common Stock on the date of
exercise as reasonably determined in good faith by the
Companys Board of Directors.
7. Compliance with Securities Act; Disposition
of Warrant or Shares of Common Stock.
(a) Compliance with Securities
Act. The holder of this Warrant, by
acceptance hereof, agrees that this Warrant, and the Shares to
be issued upon exercise hereof, are being acquired for
investment and that such
B-4
holder will not offer, sell or otherwise dispose of this
Warrant, or any Shares except under circumstances which will not
result in a violation of the Securities Act of 1933, as amended
(the Act) or any applicable state securities
laws. Upon exercise of this Warrant, unless the Shares being
acquired are registered under the Act and any applicable state
securities laws or an exemption from such registration is
available, the holder hereof shall confirm in writing that the
Shares so purchased are being acquired for investment and not
with a view toward distribution or resale in violation of the
Act and shall confirm such other matters related thereto as may
be reasonably requested by the Company. This Warrant and all
Shares issued upon exercise of this Warrant (unless registered
under the Act and any applicable state securities laws) shall be
stamped or imprinted with a legend in substantially the
following form:
THE SECURITIES EVIDENCED HEREBY HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE
SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT
(I) AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO,
(II) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY
SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATION IS NOT
REQUIRED, (III) RECEIPT OF NO-ACTION LETTERS FROM THE
APPROPRIATE GOVERNMENTAL AUTHORITIES, OR (IV) OTHERWISE
COMPLYING WITH THE PROVISIONS OF SECTION 7 OF THE WARRANT
UNDER WHICH THESE SECURITIES WERE ISSUED, DIRECTLY OR
INDIRECTLY.
Said legend shall be removed by the Company, upon the request of
a holder, at such time as the restrictions on the transfer of
the applicable security shall have terminated. For the avoidance
of doubt, the holder acknowledges that the Shares issued upon
exercise of the Warrant at any time will be unregistered
securities, subject to the rights of such holder to have the
Shares registered as provided in Section 9 below.
In addition, in connection with the issuance of this Warrant,
the holder specifically represents to the Company by acceptance
of this Warrant as follows:
(1) The holder is aware of the Companys business
affairs and financial condition, and has acquired information
about the Company sufficient to reach an informed and
knowledgeable decision to acquire this Warrant. The holder is
acquiring this Warrant for its own account for investment
purposes only and not with a view to, or for the resale in
connection with, any distribution thereof in
violation of the Act.
(2) The holder understands that this Warrant has not been
registered under the Act in reliance upon a specific exemption
therefrom, which exemption depends upon, among other things, the
bona fide nature of the holders investment intent as
expressed herein.
(3) The holder further understands that this Warrant must
be held indefinitely unless subsequently registered under the
Act and qualified under any applicable state securities laws, or
unless exemptions from registration and qualification are
otherwise available. The holder is aware of the provisions of
Rule 144, promulgated under the Act.
(4) The holder is an accredited investor as
such term is defined in Rule 501 of Regulation D
promulgated under the Act.
(b) Disposition of Warrant or
Shares. Subject to compliance with any
applicable securities laws and conditions set forth in this
Section 7(b), this Warrant and all rights hereunder are
transferable, in whole or in part, upon surrender of this
Warrant at the principal office of the Company, together with a
written assignment of this Warrant in form and substance
reasonably acceptable to the Company and the holder, Upon such
surrender, the Company shall execute and deliver a new Warrant
or Warrants in the name of the assignee(s) in the denomination
specified in such instrument of assignment, and shall issue to
the assignor a new Warrant and this Warrant shall be promptly be
cancelled. A Warrant, if properly assigned, may be exercised by
a new holder for the purchase of Shares without having a new
Warrant issued. With respect to any offer, sale or other
disposition of this Warrant or any Shares acquired pursuant to
the exercise of this Warrant prior to registration of such
Warrant or Shares, the holder hereof agrees to give written
notice to the Company prior thereto, describing briefly the
manner thereof, together with a written opinion of such
holders counsel, or other evidence satisfactory to the
Company, to the effect that such offer, sale or other
disposition may be effected
B-5
without registration or qualification (under the Act as then in
effect or any federal or state securities law then in effect) of
this Warrant or the Shares and indicating whether or not under
the Act certificates for this Warrant or the Shares to be sold
or otherwise disposed of require any restrictive legend as to
applicable restrictions on transferability in order to ensure
compliance with such law. Upon receiving such written notice and
reasonably satisfactory opinion or other evidence, the Company,
as promptly as practicable but no later than one
(1) business day after receipt of the written notice, shall
notify such holder that such holder may sell or otherwise
dispose of this Warrant or such Shares, all in accordance with
the terms of the notice delivered to the Company. If a
determination has been made pursuant to this Section 7(b)
that the opinion of counsel for the holder or other evidence is
not reasonably satisfactory to the Company, the Company shall so
notify the holder promptly with details thereof after such
determination has been made. Notwithstanding the foregoing, this
Warrant or such Shares may, as to such federal laws, be offered,
sold or otherwise disposed of in accordance with Rule 144
or 144A under the Act, provided that the Company shall have been
furnished with such information as the Company may reasonably
request to provide a reasonable assurance that the provisions of
Rule 144 or 144A have been satisfied. Each certificate
representing this Warrant or the Shares thus transferred (except
a transfer pursuant to Rule 144) shall bear a legend
as to the applicable restrictions on transferability in order to
ensure compliance with such laws, unless in the aforesaid
opinion of counsel for the holder, such legend is not required
in order to ensure compliance with such laws. The Company may
issue stop transfer instructions to its transfer agent in
connection with such restrictions.
(c) Applicability of
Restrictions. Neither any restrictions of any
legend described in this Warrant nor the requirements of
Section 7(b) above shall apply to any transfer or grant of
a security interest in, this Warrant (or the shares of Common
Stock obtainable upon exercise thereof) or any part hereof
(i) to a partner of the holder if the holder is a
partnership or to a member of the holder if the holder is a
limited liability company, (ii) to a partnership of which
the holder is a partner or a limited liability company of which
the holder is a member, (iii) to another investment vehicle
controlled or advised by the same manager or one of its
affiliates in the case of any collective investment vehicle or
similar holder, or (iv) to any affiliate of the holder if
the holder is a corporation; provided, however, in any such
transfer, if applicable, the transferee shall on the
Companys request agree in writing to be bound by the terms
of this Warrant as if an original holder hereof.
8. Rights as
Stockholders. No holder of this Warrant, as
such, shall be entitled to vote or receive dividends or be
deemed the holder of Common Stock or any other securities which
may at any time be issuable on the exercise hereof for any
purpose, nor shall anything contained herein be construed to
confer upon the holder of this Warrant, as such, any of the
rights of a stockholder of the Company or any right to vote for
the election of directors or upon any matter submitted to
stockholders at any meeting thereof, or to receive notice of
meetings, or to receive dividends or subscription rights or
otherwise until this Warrant shall have been exercised and the
Shares purchasable upon the exercise hereof shall have become
deliverable, as provided herein.
9. Registration Rights. The
Company grants registration rights to the holder of this Warrant
for any shares of Common Stock of the Company obtained upon
exercise hereof as set forth in the Securities Purchase
Agreement.
10. Modification and
Waiver. This Warrant and any provision hereof
may be changed, waived, discharged or terminated only by an
instrument in writing signed by the party against which
enforcement of the same is sought.
11. Notices. All notices,
requests, consents and other communications hereunder shall be
in writing, shall be mailed (A) if within the United States
by first-class registered or certified airmail, or nationally
recognized overnight express courier, postage prepaid, or by
facsimile or electronic mail, or (B) if delivered from
outside the United States, by International Federal Express (or
other recognized international express courier) or facsimile,
and shall be deemed given (i) if delivered by first-class
registered or certified mail, three business days after so
mailed, (ii) if delivered by nationally recognized
overnight carrier, one business day after so mailed,
(iii) if delivered by International Federal Express (or
other recognized international express
B-6
courier), two business days after so mailed, or (iv) if
delivered by facsimile or electronic mail, upon electronic
confirmation of receipt and shall be delivered as addressed as
follows:
if to the Company, to:
NxStage Medical, Inc.
439 S. Union St., 5th Floor
Lawrence, MA 01843
Phone:
(978) 687-4700
Fax:
(978) 687-4825
Attn: Winifred Swan
Email: wswan@nxstage.com
With a copy to:
OMelveny & Myers LLP
2765 Sand Hill Road
Menlo Park, CA 94025
Fax:
(650) 473-2601
Attn: Sam Zucker
if to the holder, at its address as shown on the books of the
Company.
12. Binding Effect on
Successors. This Warrant shall be binding
upon any corporation succeeding the Company by merger,
consolidation or acquisition of all or substantially all of the
Companys assets, and all of the obligations of the Company
relating to the Shares issuable upon the exercise or conversion
of this Warrant shall survive the exercise, conversion and
termination of this Warrant and all of the covenants and
agreements of the Company shall inure to the benefit of the
successors and assigns of the holder hereof.
13. Lost Warrants or Stock
Certificates. The Company covenants to the
holder hereof that, upon receipt of evidence reasonably
satisfactory to the Company of the loss, theft, destruction or
mutilation of this Warrant or any stock certificate and, in the
case of any such loss, theft or destruction, upon receipt of an
indemnity reasonably satisfactory to the Company, or in the case
of any such mutilation upon surrender and cancellation of such
Warrant or stock certificate, the Company will make and deliver
a new Warrant or stock certificate, of like tenor, in lieu of
the lost, stolen, destroyed or mutilated Warrant or stock
certificate.
14. Descriptive
Headings. The descriptive headings of the
several paragraphs of this Warrant are inserted for convenience
only and do not constitute a part of this Warrant. The language
in this Warrant shall be construed as to its fair meaning
without regard to which party drafted this Warrant.
15. Governing Law. This
Warrant shall be construed and enforced in accordance with, and
the rights of the parties shall be governed by, the laws of the
State of Delaware.
16. Survival of Representations, Warranties and
Agreements. All representations and
warranties of the Company and the holder hereof contained herein
shall survive the Date of Grant, the exercise or conversion of
this Warrant (or any part hereof) or the termination or
expiration of rights hereunder. All agreements of the Company
and the holder hereof contained herein shall survive
indefinitely until, by their respective terms, they are no
longer operative.
17. Remedies. In case any
one or more of the covenants and agreements contained in this
Warrant shall have been breached, the holders hereof (in the
case of a breach by the Company), or the Company (in the case of
a breach by a holder), may proceed to protect and enforce their
or its rights either by suit in equity
and/or by
action at law, including, but not limited to, an action for
damages as a result of any such breach
and/or an
action for specific performance of any such covenant or
agreement contained in this Warrant.
18. No Impairment of
Rights. The Company will not, by amendment of
its certificate of incorporation or through any other means,
avoid or seek to avoid the observance or performance of any of
the terms of this Warrant, but will at all times in good faith
assist in the carrying out of all such terms and in the taking
of all
B-7
such action as may be necessary or appropriate in order to
protect the rights of the holder of this Warrant against
impairment.
19. Severability. Whenever
possible, each provision of this Warrant shall be interpreted in
such a manner as to be valid, legal and enforceable under all
applicable laws and regulations. If, however, any provision of
this Warrant shall be invalid, illegal or unenforceable under
any such law or regulation in any jurisdiction, it shall, as to
such jurisdiction, be deemed modified to conform to the minimum
requirements of such law or regulation, or, if for any reason it
is not deemed to be so modified, it shall be invalid, illegal or
unenforceable only to the extent of such invalidity, illegality
or limitation on enforceability without affecting the remaining
provisions of this Warrant or the validity, legality or
enforceability of such provision in any other jurisdiction.
20. Entire Agreement;
Modification. This Warrant constitutes the
entire agreement between the parties pertaining to the subject
matter contained in it and supersedes all prior and
contemporaneous agreements, representations, and undertakings of
the parties, whether oral or written, with respect to such
subject matter.
B-8
[Remainder of page intentionally left blank]
B-9
IN WITNESS WHEREOF, the parties have executed this Warrant as of
the date first written above.
NXSTAGE MEDICAL, INC.
Name:
Title:
|
|
|
|
Address:
|
439 S. Union St., 5th Floor
|
Lawrence, MA 01843
B-10
Exhibit A
Notice of
Exercise
|
|
1. |
The undersigned hereby:
|
|
|
|
|
o
|
elects to
purchase
shares of Common Stock of the Company pursuant to the terms of
the attached Warrant, and tenders herewith payment of the
purchase price of
such shares
in full.
|
|
|
o
|
elects to exercise its issuance rights pursuant to
Section 2(b) of the attached Warrant with respect to
shares of Common Stock of the Company.
|
|
|
2. |
Please issue a certificate or certificates representing said
shares in the name of the undersigned or in such other name or
names as are specified below:
|
(Name)
(Address)
|
|
3. |
The undersigned represents that the aforesaid shares are being
acquired for the account of the undersigned for investment and
not with a view to, or for resale in connection with, the
distribution thereof and that the undersigned has no present
intention of distributing or reselling such shares, all except
as in compliance with applicable securities laws.
|
(Signature)
Dated:
B-11
APPENDIX A
Black Scholes Option Pricing formula to be used when calculating
the value of the Warrant shall be:
CCorp multiplied by the number of Shares for which the Warrant
could have been exercised immediately prior to the occurrence of
the Change of Control Event, where:
CCorp =
SCorpe − l
(TCorp − tCorp)N(d1) −
KCorpe-r(TCorp − tCorp)N(d2)
CCorp = value of the Warrant
SCorp = price of Company stock as determined by reference to the
average of the closing prices on the Nasdaq National Market or
other securities exchange upon which the Companys stock
may then be traded over the
20-day
period ending three trading days prior to the closing of the
Change of the Control Event, or the average of the closing bid
or sale prices (whichever is applicable) in the over-the-counter
market over the
20-day
period ending three trading days prior to the closing of the
Change of Control Event, if the Companys stock is then
actively traded in the over-the-counter market, or the then most
recently completed financing if the Companys stock is not
then traded on a securities exchange or system or in the
over-the-counter market.
TCorp = expiration date of the Warrant
tCorp = date of public announcement of Change of Control Event
TCorp-tCorp = time until the Warrant would have expired, but for
the occurrence of the Change of Control Event, expressed in years
s = volatility =
the annualized standard deviation of daily log-returns (using a
262-day
annualization factor) of the Companys stock price on
Nasdaq National Market or other securities exchange upon which
the Companys stock may then be traded over a
20-day
trading period, determined by the holder of the Warrant, that is
within the
100-day
trading period ending on the trading day immediately after the
public announcement of the Change of Control Event, or the
annualized standard deviation of daily-log returns (using a
262-day
annualization factor) of the closing bid or sale prices
(whichever is applicable) in the over-the-counter market over a
20-day
trading period, determined by the holder of Warrant, that is
within the
100-day
trading period ending on the trading day immediately after the
public announcement of the Change in Control Event if the
Companys stock is then actively traded in the
over-the-counter market, or 0.6 (or 60%) if the Companys
stock is not then traded on a securities exchange or system or
in the over-the-counter market.
N = cumulative normal distribution function
d1 = (ln(SCorp/KCorp) +
(r − l
+ ó2/2)(TCorp − tCorp)) (
sÖ(TCorp − tCorp))
ln = natural logarithm
l = dividend rate
of the Company for the most recent
12-month
period at the time of closing of the Change of Control Event.
KCorp = strike price of warrant
r = annual yield, as reported by Bloomberg at time tCorp, of the
United States Treasury security measuring the nearest time TCorp
d2 =
d1 − s
sÖ(TCorp − tCorp)
B-12
Annex C
FORM OF
VOTING AGREEMENT
VOTING
AGREEMENT
This VOTING AGREEMENT, dated as of May 22, 2008 (the
Agreement) is by and between the undersigned
stockholder (the Stockholder) of the Company (as
hereinafter defined) and NxStage Medical, Inc., a Delaware
corporation (Company).
WHEREAS, as of the date hereof, the Stockholder owns of record
and beneficially (as determined in accordance with
Rule 13d-3
promulgated under the Securities Exchange Act of 1934, as
amended) the number of shares of capital stock of the Company
set forth on the signature page hereto (such shares, or any
other voting or equity of securities of the Company hereafter
acquired by the Stockholder prior to the termination of this
Agreement, being referred to herein collectively as the
Shares);
WHEREAS, the Company, the Stockholder and certain other
investors (the Investors) in the Company have
entered into certain Securities Purchase Agreements, each dated
as of May 22, 2008 (collectively, the Purchase
Agreements), pursuant to which, upon the terms and subject
to the conditions thereof, the Investors will purchase
(collectively in two or more closings) shares of common stock of
Company and warrants to purchase shares of common stock of the
Company (the PIPE Transactions); and
WHEREAS, as a condition to the willingness of Company to enter
into the PIPE Transactions, Company has required that the
Stockholder agree, and in order to induce Company to enter into
the PIPE Transactions, the Stockholder is willing to agree to
vote in favor of the PIPE Transactions upon the terms and
subject to the conditions set forth herein.
NOW, THEREFORE, in consideration of the foregoing and the mutual
covenants and agreements contained herein, and intending to be
legally bound hereby, the parties hereby agree as follows:
Section 1. Voting
of Shares.
(a) Voting. The Stockholder
covenants and agrees that until the termination of this
Agreement in accordance with the terms hereof, at any meeting of
the stockholders of the Company, however called with respect to
any of the following, and in any action by written consent of
the stockholders of the Company with respect to any of the
following, the Stockholder will vote, or cause to be voted, all
of his, her or its respective Shares (i) in favor of any
matter that could reasonably be expected to facilitate the PIPE
Transactions, and (ii) against any matter that could
reasonably be expected to hinder, impede or delay the
consummation of the PIPE Transactions.
(b) Irrevocable Proxy.
(i) The Stockholder hereby irrevocably grants to and
appoints, and hereby authorizes and empowers, Company, and any
individual designated in writing by it, and each of them
individually, as the Stockholders sole and exclusive proxy
and attorney-in-fact (with full power of substitution and
resubstitution), for and in the Stockholders name, place
and stead, to vote and exercise all voting and related rights
(to the fullest extent that the Stockholder is entitled to do
so) with respect to his, her or its Shares at any meeting of the
stockholders of the Company called, and in every written consent
in lieu of such meeting, with respect to any of the matters
specified in, and in accordance and consistent with, this
Section 1. The Stockholder may vote the Shares on all other
matters not contemplated by this Section 1.
(ii) The Stockholder understands and acknowledges that
Company is entering into the PIPE Transactions in reliance upon
the Stockholders execution and delivery of this Agreement.
The Stockholder hereby affirms that the irrevocable proxy set
forth in this Section 1(b) constitutes an inducement for
Company to enter into the PIPE Transactions, is given in
connection with the execution of the Purchase Agreement between
the Stockholder and the Company dated as of the date hereof, and
is given to secure the performance of the duties of the
Stockholder under such Purchase Agreement. Except as otherwise
provided for herein, the Stockholder hereby (i) affirms
that the irrevocable proxy is coupled with an interest and may
under no circumstances be revoked, (ii) ratifies and
confirms all that the proxies appointed hereunder may lawfully
do or cause to be
C-1
done by virtue hereof and (iii) affirms that such
irrevocable proxy is executed and intended to be irrevocable in
accordance with the provisions of Section 212(e) of the
Delaware General Corporation Law.
(iii) Upon the execution of this Agreement by the
Stockholder, the Stockholder hereby revokes any and all prior
proxies or powers of attorney given by the Stockholder with
respect to the Shares. The Stockholder acknowledges and agrees
that no subsequent proxies with respect to such Shares shall be
given, and if given, shall not be effective. All authority
conferred herein shall survive the death or incapacity of the
Stockholder and any obligation of the Stockholder hereunder
shall be binding upon the heirs, personal representatives,
successors and assigns of the Stockholder. Notwithstanding any
other provisions of this Agreement, the irrevocable proxy
granted hereunder shall automatically terminate upon the
Expiration Date (as defined in Section 4).
Section 2. Transfer
of Shares.
(a) Until the consummation of all of the PIPE Transactions
or unless the transferee agrees to be bound by the terms of this
Agreement, the Stockholder covenants and agrees that the
Stockholder will not directly or indirectly, (i) sell,
assign, transfer (including by merger, testamentary disposition,
interspousal disposition pursuant to a domestic relations
proceeding or otherwise by operation of law), pledge, encumber
or otherwise dispose of any of the Shares, (ii) deposit any
of the Shares into a voting trust or enter into a voting
agreement or arrangement with respect to the Shares or grant any
proxy or power of attorney with respect thereto which is
inconsistent with this Agreement or (iii) enter into any
contract, option or other arrangement or undertaking with
respect to the direct or indirect sale, assignment, transfer
(including by merger, testamentary disposition, interspousal
disposition pursuant to a domestic relations proceeding or
otherwise by operation of law) or other disposition of any
Shares.
(b) The Company shall not recognize the transfer of any
Shares in violation of the transfer restrictions set forth in
Section 2(a) of this Agreement.
Section 3. Representations
and Warranties of the Stockholder. The
Stockholder hereby represents and warrants to the Company with
respect to the Stockholder and its, his or her ownership of the
Shares as follows:
(a) Ownership of Shares. The
Stockholder owns of record and beneficially all of the Shares
set forth on the signature page hereto and has good and
marketable title to such Shares, free and clear of any claims,
liens, encumbrances and security interests whatsoever, other
than liens under applicable law or as expressly provided in this
Agreement. The Stockholder owns no equity interest in the
Company other than the Shares as set forth on the signature page
hereto. The Stockholder has sole voting power (or shared voting
power solely with its affiliates), without restrictions, with
respect to all of the Shares.
(b) Power, Binding Agreement. The
Stockholder has the legal capacity and all requisite power and
authority to enter into and perform all of its, his or her
obligations under this Agreement. This Agreement has been duly
and validly executed and delivered by the Stockholder and
constitutes a valid and binding obligation of the Stockholder,
enforceable against the Stockholder in accordance with its terms.
Section 4. Termination. This
Agreement shall terminate upon the Expiration Date; provided,
however, that no such termination shall relieve any party of
liability for a willful breach hereof prior to termination. As
used herein, Expiration Date shall mean the earlier
to occur of (i) the consummation of all of the PIPE
Transactions, (ii) the one (1) year anniversary of the
date hereof, and (iii) the date the Purchase Agreement
between the Company and affiliates of OrbiMed Advisors, LLC is
terminated in accordance with the terms thereof.
Section 5. Specific
Performance. The parties hereto agree that
irreparable damage would occur in the event any provision of
this Agreement was not performed in accordance with the terms
hereof and that the parties shall be entitled to specific
performance of the terms hereof, in addition to any other remedy
at law or in equity.
Section 6. Additional
Documents. Stockholders hereby covenants and
agrees to execute and deliver any additional documents necessary
or desirable, in the reasonable opinion of Company and the
Stockholder, as the case may be, to carry out the intent of this
Agreement.
C-2
Section 7. Miscellaneous.
(a) Entire Agreement. This
Agreement constitutes the entire agreement between the parties
hereto with respect to the subject matter hereof and supersedes
all prior agreements and understandings, both written and oral,
between the parties with respect thereto. This Agreement may not
be amended, modified or rescinded except by an instrument in
writing signed by each of the parties hereto. Nothing contained
in this Agreement shall be construed to limit or effect in any
way any voting, trading or other rights of any entity (whether
affiliated with the Stockholder or otherwise) that is not
explicitly a party to this Agreement or a substantially
identical version of this Agreement.
(b) Severability. If any term or
other provision of this Agreement is invalid, illegal or
incapable of being enforced by any rule of law, or public
policy, all other conditions and provisions of this Agreement
shall nevertheless remain in full force and effect. Upon such
determination that any term or other provision is invalid,
illegal or incapable of being enforced, the parties hereto shall
negotiate in good faith to modify this Agreement so as to effect
the original intent of the parties as closely as possible to the
fullest extent permitted by applicable law in a mutually
acceptable manner in order that the terms of this Agreement
remain as originally contemplated to the fullest extent possible.
(c) Governing Law. This Agreement
shall be governed by and construed in accordance with the
internal laws of the State of Delaware without giving effect to
any choice or conflict of law provision or rule (whether of the
State of Delaware or any other jurisdiction) that would cause
the application of laws of any jurisdictions other than those of
the State of Delaware.
(d) Counterparts. This Agreement
may be executed in two or more counterparts, each of which shall
be deemed an original but all of which together shall constitute
one and the same instrument. This Agreement may be executed by
facsimile signature.
(e) Notices.
All notices, requests, consents and other communications
hereunder shall be in writing, shall be mailed (A) if
within the United States by first-class registered or certified
airmail, or nationally recognized overnight express courier,
postage prepaid, or by facsimile or electronic mail, or
(B) if delivered from outside the United States, by
International Federal Express (or other recognized international
express courier) or facsimile, and shall be deemed given
(i) if delivered by first-class registered or certified
mail, three business days after so mailed, (ii) if
delivered by nationally recognized overnight carrier, one
business day after so mailed, (iii) if delivered by
International Federal Express (or other recognized international
express courier), two business days after so mailed, or
(iv) if delivered by facsimile or electronic mail, upon
electronic confirmation of receipt and shall be delivered as
addressed as follows:
if to the Company, to:
NxStage Medical, Inc.
439 S. Union St., 5th Floor
Lawrence, MA 01843
Phone:
(978) 687-4700
Fax:
(978) 687-4825
Attn: Winifred Swan
Email: wswan@nxstage.com
With a copy to:
OMelveny & Myers LLP
2765 Sand Hill Road
Menlo Park, CA 94025
Fax:
(650) 473-2601
Attn: Sam Zucker
if to the Stockholder, at its address as shown on the books of
the Company.
C-3
(f) Assignment. This Agreement
shall not be assigned by operation of law or otherwise;
provided, however, that Company may assign any or all of its
rights and obligations under this Agreement to any wholly-owned
subsidiary of Company, but no such assignment shall relieve
Company of its obligations hereunder if such assignee does not
perform such obligations.
(g) Legal Counsel. Stockholder
acknowledges that he, she or it has been advised to, and has had
the opportunity to consult with his, her or its personal
attorney prior to entering into this Agreement. Stockholder
further acknowledges that attorneys for the Company represent
the Company and do not represent Stockholder or any of the
stockholders of the Company in connection with the this
Agreement or any of the transactions contemplated hereby.
(h) Agreement
Negotiated. Stockholder acknowledges that he,
she or it has been advised to, and has had the opportunity to,
consult with his, her or its personal attorney prior to entering
into this Agreement. As a consequence, Stockholder does not
believe or intend that any laws or rules relating to the
interpretation of contracts against the drafter of any
particular clause should be applied in this case and therefore
waive its effects.
(i) Interpretation. When reference
is made in this Agreement to an Article or a Section, such
reference shall be to an Article or Section of this Agreement,
unless otherwise indicated. The headings contained in this
Agreement are for convenience of reference only and shall not
affect in any way the meaning or interpretation of this
Agreement. The language used in this Agreement shall be deemed
to be the language chosen by the parties hereto to express their
mutual intent, and no rule of strict construction shall be
applied against any party. Whenever the context may require, any
pronouns used in this Agreement shall include the corresponding
masculine, feminine or neuter forms, and the singular form of
nouns and pronouns shall include the plural, and vice versa. Any
reference to any federal, state, local or foreign statute or law
shall be deemed also to refer to all rules and regulations
promulgated thereunder, unless the context requires otherwise.
Whenever the words include, includes or
including are used in this Agreement, they shall be
deemed to be followed by the words without
limitation. No summary of this Agreement prepared by the
parties shall affect in any way the meaning or interpretation of
this Agreement.
(j) Submission to
Jurisdiction. Each of the parties to this
Agreement (i) submits to the jurisdiction of any state or
federal court sitting in New York, New York in any action or
proceeding arising out of or relating to this Agreement or any
of the transactions contemplated by this Agreement,
(ii) agrees that all claims in respect of such action or
proceeding may be heard and determined in any such court, and
(iii) agrees not to bring any action or proceeding arising
out of or relating to this Agreement or any of the transactions
contemplated by this Agreement in any other court. Each of the
parties hereto waives any defense of inconvenient forum to the
maintenance of any action or proceeding so brought and waives
any bond, surety or other security that might be required of any
other party with respect thereto. Any party hereto may make
service on another party by sending or delivering a copy of the
process to the party to be served at the address and in the
manner provided for the giving of notices in Section 7(e).
Nothing in this Section 7(j), however, shall affect the
right of any party to serve legal process in any other manner
permitted by law.
(k) WAIVER OF JURY TRIAL. EACH OF
THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ALL RIGHTS TO TRIAL
BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED
ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO
THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THE
ACTIONS OF THE COMPANY OR THE STOCKHOLDER IN THE NEGOTIATION,
ADMINISTRATION, PERFORMANCE AND ENFORCEMENT OF THIS AGREEMENT.
C-4
IN WITNESS WHEREOF, each of the parties hereto has caused this
Agreement to be signed individually or by its respective duly
authorized officer as of the date first written above.
NXSTAGE MEDICAL, INC.
STOCKHOLDER:
|
|
|
|
|
Number of Shares of
|
Stock
|
|
Common Stock
|
Certificate
|
|
Represented
|
Number
|
|
Thereby
|
C-5
. NNNNNNNNNNNN NNNNNNNNNNNNNNN C123456789 000004 000000000.000000 ext 000000000.000000 ext
000000000.000000 ext 000000000.000000 ext MR A SAMPLE DESIGNATION (IF ANY) 000000000.000000 ext
000000000.000000 ext ADD 1 Electronic Voting Instructions ADD 2 ADD 3 You can vote by Internet
or telephone! ADD 4 Available 24 hours a day, 7 days a week! ADD 5 Instead of mailing your
proxy, you may choose one of the two voting ADD 6 methods outlined below to vote your proxy.
NNNNNNNNN VALIDATION DETAILS ARE LOCATED BELOW IN THE TITLE BAR. Proxies submitted by the
Internet or telephone must be received by 11:59 p.m., Eastern Time, on July 30, 2008. Vote by
Internet Log on to the Internet and go to www.investorvote.com/NXTM Follow the steps
outlined on the secured website. Vote by telephone Call toll free 1-800-652-VOTE (8683) within
the United States, Canada & Puerto Rico any time on a touch tone telephone. There is NO CHARGE to
you for the call. Using a black ink pen, mark your votes with an X as shown in X Follow the
instructions provided by the recorded message. this example. Please do not write outside the
designated areas. Special Meeting Proxy Card 123456 C0123456789 12345 3 IF YOU HAVE NOT VOTED
VIA THE INTERNET OR TELEPHONE, FOLD ALONG THE PERFORATION, DETACH AND RETURN THE BOTTOM PORTION IN
THE ENCLOSED ENVELOPE. 3 A Proposals The Board of Directors recommends a vote FOR Proposal 1.
1. To approve the issuance and sale of 4,000,000 shares of our common stock, at For Against
Abstain + $4.50 per share, and warrants exercisable for 800,000 shares of our common stock, at an
initial exercise price of $5.50 per share, to certain investors, including investors who are
affiliates, either directly or through affiliates, of NxStage, among them a member of our board of
directors, in exchange for aggregate gross proceeds NxStage of $18 million at the second closing of
our private placement of securities. 2. To transact such other business as may properly come before
the meeting, including any adjournment or postponement thereof. B Non-Voting Items Change of
Address Please print new address below. Comments Please print your comments below. C
Authorized Signatures This section must be completed for your vote to be counted. Date and
Sign Below Please sign exactly as your name appears hereon. Joint owners should each sign
personally. Trustees and other fiduciaries should indicate the capacity in which they sign. If a
corporation or partnership, the signature should be that of an authorized officer who should state
his or her title. Date (mm/dd/yyyy) Please print date below. Signature 1 Please keep
signature within the box. Signature 2 Please keep signature within the box. C 1234567890 J N
T MR A SAMPLE (THIS AREA IS SET UP TO ACCOMMODATE 140 CHARACTERS) MR A SAMPLE AND MR A SAMPLE AND
MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND NNNNNNN1 U P X 0 1 8 7 4 4 1 MR A SAMPLE AND MR A
SAMPLE AND MR A SAMPLE AND + <STOCK#> 00XI4C |
ELECTION TO OBTAIN PROXY MATERIALS ELECTRONICALLY INSTEAD OF BY MAIL NxStage Medical, Inc.
stockholders may elect to receive all NxStages future annual reports, proxy statements and proxy
cards through the Internet instead of receiving copies through the mail. While NxStage has not yet
implemented electronic distribution of stockholder communications, it intends to do so in the
future to provide added convenience to its stockholders and to reduce its annual report printing
and mailing costs. To take advantage of this option, stockholders must subscribe to one of the
various commercial services that offer access to the Internet. Costs normally associated with
electronic access, such as usage and telephone charges, will be bourne by the stockholder. To
elect this electronic delivery option, while voting via the Internet, simply enter your email
address in the space provided. If you consent to receive NxStages future proxy materials
electronically, your consent will remain in effect unless you revoke your consent by logging into
Investor Centre at www.computershare.com. YOU MAY ACCESS THE NxSTAGE MEDICAL, INC. ANNUAL REPORT
AND PROXY STATEMENT AT: http://www.nxstage.com 3 IF YOU HAVE NOT VOTED VIA THE INTERNET OR
TELEPHONE, FOLD ALONG THE PERFORATION, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED
ENVELOPE. 3 Proxy NxStage Medical, Inc. SPECIAL MEETING OF STOCKHOLDERS 10:00 A.M. THURSDAY,
JULY 31, 2008 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS Those signing on the
reverse side, revoking any prior proxies, hereby appoint(s) Robert S. Brown and Winifred L. Swan,
or each of them with full power of substitution, as proxies for those signing on the reverse side
to act and vote at the 2008 Special Meeting of Stockholders of NxStage Medical, Inc. and at any
adjournments thereof as indicated upon all matters referred to on the reverse side and described in
the proxy statement for the Special Meeting, and, in their discretion, upon any other matters which
may properly come before the Special Meeting. THIS PROXY, WHEN PROPERLY EXECUTED, WILL BE VOTED AS
DIRECTED BY THE UNDERSIGNED STOCKHOLDER. IF NO SUCH DIRECTIONS ARE MADE, THIS PROXY WILL BE VOTED
FOR PROPOSAL NUMBER 1. UNLESS YOU INTEND TO VOTE YOUR SHARES BY INTERNET OR TELEPHONE, PLEASE
MARK, SIGN, DATE, AND RETURN THIS PROXY CARD PROMPTLY IN THE ENCLOSED REPLY ENVELOPE. PLEASE REFER
TO THE REVERSE SIDE FOR TELEPHONE AND INTERNET VOTING INSTRUCTIONS. If you vote by telephone or the
Internet, please DO NOT mail back this proxy card. |